Heterocyclic spiro compounds and methods of use

Abstract

Provided are compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of International Patent Application No. PCT / CN2020 / 122197, filed October 20,2020, which is incorporated herein by reference in its entirety. FIELD The present disclosure provides compounds having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers. BACKGROUND From its identification as one of the first human oncogenes in 1982 (Der et al., 1982), KRAS (the Kirsten rat sarcoma viral oncogene homologue) has been the focus of extensive academic and industrial research, as a key node in the MAPK signal transduction pathway, as a transforming factor in a network of parallel effector pathways (e.g., PI3K / AKT) (Vojtek et al., 1998) and as a potential target for anti-cancer agents (Malumbres et al., 2003). Despite progress in the development of inhibitors of upstream and downstream nodes in the MAPK pathway (e.g., EGFR (Sridhar et al., 2003), BRAF (Holderfield et al., 2014), and MEK (Caunt et al., 2015), the KRAS protein has historically proven resistant to direct inhibition. KRAS is a G-protein that couples extracellular mitogenic signaling to intracellular, pro-proliferative responses. KRAS serves as an intracellular “on / off ’ switch. Mitogen stimulation induces the binding of GTP to KRAS, bringing about a conformational change which enables the interaction of KRAS with downstream effector proteins, leading to cellular proliferation. Normally, pro-proliferative signaling is regulated by the action of GTPase-activating proteins (GAPs), which return KRAS to its GDP-bound, non-proliferative state. Mutations in KRAS impair the regulated cycling of KRAS between these GDP- and GTP-bound states, leading to the accumulation of the GTP-bound active state and dysregulated cellular proliferation (Simanshu et al., 2017). 1 RECTIFIED SHEET (RULE 91) ISA / CN 2021363262   14 Oct 2026 Attempts to develop inhibitors of mutated KRAS proteins have historically been thwarted by the absence of druggable pockets on the surface of the protein (Cox et al., 2014). In 2013, Shokat and colleagues identified covalent inhibitors of a common (O'Bryan, 2019) oncogenic mutant of KRAS, KRASG12C, which bound to a previously unrecognized allosteric pocket on GDP-KRASG12C and prevented its subsequent activation (Ostrem et al., 2013). This discovery brought about significant new efforts in KRAS inhibitor research, which have recently culminated in the entry of KRAS inhibitors into human clinical trials. See, e.g., https: / / clinicaltrials.gov / : e.g., NCT03600883 & NCT04185883 (AMG 510) and NCT03785249 (MRTX849) (last accessed August 29, 2020). While some progress has been made, the need for further KRASG12C inhibitors for the treatment of disorders, such as cancer, remains. Any discussion of the prior art throughout the specification should not be considered as an express or implied admission that such prior art is widely known or forms part of the common general knowledge in the field. It is an object of the present invention to overcome or ameliorate one or more of the disadvantages of the prior art, or at least to provide a useful alternative. SUMMARY In a first aspect there is provided a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein 2021363262   14 Oct 2026 R1 at each occurrence independently is H, 2H, C1-4haloalkyl, C1-4alkoxy, -CH2OH, -(CH2)O(C1-4alkyl), -(CH2)O(C1-4haloalkyl), -(CH2)-C1-4dialkylamino, aziridin-1-yl-methyl, azetidin-1-yl-methyl, pyrrolidine-1-yl-methyl, piperidin-1-yl-methyl, or morpholin-1-yl-methyl; R2 is H, 2H, halogen, -CN, C1-4alkyl, C1-4haloalkyl, -CH2CN, -CH2OH, C1-4alkoxy, or C1-4haloalkoxy; wherein, optionally, one R1 and R2 together with the carbon atoms to which they I — pl are attached form a *         group; R3 at each occurrence independently is H, halogen, CN, OH, C1-4alkyl, C1-4haloalkyl, -CH2CN, -CH2OH, C1-4alkoxy, or C1-4haloalkoxy, wherein two substituents R3 attached to the same carbon atom optionally form together with said carbon atom a C3-6cycloalkyl or a carbonyl group; A at each occurrence independently is CR3R3 or absent; R4 is 1,2,3,4-tetrahydro-8-quinolinyl, 6 or 10 membered aryl, or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected from OH, halogen, -CN, NH2, C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, -SO2NH2, -NHSO2CH3, wherein the C1-4alkyl is optionally substituted with OH; X1 is CR5 or N; X2 is CH, CF, or N; X3 is C or N; X4 is C or N; R5 is H, halogen, CN, -COO(C1-4alkyl), C1-4alkyl, C2-4alkenyl, C1-4haloalkyl, -(CH2)m(C1-4alkoxy), -(CH2)m(C1-4haloalkoxy), C3-5cycloalkyl, C3-5cyclohaloalkyl, or C3-5heterocycloalkyl; B together with the atoms to which it is attached forms a 4 to 7 membered fully saturated, fully unsaturated, or partially unsaturated carbocyclic or heterocyclic ring system, wherein the heterocyclic ring system comprises 1 to 5 heteroatoms independently selected from N, O, and S, wherein the ring system is optionally substituted with 1 to 5 substituents R6; 2021363262   14 Oct 2026 R6 at each occurrence independently is halogen, OH, -CN, -NH2, C1-6alkyl, C1-6haloalkyl, Ci-4alkoxy, Ci-4haloalkoxy, -C(=O)Ci-6alkyl, -R7-(C3—5cycloalkyl), -R7-(C3. 5cyclohaloalkyl), -R7-(C3-6heterocycloalkyl), -R7-(phenyl), or - R7-(5 to 6 membered heteroaryl), wherein the C1-6alkyl is optionally substituted with C1-4alkoxy, C1-4alkylamino, C1-4dialkylamino, -CO(C1-4alkylamino) or -CO(C1-4dialkylamino), wherein the C1-6haloalkyl is optionally substituted with a OH, wherein the C3-6heterocycloalkyl is optionally substituted with 1 to 3 substituents independently selected from (=O) and C1-6alkyl, wherein the phenyl is optionally substituted with 1 to 3 substituents independently selected from halogen and C1-4alkoxy, wherein the heteroaryl is optionally substituted with 1 to 3 substituents independently selected from halogen, -(CH2)1-3OH, (CH2)1-3O(C1-4alkyl), -(CH2)1-3O(C1-4haloalkyl), C1-4alkyl, and C1-4haloalkyl, wherein two substituents R6 together optionally form a -(CH2)n- group creating a ring together with the ring atom or ring atoms to which the two substituents R6 are attached, wherein the -(CH2)n- group optionally has one -CH2- group substituted with one heteroatom selected from N, O, and S, and wherein the -(CH2)n- group is optionally substituted with 1 to 3 substituents independently selected from halogen and C1-6alkyl; R7 is (CH2)m or CO; n is 1, 2, 3, 4, 5 or 6; and m is 0 or 1. In a second aspect there is provided a pharmaceutical composition comprising the compound according to the first aspect or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In a third aspect there is provided a method of treating cancer, said method comprising administering a therapeutically effective amount of the compound according to the first aspect or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to the second aspect, to a subject in need thereof, wherein one or more cells express KRAS G12C mutant protein. 2021363262   14 Oct 2026 In a fourth aspect there is provided use of the compound according to the first aspect or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to the second aspect, in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein one or more cells express KRAS G12C mutant protein. First, provided herein is a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1 at each occurrence independently is H, 2H, C1-4haloalkyl, C1-4alkoxy, -CH2OH, -(CH2)O(C1-4alkyl), -(CH2)O(C1-4haloalkyl), -(CH2)-C1-4dialkylamino, aziridin-1-yl-methyl, azetidin-1-yl-methyl, pyrrolidine-1-yl-methyl, piperidin-1-yl-methyl, or morpholin-1-yl-methyl; R2 is H, 2H, halogen, -CN, C1-4alkyl, C1-4haloalkyl, -CH2CN, -CH2OH, C1-4alkoxy, or C1-4haloalkoxy; wherein, optionally, one R and Rz together with the carbon atoms to which they are |     __pi attached form a *         group; R3 at each occurrence independently is H, halogen, CN, OH, (. .wJkyl. Ci-4haloalkyl, -CH2CN, -CH2OH, Cwalkoxy, or CMhaloalkoxy, wherein two substituents R3 attached to the same carbon atom optionally form together with said carbon atom a Cs-ecycloalkyl or a carbonyl group; A at each occurrence independently is CRJR3 or absent; R4 is l,2,3,4-tetrahydro-8-quinolinyl, 6 or 10 membered atyl, or 5 to 10 membered heteroaryl, wherein the atyl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected from OH, halogen, -CN, NH2, Chalky!, CMdeuteroalkyl, Ci. 4haloalkyl, Cwalkoxy, CMhaloalkoxy, -SO2NH2, -NHSO2CH3, wherein the Cwalkyl is optionally substituted with OH; Xs is CR5 orN; X2 is CH, CF, or N; X ' is C or N; X4 is C or N; R5 is H, halogen, CN, -COO(CMalkyl), Cwalkyl, C2-4alkenyl, Cwhaloalkyl, -(CH2)m(Ci.4aikoxy), -(CH2)m(Ci.4haloalkoxy), Cs-scycloalkyl, Cs-scyclohaloalkyl, or C3. sheterocycloalkyl; B together with the atoms to which it is attached forms a 4 to 7 membered fully saturated, fully unsaturated, or partially unsaturated carbocyclic or heterocyclic ring system, wherein the heterocyclic ring system comprises 1 to 5 heteroatoms independently selected from N, O, and S, wherein the ring system is optionally substituted with 1 to 5 substituents R°; R° at each occurrence independently is halogen, OH, -CN, -NH2, Cuealkyl, Ci. ehaloalkyl, Ci-4alkoxy, CMhaloalkoxy, -C(=O)Ci-6alkyl, -R7-(C3-5cycloalkyl), R -((.2. □cyclohaloalkyl), --R7-(C3.6heterocycloalkyl), -R7-(phenyl), or - R7-(5 to 6 membered heteroaryl), wherein the Cu6alkyl is optionally substituted with CMalkoxy, Ci. 4alkylamino, CMdialkylamino, -CO(CMalkylamino) or -CO(CMdialkylamino), wherein the Ci-6haloalkyl is optionally substituted with a OH, wherein the Cs-eheterocycloalkyl is optionally substituted with 1 to 3 substituents independently selected from (=0) and Cusalkyl, wherein the phenyl is optionally substituted with 1 to 3 substituents independently selected from halogen and Cwalkoxy, wherein the heteroaryl is optionally substituted with 1 to 3 substituents independently selected from halogen, -(CH2)i-3OH, (CH2)i-3O(Ci-4alkyl), -(CH2)n 3O(Cj-4haloalkyl), Ci-4alkyl, and Ci-4haloalkyl, wherein two substituents Rb together optionally form a -(CH2)n” group creating a ring together with the ring atom or ring atoms to which the two substituents R" are attached, wherein the -(CH2)n- group optionally has one -CH2- group substituted with one heteroatom selected from N, O, and S, and wherein the -(CH2)n- group is optionally substituted with 1 to 3 substituents independently selected from halogen and Ci-ealkyl; R7 is (CH2)m or CO; n is 1,2, 3, 4, 5 or 6; and m is 0 or 1. Second, provided herein is a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Third, provided herein is a compound of Formula 1 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described hereinabove, for use in treating cancer. Reference will now be made in detail to embodiments of the present disclosure. While certain embodiments of the present disclosure will be described, it will be understood that it is not intended to limit the embodiments of the present disclosure to those described embodiments. To the contrary, reference to embodiments of the present disclosure is intended to cover alternatives, modifications, and equivalents as may be included within the spirit and scope of the embodiments of the present disclosure as defined by the appended claims. DETAILED DESCRIPTION Provided herein as Embodiment 1 is a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1 at each occurrence independently is H, 2H, Cndialoalkyl, Ci.4alkoxy, -CI-bOH, -(CH2)O(Ci-4alkyl), -(CH2)O(Ci.4haloalkyl), -(CH2)-Ci-4diaIkylamino, aziridin-l-yl-methyl, azetidin-l-yl-methyl, pyrrolidine-1-yl-methyl, piperidin-1-yl-methyl, or morpholin-1-yl- methyl; R2 is H, 2H, halogen, -CN, Cwalkyl, C Mhaloalkyl, -CH2CN, -CH2OH, Cwalkoxy, or CMhaloalkoxy; wherein, optionally, one R1 and Rz together with the carbon atoms to which they are | --- P1 attached form a «         group; R’ at each occurrence independently is H, halogen, CN, OH, Cwalkyl, Ci^haloalkyl, -CH2CN, -CH2OH, Ci-4alkoxy, or Cs^haloalkoxy, wherein two substituents R3 attached to the same carbon atom optionally form together with said carbon atom a Cs-ecycloalkyl or a carbonyl group; A at each occurrence independently is CR’R’ or absent; R4 is 1,2,3,4-tetrahydro-8-quinolinyl, 6 or 10 membered aryl, or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected from OH, halogen, -CN, NH2, Cwalkyl, Cwdeuteroalkyl, Ci. 4haloalkyl, CMalkoxy, Cwhaloalkoxy, -SO2NH2, -NHSO2CH3, wherein the Ciwkyl is optionally substituted with OH; X1 is CR5 orN; X2 is CH, CF, or N; X3isCorN; X4 is C or N; Rs is H, halogen, CN, -COO(CMalkyl), Ci^alkyl, C24alkenyl, Ci^haloalkyl, -(CH2)m(CMalkoxy), 4CH2)m(Ci-4haloaIkoxy), Cs-scycloalkyl, Q.scyclohaloalkyl, or C3. sheterocycloalkyl; B together with the atoms to which it is attached forms a 4 to 7 membered fully saturated, fully unsaturated, or partially unsaturated carbocyclic or heterocyclic ring system, wherein the heterocyclic ring system comprises 1 to 5 heteroatoms independently selected from N, O, and S, wherein the ring system is optionally substituted with 1 to 5 substituents R°; Rb at each occurrence independently is halogen, OH, -CN, -NH2, Ci^alkyl, Ci. ehaloalkyl, Ci^alkoxy, Ci.ahaloalkoxy, -C(=O)Ci4alkyl, -R7-(C3-5cycloalkyl), -R7-(C3-scyclohaloalkyl), -R'-(C3-6heterocycloalkyl), -R'-(phenyl), or - R?-(5 to 6 membered heteroaryl), wherein the Cuealkyl is optionally substituted with Cwalkoxy, Ct. 4alkylamino, Ct-4dialkylamino, -CO(Ci-4alkylamino) or -CO(CMdialkylamino), wherein the Cuehaloalkyl is optionally substituted with a OH, wherein the Cs-sheterocycloalkyl is optionally substituted with 1 to 3 substituents independently selected from (=0) and Cnealkyl, wherein the phenyl is optionally substituted with 1 to 3 substituents independently selected from halogen and Ci^alkoxy, wherein the heteroaryl is optionally substituted with 1 to 3 substituents independently selected from halogen, -(CH2)i-3OH, (CH2)i-3O(Ci-4alkyl), -(CH2h-sOfCi^haloalkyl), Ci-4alkyl, and Ci-4haloalkyl, wherein two substituents R6 together optionally form a -(CH2)n- group creating a ring together with the ring atom or ring atoms to which the two substituents R6 are attached, wherein the -(CFDn- group optionally has one -CH2- group substituted with one heteroatom selected from N, O, and S, and wherein the -(CH?.),)- group is optionally substituted "with 1 to 3 substituents independently selected from halogen and Ci-6alkyl; R7 is (CIH. or CO; n is 1, 2, 3, 4, 5 or 6; and m is 0 or 1. Provided herein as Embodiment 2 is the compound according to Embodiment 1 or a pharmaceutically acceptable salt thereof, wherein R2 is not methyl; or R4 is not 4-cyano-l-methyl-lH-pyrazol-5-yl, 2-fluoro-5-cyano-phenyl, 2-methyl-5-hydroxymethyl-phenyl, 2-chloro-5-(difluoromethoxy)phenyl, 2-methyl-5-(difluoromethyl)-phenyl, 3-methoxy-5-(trifluoromethyl)phenyl, 2-fluoro-3-methoxyphenyl, 5-hydroxy-2-(2-propanyl)phenyl, 3-methyl-4-pyridinyl, 6-amino-3-methyl-pyridin-2-yl, 5-(trifluoromethyl)-3-pyridinyl, 6-oxo-1,6-dihydro-3-pyridinyl, 4-oxo-6-(2-propanyl)-1,4-dihydro-2-pyridinyl, 5-pyrimidinyl, 5-methyl-l,2-benzoxazol-4-yl, 5-methyl-lH-pyrrolo[2,3-b]pyridin-4-yl, imidazo[l,2-a]pyridin-3-yl, pyrazolo[l,5-a]pyridin-3-yl, lH-pyrrolo[3,2-c]pyridin-7-yl, 6-hydroxy-2-methyl-naphthalen-l-yl, isoquinolin-4-yl, 2-oxo-l,2-dihydroquinolin-4-yl, or 6-hydroxy-8-quinolinyl; or R° is not 3-chlorophenyl or 8-methylnaphthalen-l-yl; or wherein the compound is not a compound, wherein IT is 3-fluoro-2-pyridinyl, X‘ is CCH3 and X2 is N. Provided herein as Embodiment 3 is the compound according to Embodiment 1 or a pharmaceutically acceptable salt thereof, wherein the compound is not l-(6-(4-(2-fluorophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-2 -y 1)-2,6-diazaspiro[3.4] octan-2-yl)-2-propen-1 -one; l-(6-(4-(2-fluorophenyl)-8-methyl-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)- 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(7-methyl-4-(5-methyl-lH-indazol-4-yl)-6,7-dihydro-5H-pyrrolo[2,3- d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)prop-2-en-l-one; l-(6-(4-(2-fluorophenyl)-7-(8-methyl-l-naphthalenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-4-(5-cyano-2-fluorophenyl)quinolme-3-carbonitrile; l-(6-(4-(2-chloro-5-(difluoromethoxy)phenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-fluorophenyl)-7-(8-methylnaphthalen-l -yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)prop-2-en-l-one; l-(6-(4-(4-isoquinolinyl)-5,6,7,8-telrahydro-2-quinazolinyl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-(difluoromethyl)-2-methylphenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-(hydroxymethyl)-2-methylphenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)- 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-methyl-lH-indazol-4-yl)pyrido[3,2-d]pyrimidin-2-yl)-2,6- diazaspiro[3,4]octan-2-yl)-2,-propen-l-one; l-(6-(4-(6-amino-3-methyl-2-pyridinyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-2-methyl-l-naphthalenyl)-5,6,7,8-tetraliydro-2-quinazolmyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-8-quinolinyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(8-(3-chlorophenyl)-4-(2-fluorophenyl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-fluoro-3-methoxyphenyl)-7-methoxy-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1-(6-(8-(2,3-difluorophenyl)-6-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; 4-(5-hydroxy-2-(2-propanyl)phenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-y 1) - 3 -quinol inecarbon itril e; 1-(6-(4-(2,3-dimethy3phenyl)pyrido[3,2-d]pyrimidin-2-yl)-2,6-diazaspiro[ 3.4]octan-2-yl)-2-propen-1 -one; 7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(5-pyrimidinyl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-methyl-2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; l-(6-(3-methyl-4-(3-methyl-4-pyridmyl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one; 4-(4-cyano-l-methyl-lH-pyrazol-5-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,7-dihydrofuro[3,4-b]pyridine-3-carbonitrile; 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-((lR,4R)-l-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(5-methyl-l,2-benzoxazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-q uinolinecarboni trile; 4-(5-methyl-lH-pyrrolo[2,3-b]pyridin-4-yl)-2-(2-(2-propenoyl)~2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarboni trile; 4-(imidazo[l,2-a]pyridin-3-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(pyrazolo[l,5-a]pyridin-3-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 4-(1,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-2-(6-(2-propenoyl)-6,l 0- diazadispiro[2.0.34.33]decan-10-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 2'-oxo-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4joctan-6-yl)-r,2'-dihydro[4,4'-biquinoline]-3 -carbonitrile; (lR,9R)-10,10-dimethyl-4-(2-(2-propenoyr)-2,6-diazaspiro[3.4]octan-6-yr)-6-(5-(trifluoromethyl)-3-pyridinyl)-3-azatricyclo[7.1.1.027]undeca-2,4,6-triene-5-carbonitrile; (1 R,9R)-6-(3-methoxy-5-(trifluoromethyl)phenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’7jundeca-2,4,6-triene-5-carbonitrile; 4-(2,4-difluorophenyl)-7-(2-propanyl)-2-(2-(2-propenoyl)-2,7-diazaspiro[3.5]nonan-7-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; (1 R,9R)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6-(l H-pyrrolo[3,2-c]pyridin-7-yl)-3-azatricyclo[7.1.1.0A7]undeca-2,4,6-triene-5-carbonitrile; (1 R,9R)-6-(l -(difluoromethyl)-6-oxo-l ,6-dihydro-3-pyridinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’ / ]undeca-2,4,6-triene-5-carbonitrile; l-(6-(4-(3-fluoro-2-pyridinyl)-3,7,7-1rimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridm-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; or 7,7-dimethyl-4-(4-oxo-6-(2-propanyl)-l,4-dihydro-2-pyridinyl)-2-(2-(2-propenoyl)- 2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile. Provided herein as Embodiment 4 is the compound according to Embodiment 1 or a pharmaceutically acceptable salt thereof, wherein the compound has an IC50 of less than 10 uM in the 2h coupled exchange assay or the 20h coupled exchange assay. Provided herein as Embodiment 5 is the compound according to any one of Embodiments 1-4 or a pharmaceutically acceptable salt thereof, wherein R1 at each occurrence independently is H, 2H, C Mhaloalkyl, -CH2OH, -(CH2)O(Ci-4alkyl), -(CH2)O(Ci-4haloalkyl), or -(CH2)-Ci-4dialkylamino. Provided herein as Embodiment 6 is the compound according to any one of Embodiments 1-4 or a pharmaceutically acceptable salt thereof, wherein R at each occurrence independently is H, ZH, Ci.4haloalkyl, or -(CH2)-Ci. 4dialkylamino. Provided herein as Embodiment 7 is the compound according to any one of Embodiments 1-4 or a pharmaceutically acceptable salt thereof, wherein R1 at each occurrence independently is H, 2H, CEEF, CHF2, CF3, -CEFOH, -CH2OCH3, -(CH2)OCHF2, or -(CH2)-N(CH3)2. Provided herein as Embodiment 8 is the compound according to any one of Embodiments 1-4 or a pharmaceutically acceptable salt thereof, wherein R1 at each occurrence independently is H, 2H, CHF2, or -(CH2,)-N(CH3)2. Provided herein as Embodiment 9 is the compound according to any one of Embodiments 1-4 or a pharmaceutically acceptable salt thereof, wherein R1 is H. Provided herein as Embodiment 10 is the compound according to any one of Embodiments 1-4 or a pharmaceutically acceptable salt thereof, wherein one Rl and R2 together with the carbon atoms to which they are attached form a j = R1 '          group. Provided herein as Embodiment 11 is the compound according to Embodiment 10 or a pharmaceutically acceptable salt thereof, wherein ,  { — R1 .   — H the *           group is *          . Provided herein as Embodiment 12 is the compound according to any one of Embodiments 1-10 or a pharmaceutically acceptable salt thereof, wherein R2 is H or halogen. Provided herein as Embodiment 13 is the compound according to any one of Embodiments 1-10 or a pharmaceutically acceptable salt thereof, wherein R2 is Br or Cl. Provided herein as Embodiment 14 is the compound according to any one of Embodiments 1-10 or a pharmaceutically acceptable salt thereof, wherein R2 is H. Provided herein as Embodiment 15 is the compound according to any one of Embodiments 1-14 or a pharmaceutically acceptable salt thereof, wherein R’ at each occurrence independently is H, halogen, Cwalkyl, Cs-ihaloalkyl, or -CH2OH. Provided herein as Embodiment 16 is the compound according to any one of Embodiments 1-14 or a pharmaceutically acceptable salt thereof, wherein R ’ at each occurrence independently is H, halogen, or Ci^alkyl. Provided herein as Embodiment 17 is the compound according to any one of Embodiments 1-14 or a pharmaceutically acceptable salt thereof, wherein RJ at each occurrence independently is H, F, methyl, CH2F, CHF2, or -CH2OH. Provided herein as Embodiment 18 is the compound according to any one of Embodiments 1-14 or a pharmaceutically acceptable salt thereof, wherein R’ at each occurrence independently is H, F, methyl, or CH2F. Provided herein as Embodiment 19 is the compound according to any one of Embodiments 1 -14 or a pharmaceutically acceptable salt thereof, wherein R3 is H. Provided herein as Embodiment 20 is the compound according to any one of Embodiments 1-19 or a pharmaceutically acceptable salt thereof, wherein one A is absent and the other A is CR3R3. Provided herein as Embodiment 21 is the compound according to any one of Embodiments 1-19 or a pharmaceutically acceptable salt thereof, wherein both A are absent. Provided herein as Embodiment 22 is the compound according to any one of Embodiments 1-14 or a pharmaceutically acceptable salt thereof, wherein Provided herein as Embodiment 23 is the compound according to any one of 5 Embodiments 1 -14 or a pharmaceutically acceptable salt thereof, wherein Provided herein as Embodiment 24 is the compound according to any one of Embodiments 1-14 or a pharmaceutically acceptable salt thereof, wherein 10 Provided herein as Embodiment 25 is the compound according to any one of Embodiments 1 -24 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected from OH, halogen, -CN, NH2, Cwalkyl, Cbadeuteroalkyl, Ci-4haloalkyl, Ci.4alkoxy, -SO2NH2, -NHSO2CH3, wherein the Chalky! is optionally substituted with OH, Provided herein as Embodiment 26 is the compound according to any one of Embodiments 1 -24 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from OH, halogen, -CN, NH2, Ci-«alkyl, or CMhaloalkyl. Provided herein as Embodiment 27 is the compound according to any one of Embodiments 1 -24 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected from OH, F, Cl, Br, -CN, NH2, methyl, ethyl, isopropyl, CD3, CHF2, CF3, methoxy, -SO2NH2, -NHSO2CH3, -CH-OH. or -CH(OH)CH3. Provided herein as Embodiment 28 is the compound according to any one of Embodiments 1 -24 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from OH, F, Cl, -CN, NH2, methyl, or CF3. Provided herein as Embodiment 29 is the compound according to any one of Embodiments 1 -24 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from OH, F, Cl, or methyl. Provided herein as Embodiment 30 is the compound according to any one of Embodiments 25-29 or a pharmaceutically acceptable salt thereof, wherein the 6 or 10 membered aryl is phenyl. Provided herein as Embodiment 31 is the compound according to any one of Embodiments 25-29 or a pharmaceutically acceptable salt thereof, wherein the 6 or 10 membered aryl is naphthalenyl. Provided herein as Embodiment 32 is the compound according to any one of Embodiments 25-29 or a pharmaceutically acceptable salt thereof, wherein the 5 to 10 membered heteroaryl is 1,3-thiazolyl, pyrazolyl, pyridyl, benzothiophenyl, indolyl, indazolyl, 1,3-benzothiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzoxadiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, imidazo[l,5-a]pyridinyl, or pyrazolo[3,4-b]pyridinyl. Provided herein as Embodiment 33 is the compound according to any one of Embodiments 25-29 or a pharmaceutically acceptable salt thereof, wherein the 5 to 10 membered heteroaryl is pyridyl, indazolyl, 1,3-benzothiazolyl, or quinolinyl. Provided herein as Embodiment 34 is the compound according to any one of Embodiments 25-29 or a pharmaceutically acceptable salt thereof, wherein the 5 to 10 membered heteroaryl is indazolyl. Provided herein as Embodiment 35 is the compound according to any one of Embodiments 1-24 or a pharmaceutically acceptable salt thereof, wherein Provided herein as Embodiment 36 is the compound according to any one of 5 Embodiments 1-24 or a pharmaceutically acceptable salt thereof, wherein Provided herein as Embodiment 37 is the compound according to any one of Embodiments 1-36 or a pharmaceutically acceptable salt thereof, wherein 10           X1 is CR5. Provided herein as Embodiment 38 is the compound according to any one of Embodiments 1-36 or a pharmaceutically acceptable salt thereof, wherein XI is N. Provided herein as Embodiment 39 is the compound according to any one of Embodiments 1-38 or a pharmaceutically acceptable salt thereof, wherein X2 is CH. Provided herein as Embodiment 40 is the compound according to any one of Embodiments 1-38 or a pharmaceutically acceptable salt thereof, wherein X2 is N. Provided herein as Embodiment 41 is the compound according to any one of Embodiments 1 -40 or a pharmaceutically acceptable salt thereof, wherein X3 is C. Provided herein as Embodiment 42 is the compound according to any one of Embodiments 1-40 or a pharmaceutically acceptable salt thereof, wherein X3isN. Provided herein as Embodiment 43 is the compound according to any one of Embodiments 1 -42 or a pharmaceutically acceptable salt thereof, wherein X4 is C. Provided herein as Embodiment 44 is the compound according to any one of Embodiments 1-42 or a pharmaceutically acceptable salt thereof, wherein X4 is N. Provided herein as Embodiment 45 is the compound according to any one of Embodiments 1-36 or a pharmaceutically acceptable salt thereof, wherein X! is N, X2 is N, X3 is C, and X4 is C; or X! is CR5, X2 is N, X3 is C, and X4 is C; or \ is CR5, X2 is CH, X3 is C, and X4 is C; or X! is CR5, X2 is CH, X3 is N, and X4 is C; or Xs is CR5, X2 is CH, X3 is C, and X4 is N. Provided herein as Embodiment 46 is the compound according to any one of Embodiments 1-36 or a pharmaceutically acceptable salt thereof, wherein Xs is CR5, X2 is N, X3 is C, and X4 is C. Provided herein as Embodiment 47 is the compound according to any one of Embodiments 1-37, 45, and 46 or a pharmaceutically acceptable salt thereof, wherein Rs is H, halogen, CN, -COO(CMalkyl), Ci^alkyl, C2^alkenyl, CWialoalkyl, -(CH2)m(Ci-4aikoxy), or, Cs-scycloalkyl. Provided herein as Embodiment 48 is the compound according to any one of Embodiments 1-37, 45, and 46 or a pharmaceutically acceptable salt thereof, wherein R5 is halogen, CN, or Chalky 1. Provided herein as Embodiment 49 is the compound according to any one of Embodiments 1-37, 45, and 46 or a pharmaceutically acceptable salt thereof, wherein R5 is H, F, Cl, CN, -COOCH3, methyl, -CHCH2, Cwhaloalkyl, -CH2OCH3, or cyclopropyl. Provided herein as Embodiment 50 is the compound according to any one of Embodiments 1-37, 45, and 46 or a pharmaceutically acceptable salt thereof, wherein R5 is F, Cl, CN, or methyl. Provided herein as Embodiment 51 is the compound according to any one of Embodiments 1-37, 45, and 46 or a pharmaceutically acceptable salt thereof, wherein R5 is F, Cl, or methyl. Provided herein as Embodiment 52 is the compound according to any one of Embodiments 1-40, 45, and 47-51 or a pharmaceutically acceptable salt thereof, wherein B together with the atoms to which it is attached forms a ring system selected from wherein the ring system is optionally substituted with 1 to 5 substituents R6. Provided herein as Embodiment 53 is the compound according to any one of Embodiments 1-40, 45, and 47-51 or a pharmaceutically acceptable salt thereof, wherein B together with the atoms to which it is attached forms a ring system selected from wherein the ring system is optionally substituted with 1 to 5 substituents R6. Provided herein as Embodiment 54 is the compound according to any one of Embodiments 1-40 and 45-51 or a pharmaceutically acceptable salt thereof, wherein B together with the atoms to which it is attached forms a ring system selected from wherein the ring system is optionally substituted with 1 to 5 substituents R6. Provided herein as Embodiment 55 is the compound according to any one of Embodiments 1-40 and 45-51 or a pharmaceutically acceptable salt thereof, wherein B together with the atoms to which it is attached forms a ring system selected from Provided herein as Embodiment 56 is the compound according to any one of Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula II R1 at each occurrence independently, Rz, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and 5             p is 0 to 5. Provided herein as Embodiment 57 is the compound according to any one of Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula III 10           Rl at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 3. Provided herein as Embodiment 58 is the compound according to any one of Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula IV R3- R3' R3" R' R3 -R3 R3 (IV), wherein R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R\ and R° at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 5. Provided herein as Embodiment 59 in the compound according to any one of 10 Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula V R1 r1-4 p R3- R3‘ R3^ R: • R3 R3 (V), wherein R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R3, and R° at each occurrence independently are defined as in the preceding Embodiments; 15 and p is 0 to 4. Provided herein as Embodiment 60 is the compound according to any one of Embodiments 1 -20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula VI (VI), wherein R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, md R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 5. 10           Provided herein as Embodiment 61 is the compound according to any one of Embodiments 1 -20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula VII Rl at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 5. Provided herein as Embodiment 62 is the compound according to any one of Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula VIII J P (VIII), wherein R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, 10   R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 5. Provided herein as Embodiment 63 is the compound according to any one of Embodiments 1-20 and 22,-51 or a pharmaceutically acceptable salt thereof, wherein the 15 compound is a compound of Formula IX R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and 5             p is 0 to 5. Provided herein as Embodiment 64 is the compound according to any one of Embodiments 1-20 and 22,-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula X 10           R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 5. Provided herein as Embodiment 65 is the compound according to any one of Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula XI 5           Rl at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 2. Provided herein as Embodiment 66 is the compound according to any one of 10 Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula XII R1 at each occurrence independently, Rz, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; 15 and p is 0 to 5. Provided herein as Embodiment 67 is the compound according to any one of Embodiments 1 -20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula XIII R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 5. 10           Provided herein as Embodiment 68 is the compound according to any one of Embodiments 1 -20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula XIV R at each occurrence independently, R , R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 5. Provided herein as Embodiment 69 is the compound according to any one of Embodiments 1-20 and 22-51 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula XV R3-R3 •R3 R3 (XV), wherein Rl at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding Embodiments; and p is 0 to 3. Provided herein as Embodiment 70 is the compound according to any one of Embodiments 1-54 and 56-69 or a pharmaceutically acceptable salt thereof, wherein R° at each occurrence independently is Cusalkyl, Ci-ehaloalkyl, Cwalkoxy, -R'-fCh. 5cycloalkyl),-R'-(C3-6heterocycloalkyl), -R7-(phenyl), or - R7-(5 to 6 membered heteroaryl), wherein the Ci^alkyl is optionally substituted with Ci-4alkoxy, wherein the Cs.oheterocycloalkyl is optionally substituted with Ci-ealkyl, wherein the phenyl is optionally substituted with Ci-4alkoxy, wherein the heteroaryl is optionally substituted with 1 to 3 substituents independently selected from halogen, -(CH2)i-3OH and Cwalkyl, and wherein two substituents R6 together optionally form a -(CHzV group creating a ring together with the ring atom or ring atoms to which the two substituents R" are attached, wherein the -(CIEln- group optionally has one -CH2- group substituted with an -O-atom. Provided herein as Embodiment 71 is the compound according to any one of Embodiments 1-54 and 56-69 or a pharmaceutically acceptable salt thereof, wherein R6 at each occurrence independently is Ci-ealkyl, -R'-(C3.6heterocycloalkyl), or R'-(5 to 6 membered heteroaryl), wherein the heteroaryl is optionally substituted with 1 to 3 Ci^alkyl, and wherein two substituents R6 together optionally form a -(CH2V group creating a ring together with the ring atom or ring atoms to which the two substituents R6 are attached. Provided herein as Embodiment 72 is the compound according to any one of Embodiments 1-54 and 56-69 or a pharmaceutically acceptable salt thereof, wherein R6 at each occurrence independently is methyl, isopropyl, l-methoxy-propan-2-yl, CF3, methoxy, cyclopropyl, oxetan-3-yl, 3-methyloxetan-3-yl, 4-methyl-l-piperazinyl, 4-methoxyphenyl, 4-methyl-l,3-thiazol-5-yl, 4-(hydroxymethyl)-l,3-thiazol-5-yl, 2-methyl-lH-imidazol-1 -yl, 1 -methyl-1 H-pyrazol-5 -yl, or 1,4-dimethyl-1 H-pyrazol-5 -yl wherein two substituents R° together optionally form a -(CEhV group creating a ring together with the ring atom or ring atoms to which the two substituents R° are attached, wherein the -(CH2)n- group optionally has one -CH2- group substituted w>th an -O-atom. Provided herein as Embodiment 73 is the compound according to any one of Embodiments 1-54 and 56-69 or a pharmaceutically acceptable salt thereof, wherein R° at each occurrence independently is methyl, oxetan-3-yl, or 1,4-dimethyl-lH-pyrazol-5-yl, wherein two substituents R6 together optionally form a -(CH2)n- group creating a ring together with the ring atom or ring atoms to which the two substituents R" are attached. Provided herein as Embodiment 74 is the compound according to any one of Embodiments 1-54 and 56-70 or a pharmaceutically acceptable salt thereof, wherein R is (( H . Provided herein as Embodiment 75 is the compound according to any one of Embodiments 1-54 and 56-73 or a pharmaceutically acceptable salt thereof, wherein n is 1. Provided herein as Embodiment 76 is the compound according to any one of Embodiments 1-54 and 56-73 or a pharmaceutically acceptable salt thereof, wherein n is 2. Provided herein as Embodiment 77 is the compound according to any one of Embodiments 1-54 and 56-73 or a pharmaceutically acceptable salt thereof, wherein n is 3. Provided herein as Embodiment 78 is the compound according to any one of Embodiments 1 -54 and 56-73 or a pharmaceutically acceptable salt thereof, wherein n is 4. Provided herein as Embodiment 79 is the compound according to any one of Embodiments 1-54 and 56-73 or a pharmaceutically acceptable salt thereof, wherein n is 5. Provided herein as Embodiment 80 is the compound according to any one of Embodiments 1-54 and 56-73 or a pharmaceutically acceptable salt thereof, wherein n is 6. Provided herein as Embodiment 81 is the compound according to any one of Embodiments 1-37, 45-47, 52-71, and 74-80 or a pharmaceutically acceptable salt thereof, wherein m is 0. Provided herein as Embodiment 82 is the compound according to any one of Embodiments 1-37, 45-47, 52-71, and 74-80 or a pharmaceutically acceptable salt thereof, wherein m is 1. Provided herein as Embodiment 83 is the compound according to Embodiment 1 or a pharmaceutically acceptable salt thereof, wherein the compound is 8-fluoro-2-(5-(fluoromethyl)-2-(2-propenoyl)-2,6-diazaspiro[3,41octan-6-yl)-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarbonitrile; 8-(5-methyl-lH-indazol-4-yl)~3-(4-methyl-l-piperazinyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)imidazo[l,2-a]pyridine-7-carbonitrile; 8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yr)-2-(1,3-thiazol-2-yl)imidazo[ 1,2-a]pyridine-7-carbomtrile; 4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carbonitrile; (P)-l-(6-(3,7,7-trimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazasp iro[ 3.4] octan-2-yl)-2-propen-1 -one; l-(6-(4-(6-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4] octan-2-yl)-2-pr open-1 -one; (P)-l-(6-(4-(6-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-amino-7-fluoro-l,3’benzothiazol-4-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(4-(2-amino-7-fluoro-l,3-benzothiazol-4-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1-(6-(4-(1,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazasp iro[ 3.4] octan-2-yl)-2-propen-1 -one; (P)-l-(6-(3,7,7-trimethyl-4-(6-methyl-lH-indazol-7-yl)-5,6,7,8-tetrahydro-2-quinolinyr)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(3-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1-(6-(3,7,7-trimethyl-4-(5-methyl-lH-mdazol-4-yl)-5,6,7,8-tetrahydro-2-qumolinyl)“ 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (lR,9R)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6-(5-(trifluoromethyl)-lH-indazol-4-yl)-3-azatricyclo[7.1.1.02, / ]undeca-2,4,6-triene-5-carbonitrile; l-(6-(4-(6-chloro-5-methyl-lH-indazol~4-yl)-3,7,7-trimethyl-7,8-dihydrO“5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-(lR,8S)-6-(3-hydroxy-l-naphthalenyl)-4-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile; (lR,8S)-6-(3-hydroxy-l-naphthal enyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2,1.02,7]undeca-2,4,6-triene-5-carbonitrile or (lS,8R)-6-(3-hydroxy-l-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile; (M)-(lR,8S)-6-(3-hydroxy-l-naphthalenyl)-4-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile; (lR,9R)-6-(6-hydroxy-8-isoqumolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1 Xj2’7]undeca-2,4,64riene~5-carbonitrile; (lR,9R)-6-(7-hydroxy-5-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’']undeca-2,4,6-triene-5-carbonitrile; (P)-(lR,9R)-6-(6-hydroxy-8-quinoliny 1)-10,10-dimethyl-4-(2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’7]undeca-2,4,6-triene-5-carbonitrile; (P)-(lR,9R)-6-(7-hydroxy-5-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbomtrile; l-(6-(7-methoxy-3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 8-(3-hydroxy-l-naphthalenyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile; (M)-8-(3-hydroxy-l-naphthalenyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile; l-((5S)-5-methyl-6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l"((5S)-6"(7-fluorO”3-methyl”4-(5"methyl~lH"indazol-4”yl)”2-qumolinyl)“5-methyl-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (1 R,9R)-6-(2-chloro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-3-azatricyclo[74 Jd)2, / ]undeca-2,4,6-triene-5-carbonitrile; (lR,9R)-6-(2-fluoro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene~5-carbonitrile; (lR,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02-?]undeca-2,4,6-triene-5-carbonitrile; (P)-( 1 R,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02-7]undeca-2,4,6-triene-5-carbonitrile; (P)-( 1 R,9R)-6-(2-cliloro-5 -hydroxyphenyl)-10,10-dimethy 1-4-(2-(2 -propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile; l-(6-(3-chloro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3,4]octan-2-yl)-2-propen-1 -one; (P)-l-(6-(3-chloro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimetliyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(3-chloro-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-l-(6-(3-chloro-4-(l,6-dimethyl-lH-indazol-7-y 1)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(3-chloro-4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro

[34] octan-2-yl)-2-propen-l-one; (M)-l-(6-(3-chloro-4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; l-(6-(3-chloro-4-(6-chloro-5-methyl-lH-indazol-4-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; l-(5-methyl-lH-indazol-4-yl)-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)- 5,6,7,8-tetrahydro-2-naphthalenecarbonitrile; 8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3J4-dihydro-lH-2-benzopyran-7-carbonitrile; 1 -(1,6-dimethyl-1 H-indazol-7-yl)-6,6-dimethyl-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-2-naphthalenecarbonitrile; 3'-hydroxy-6,6-dimethyl-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5>6,7,8-tetrahydro[ 1,1 '-binaphthalene]-2-carbonitrile; (P)-8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-lH-2-benzopyran-7-carbonitrile; 8-(1,6-dimethyl-lH-indazol-7-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile; l-(6-(7-chloro-8-(l,6-dimethyl-lH-indazol-7-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 8-(5-chloro-lX)-dimethyl-lH-indazol-7-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile; 2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-metliyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 8-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-6-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile; (P)-l-(6-(3-chloro-4-(6-chloro-5-methyl-lH-indazol-4-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(7-chloro-8-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-l-(6-((lS,8R)-5-methyl-6-(l,5,6-trimethyl-lH-indazol-7-yl)-3- azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyri din-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (lR,9R)-6-(7-fluoro-5-methyl-lH-indazol-4-yl)-10,10-dimethyl-4-(2-(2-propenoyl)- 2,6-diazaspiro[3.4]octan-6-yi)-3-azatricycio[7.1.1.02’7]undeca-2,4,6-triene-5-carbonitrile; 4-(5-chloro-lH-indol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (1 R,9R)-6-(5-chloro-6-methyl-l H-indazol-4-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,']undeca-2,4,6-triene-5-carbonitrile; (1 R,9R)-10,10-dimethyl-6-(7-methylimidazo[ 1,5-a]pyridin-8-yl)-4-(2-(2-propenoyl)- 2,6-diazaspiro[3.4]octan-6-yr)-3-azatricyclo[7.1.1.0z’ / ]undeca-2,4,6-triene-5-carbonitrile; 4-(3-chloro-6-methyl-lH-indol-7-yl)-7J-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; l-(6-(4-(5-diloro-l,6~dimethyl-lH-indazol-7-yl)-3-methyl-7-(2-propanyl)-5,6,7,8-tetrahydro-l,7-naphthyridm-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3-methyl-7-(2-propanyl)- 5,6,7,8-tetrahydro-l J-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(3-methyi-7-(2-propanyl)-4-(l,5,6-trimethyl-lH-indazol-7-yl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (I R,9R)-6-(2-chloro-3-fluoro-5-hydroxyphenyl)-10,10-dimetbyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’7]undeca-2,4,6-triene-5-carbonitrile; (lR,9R)-6-(2-chloro-5-hydroxy-3-pyridinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’,']uiideca-2,4,6-triene-5-caibonitrile; (P)-(lR,9R)-6-(7-hydroxy-5-quinoxalinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’7]undeca-2,4,6-triene-5-carbonitrile; 4-(6-hydroxy-l-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octaii-6-yl)“7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carboiiitrile; (M)-l-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyri din-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-chloro-5-hydroxy-3-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-((2H3)-2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 2-(2-((2E)-4-(dimethylamino)-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 2-(2-((2E)-4,4-difluoro-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-metliyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (7R)-4-(5-methyl-lH-indazol-4-yl)~2-(2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)-7-(trifluoromethyl)-5,6,7,8-tetrahydro-3~quinolinecarbonitrile or (7S)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(trifluoromethyl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4'-(5-methyl-lH-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7',8'-dihydro-5'H-spiro[cyclopropane-l,6'-quinoline]-3'-carbonitrile; 6,6-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)~2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile; (5R,7S)-5,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile or (5S,7R)- 5>7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 4-(5-methyl-lH-mdazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,r-cyclopropane]-3-carbonitrile; 4-( 1,6-dimethyl-1 H-indazol-7-yl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-6J-dihydro-3H-cyclopenta[b]pyridine-3-cafbonitrile; (P)-4-(l,6-dimethyl-lH-indazol-7-yl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile; (7R)-4-(2-chlorophenyl)-7-(l-methyl-lH-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] odan-6-yl)“5,6;7,8-tetrahydrO“3-quinolinecarbonitrile or (7S)-4-(2-chlorophenyl)-7-(l-methyl-lH-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (7R)-4-(2-chlorophenyl)-7-(l-methyl-lH-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydrO’3-quinolinecarbonitrile; (7S)-4-(2-chlorophenyl)-7-(l-methyl-lH-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (7R)-4-(2-fluorophenyl)-7-(l-methyl-lH-pyrazol-5-yl)-2-(2-(2-propenoyl)-2.,6-diazaspiro

[34] octan-6-yl)-5,6,73-tetrahydro-3-quinolinecarbonitrile or (7S)-4-(2-fluorophenyl)-7-(l-methyl-lH-pyrazol-5-yl)-2-(2’(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (P)-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; l-(6-(3-(difluoromethyl)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(1,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3,4]octan-6-yl)“7,8-dihydro-5H-pyrano[4,3"b]pyridine-3-carbonitrile; 4'-(5-methyl-lH-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-2,3,5,5',6,8'-hexahydrospiro[pyran-4,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile; (3R)-4'-(5-methyl-lH-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4,5,5',8'-tetrahydrospiro[furan-3,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile or (3S)-4'-(5-methyl-1H-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4,5,5',8’-tetrahydrospiro[furan-3,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile; 6,6-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile or 6,6-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile; (P)-6,6-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile; (P)-4-(l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridme-3-carbonitrile; (6aR,7 aR)-4-( 1,6-dimethyl-1 H-indazol-7 -yl)-2-((5R)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3 / 4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aR,7aR)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-y 1)-6,6a, 7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aR,7aS)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-((5R)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aR,7aS)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6"diazaspiro

[34] octan-6-yl)-6,6a,7,7a-tetrahydrO“5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aR)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-((5R)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aR)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3 / 4]octan-6-yl)-6,6a,7,7a”tetraliydro-5H-cyclopropa[h]quinoline-3" carbonitrile or (6aS,7aS)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-((5R)-5-0iydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aS)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile; 4-(3-hydroxy-l-naphthalenyl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-caibonitrile; (P)-4-(34iydroxy-l-naphthalenyl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile; (P)-(6aR,7aS)-4-(4-fluoro-3-hydroxy-l-naphthalenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile; (M)-(6aR,7aS)-4-(4-fluoro-3-hydroxy-l-naphthalenyl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan”6-yl)-6,6a,7,7a-tetrahydro-5H"Cyclopropa[h]quinoline-3-caibonitrile; (P)-4-(4-fluoro-3-hydroxy-l-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (M)-2-((5S)-5-(fluoromethyl)’2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile and (P)-2-((5R)-5-(fluoromethyl)-2-(2-propenoyr)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (5aR,6aR)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[l,2-b]pyridine-3-carbonitrile or (5aR,6aS)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[l,2-b]pyridine-3-carbonitrile or (5aS,6aR)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[l,2-b]pyridine-3-carbonitrile or (5aS,6aS)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[l,2-b]pyridine-3” carbonitrile; (4bR,5aR)-4-(5-methyl- lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3,4]octan-6"yl)"4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[l,2-b]pyridine-3~ carbonitrile or (4bR,5aS)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diaz^piro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[l,2-b]pyridine-3-carbonitrile or (4bS,5aR)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile or (4bS,5aS)-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[l,2-b]pyridine-3-carbonitrile; (6R)-6-cyclopropyl-4-(5-methyl-lH-mdazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile or (6S)-6-cyclopropyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridme-3-carbonitrile; (4bR,5aR)-5,5-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan”6-yl)-4b,5,5a,6"tetrahydrocyclopropa[3,4]cyclopenta[l,2"b]pyridme-3-carbonitrile or (4bR,5aS)-5,5-dimethyl-4-(5-methyl-1 H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[l,2-b]pyridine-3-carbonitrile or (4bS,5aR)-5,5-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6’ diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[l,2-b]pyridine-3-carbonitrile or (4bS,5aS)-5,5-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[l,2-b]pyridine-3-carbonitrile; (P)-(6aR,7aS)-2-(2-((2E)-4-(dimethylamino)-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(3-hydroxy-l-naphthalenyl)-6,6a,7>7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile (3rd eluting isomer); (P)-(6aS,7aR)-2-(2-((2E)-4-(dimethylamino)-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(3-hydroxy-l-naphthalenyl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile; 7,7”dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yi)-4-(l,5,6-trimethyl-lH-indazol-7-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(l,5,6-trimethyl-lH-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (P)-7;7~dimethyl-2-(2"(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(l,5,6-trimethyl-lH-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (lR,9R)-10,10-dimethyl-6-(5-methyl-lH-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-3-azatricyclo[74 Jd)2, / ]undeca-2,4,6-triene-5-carbonitrile; (lR,9R)“10J0-dimethyl-6-(5-methyl-lH-indazol-4-yl)~4-((5R)-5-metbyi-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan"6-yl)-3-azatricyclo[7.1.1.02’']undeca-2,4,6-triene-5" carbonitrile or (1 R,9R)-10,10-dimethyl-6-(5-methyl-1 H-indazol-4-yl)-4-((5S)-5-methyl-2-(2- propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatncyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile; 7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-caibonitrile; 4'-(5-methyl-lH-indazol-4-yl)-2'-(2-(2-propenoyr)-2,6-diazaspiro[3.4]octan-6-yr)-5',8'-dihydrospiro[cyclobutane-l,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile; 7,7’dimethyl-4-(5-methyl-lH-indazol’4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6"yl)"5,7-dihydrofuro[3,4"b]pyridme-3-carbonitrile; 4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydrospiro[cyclopenta[b]pyridine-7,r-cyclopropane]-3-carbonitrile; (1 R,9R)-6-( 1 ,6-dimethyl-1 H-indazol-7-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1 a92’7]undeca-2,4,6-taene~5-carbonitrile; (M)-(lR,9R)-6-( 1,6-dimethyl- lH-indazol-7-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,']undeca-2,4,6-triene-5-carbonitrile; (lR,9R)-6-(3-hydroxy-l -naphthalenyl)-l 0,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3,4]octan-6-yl)-3-azatricyclo[7.1.1.02’7']undeca-2,4,6-triene-5-carbonitrile; (ls,9s)-6-(l,6-dimethyl-lH-indazol-7-yl)-4-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-cwbomtTile; 4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (ls,9s)-6-(54iydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02-7]undeca-2,4,6-triene-5-carbonitrile; (M)-( 1 R,9R)-10,10-dimethyl-6-(5-methyl-1 H-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02-?]undeca-2,4,6-triene-5-caibonitrile; (6aR,7aS)-4-(l.,6-dimethyl-lH-indazol-7-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3,4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aR)-4-(l,6<limethyl4H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile; (M)-(ls,9s)-6-(l,6-dimethyl-lH-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02, / ]undeca-2,4,6-triene-5-carbonitrile; (P)-(ls,9s)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene~5-carbonitrile; (P)-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (P)-( 1 R,9R)-6-(3-hydroxy-1 -naph thalenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1 .02’7']undeca-2,4,6-triene-5-carbonitrile; (ls,9s)-3-(l,6-dimethyl-lH-indazol-7-yl)-5-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-4-carbomtrile; (M)-(ls,9s)-3-(l,6-dimethyl-lH-indazol-7-yl)-5-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6-azatricyclo[7.1.1.02- / ]undeca-2,4,6-triene-4-carbonitrile; (M)-(6aR,7 aS)-4-( 1,6-dimethyl-1 H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile; (M)-(6aS,7aR)-4-(l,6-dimethyl-lH-indazol-7-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile; 4-( 1,6-dimethyl-1 H-indazol-7-yl)-7,7 -dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(5-chloro-lH-indazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octaii-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (P)-4-(l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(7-fluoro-5-methyl-lH-indazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(7-fluoro-5-methyl-lH-indazol-4-yl)-7,7-dimetliyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 4-(5-chloro-lH-indazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 7,7-dimethyl-4-(5-methyl-lH-pyrazolo[3,4-b]pyridin-4-yl)-2-(2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yr)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(2-chloro-54iydroxy-3-methylphenyl)-7 J-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 4-(2-amino-3,5-dichloro-6-fluorophenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (P)-4-(2-amino-3,5-dichloro-6-fluorophenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2>6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; l-(6-((lR,9R)-5-fluoro-6-(3-hydroxy-l-naphthalenyl)-10,10-dimethyl-3- azatricyclo[7.1.1.02’ / ]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(6-fluoro-5-methyl-lH-indazol-4-yl)-2’(2-(2-propenoyl)-2,6’diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; (lS,8R)-6-(5-methyl-lH-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02?]undeca-2,4,6-triene-5-carbonitrile; (lR,8S)-6-(5-methyMHdndazol-4-yl)-4-(2-(2qjropenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02-7]undeca-2,4,6-triene-5-carbonitrile; (P)-(lS,8R)-6-(5-methyl-lH-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02-?]undeca-2,4,6-triene-5-caibonitrile; (lR,8S)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02, / ]undeca-2,4,6-triene-5-carbonitrile; (P)-(lS,8R)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6"yr)"3-azatricyclo[6.2.1.02’7]undeca-2,4,6-triene-5-carbomtrile; (P)-(lR,8S)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octari-6-yl)-3-azata'cyclo[6.2.1.02’ / ]undeca-2,4,6-triene-5-carboriita'le; (lS,8R)-6-(l,6-dimethyl4H4ndazol-7-yl)-4-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-3~azatricyclo[6.2,1.02’7]undeca-2,4,6-triene~5”Carbonitrile; (P)-( 1 S,8R)-6-(l ,6-dimethyl-1 H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02-?]undeca-2,4,6-triene-5-caibonitrile; 4-(6-chloro-5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.41octan-6-yl)-3-quinolinecarbonitrile; 7-cyclopropyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 2-(8,8-difluoro-2-(2-propenoyl)-2,6-diaz^piro[3.4]octan-6-yl)-7-methoxy-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarbonitrile; 7-methoxy-4-(5-methyl-lH-mdazol-4-yl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4] octan-6-yl)-3-quinolinecarbonitrile or 7-methoxy-4-(5-methyl-1 H-indazol-4 -yl)-2-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; l-(6-(3,7,7-trimeth.yl-4-(5-methyl-lH-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (1 R,9R)-6-(lH-mdazol-7-yl)-l 0,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1a92,7]undeca-2,4,6-taene~5-carbonitrile; l-(6-(4-(3-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-( 1 R,9R)-6-(l H-indazol-7-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.14)2’7]undeca-2,4,6-triene-5-carbonitrile; (M)-l-(6-(4-(5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one; (P)-l-(6-(3,7,7-trimethyl-4-(5-methyl-lH-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro

[34] octan-2-yl)-2-propen-l-one; (P)-l-(6-(4-(2-amino-7-fluoro-l,3-benzothiazol-4-yl)-3,7,7-tomethyl-7,8-dihydro-5H"pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2"propeB-l"One; 1-(6-(3,7,7-trimethyl-4-(l, 5,6-trimethyl-lH-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-1-(6-(3,7,7-trimethyl-4-(l, 5,6-trimethyl- lH-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-l-naphthalenyl)-3,7,7-trimethyi-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(4-(6-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(2-chlorophenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(l,3,5-trimethyl-lH-pyrazol-4-yl)-3-quinolinecarbonitrile; (1 R,9R)-10,10-dimethyl-6-(6-methyl-1 H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02-?]undeca-2,4,6-triene-5-caibonitrile; l-(6-((lR,9R)-5-fluoro-6-(5-hydroxy-2-methylphenyl)-10,10-dimetliyl-3-azatricyclo[7.1.1.02,']undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-(lR,9R)-10,10-dimethyl-6-(6-methyl-lH-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1 a02’7]undeca-2,4,6-triene~5-carbonitrile; 4-(2-amino-7-fluoro-l,3-benzothiazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (P)-4-(2-ammo-7-fluoro-l,3-benzothiazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3A]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (P)-1 -(6-(( 1 R,9R)-5 -fluoro-6-(5-hydroxy-2-methylphenyl)-10,1O-dimethyl-3 -azatricyclo[7.1.1.02’']undeca-2,4,6-trien-4-yl)-2,6-diaz^piro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(3-fluoro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyri din-2 -yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l -one; (P)-l-(6-(3-fluoro-4-(3-hydroxy-l-naphthal enyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1 -(6-((1 R,9R)-5-fluoro-10,10-dimethyl-6-(5-methyl-1 H-indazol-4-yl)-3- azatricyclo[7.1.1.0z’7]undeca-2,4,6-taen-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-l -(6-((1 R,9R)-5-fluoro-l 0,10-dimethyl-6-(5-methyl-lH-indazol-4-yl)-3- azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-1 -(6-(( 1 R,9R)-5-fluoro-6-(3 -hydroxy-1 -naphthalenyl)-10,10-dimethyl-3 -azatricyclo[7.1.1.0z’7]undeca-2,4,6-taen-4-yl)-2,6-diazaspiror3.4]octan-2-yl)-2-propen-l-one; (M)-l-(6-(4-(5-chloro-l,6-dimefnyl-lH-indazol-7-yl)-3-fluoro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3,4]octan-2-yl)-2-propen-l-one; 7,7-dimethyl-4-(6-methyl-lH-indazol-7-yl)~2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (P)-7,7-dimethyl-4-(6-methyl-lH-indazol-7-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; (1 R,9R)-6-(2-chloro-4-fluoro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’']undeca-2,4,6-triene-5-carbonitrile; l-(6-(4-(5-chloro-6-methyl-lH-indazol-7-yl)-3-fluoro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(5-hydroxy-2-(trifluoromethyl)piienyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(5-chloro-l,6-dimethyl-lH-mdazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(5-chloro-6-methyl-lH-indazol-7-yi)-7,7~dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; l-(6-((7R)-4-(2,4-difluorophenyl)-7-(l,4-dimethyl-lH-pyrazol-5-yl)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-((7R)-4-(l,6-dimethyl-lH-indazol-7-yl)-7-(l,4-dimethyl-lH-pyrazol-5-yl)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-l-(6-(4-(3-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-chloro-l,5-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 2-amino-7-fluoro-4-(3,7,7-trimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-4-yl)-l-benzothiophene-3-carbonitrile; (M)-l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3-fluoro-7-(3-oxetanyl)- 5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-1 -(6-(4-( 1,6-dimethyl-1 H-indazol-7-y 1)-3,7,7-trimethy 1-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(5-methyl-lH-indazol-4-yl)-7-(l-methyl-lH-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3,4]octan-6-yl)-3-quinolinecarbonitrile; l-(6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-7-(4-methyl-l,3-thiazol-5-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; 4-(2-chlorophenyl)-7-(l -methyl- lH-imidazol-2-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 1 -(6-(4-(2-chloro-5-hydroxyphenyl)-3-methyl-7-(1 -methyl-1 H-pyrazol-5-yl)-2-quinolinyl)-2,6-diazasp iro[ 3.4] octan-2-yl)-2-propen-1 -one; 4-(2-chlorophenyl)-2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(1 -methyl-1 H-pyrazol-5-yl)-3 -quinolinecarbonitrile; 4-(2-chlorophenyl)-7-(2-methyl-lH-imidazol-l-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-7-(2-methyl-lH-imidazol-l-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-7-(5-methyl-lH-imidazol-l-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-chlorophenyl)-7-(5 -methyl-1 H-imidazol-1 -yl)-2-(2-(2 -propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; l-(6-(4-(6-hydroxy-l-naphthalenyl)-3-metliyl-7-(2-propanyl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(4-(6-hydroxy-l-naphthalenyl)-3-methyl-7-(2-propanyl)-5.,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-l-naphthalenyl)-3,7-dimethyl-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-l-naphthalenyl)-3-methyl-7-(3-oxetanyl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1 -(6-(4-(6-hydroxy-1 -naphthalenyl)-7-((2R)-1 -methoxy-2-propanyl)-3-methyl-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one or 1-(6-(4-(6-hydiOxy-l-naphthalenyl)-7-((2S)-l-methoxy-2-propanyl)-3-methyl-5,6,7,8-tetrahydro- l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-fluoro-5-hydroxyphenyl)-3-methyl-7-(4-methyl-l,3-thiazol-5-yl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(7-cyclopropyl-4-(6-hydroxy-l-naphthalenyl)-3-methyl-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-l-naphthalenyl)-3-metliyl-7-((2R)-3,3,3-tnfluoro-2-hydroxypropyl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one or l-(6-(4-(6-hydroxy-l-naphthalenyl)-3-methyl-7-((2S)-3.3,3-trifluoro-2-hydroxypropyl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; l-(6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-7-(2-propanyl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(2,3-dimethylphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-l,5-naphthyridine-3-carbonitrile; 4-(2-metliylplienyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-qumolinecarbonitrile; (P)-4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2,4-difluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-l,5-naphthyridine-3-carbonitrile; 4-(2-chlorophenyl)-7-(2-(hydroxymethyl)-4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-l,5-naphthyridine-3-carbonitrile; 4-(2-fluorophenyl)-7-(4-(hydroxymethyl)-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4] octan-6-y 1)-1,5-naphthyridine-3-carbonitrile; (P)-4-(2-methylphenyl)-7-(4-!r!ethyl-l,3-tbiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-3-quinolinecarbonitrile; (M)-4-(2-metbylphenyl)-7-(4-Enethyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; (M)-4-(2,3-dimethylphenyr)-7-(4-metliyl-l,3-thiazol-5-yr)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-l,5-naphthyridine-3-carbonitrile; (P)-4-(2,3-dimethylphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-y 1)-1,5-naphthyridine-3-carbonitrile; 4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; (P)-4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolmecarbonitrile; 4-(2,3*dimethylphenyl)-7-(4-meth.yl-l,3*thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-l,5-naphthyridine-3-carbomtrile; (M)-4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)4,5-naphthyridine-3-carbonitrile; (P)-4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-l,5-naphthyridine-3-carbonitrile; 4-(2,4-difluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-y 1)-1,5-naphthyridine-3-carbonitrile; 4-(2-fluorophenyl)-7-(4-(methoxymethyl)-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-qumolinecarbonitrile; 4-(2-fluorophenyl)-7-(4-(hydroxymethyl)-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6J,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(2,4-difluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l J-naphthyridine-3-carbonitrile; (8R)-4-(2-fluorophenyl)-8-methyl-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-y 1)-5,6,7,8-tetrahydro-l J-naphthyridine-3-carbonitrile or (8S)-4-(2-fluorophenyl)-8-methyl-7-(4-methyl-1,3-thi azol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3,4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; (8R)-4-(2-fluorophenyl)-8-methyl-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(2,4-difluorophenyl)-7-(4-methoxyphenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(2-chlorophenyl)-7-(4-metliyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(2-chloiO-5"hydroxyphenyl)-7"(4-methyl”l,3-thiazol-5-yl)-2"(2-(2"piOpenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(3-fluoro-2-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(2,4-difluorophenyl)-2-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(4-methyl-l>3-thiazol-5-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(2,4-difluorophenyl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(4-methyl-l,3-thiazol-5-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 4-(2-fluoro-5-hydroxyphenyl)-7-(4-inethyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; (P)-4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-5,6,7,8-tetrahydro-l,7-naph1hyridine-3-carbonitrile; (M)-4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; (P)-4-(2’Chloro-5-hydroxyphen.yl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)’ 2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphth.yridine-3-cafbonitrile; 4-(3-fluoro-2-pyridinyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-((2H3)-2-propenoyl)-2,6-diazaspiro

[34] octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; 7-cyclopropyl-4-(2-fluorophenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; l-(6-((7R)-4-(2,3*dimethylphenyl)-7-(4-methyl-l,3*tbiazol-5-yl)-5,6,7>8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; (7R)-4-(2-methylpheny])-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile or (7S)~4-(2-methylphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (M)-(7R)-4-(2-methylphenyl)-7-(4-methyl-l,3-™azol-5-yl)-2-(2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-qinnolinecarbonitrile; (P)-(7S)-4-(2-methylphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydrO’3-quinolinecarbonitrile; (P)-(7R)-4-(2-methylphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (M)-(7S)-4-(2-methylphenyl)-7-(4-melhyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diaz^piro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(2-methylphenyl)-7-(4-methyl-l,3-thiazol-5-yr)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; (7S)-4-(2-fluorophenyl)-7-methyl-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (7R)-4-(2-fluorophenyl)-7-methyl-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(2-chlorophenyl)-7-(1 -methyl-1H -pyrazol-5 -yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-qumolinecarbonitrile; (7R)-4-(2,4-difluorophenyl)-7-(4-methyl-13-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro

[34] oc4an-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridiiie-3-carboiiitrile or (7S)-4-(2,4-difluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 4-(2-diloro-4-fluorophenyi)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-y 1)-5,6-dihydro-3-quinolinecarbonitrile; 4-(2,4-difluorophenyl)-7-(4-methyl~l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3,4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; (M)-4-(2-methylplieiiyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propeiioyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; (P)-4-(2-methylphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; (7R)-4-(2-chloro-4-fluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile; 4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(4-fluorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-qumolinecarbonitrile; (P)-4-(2’Chloro-4-fluorophen.yl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(2-chloro-6-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(2-fluoro-5-methoxyphenyl)-7-(4-methyl-l,3-tbiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6’dihydro-3-quinolinecarbonitrile; 4-(2-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-y 1)-5,6-dihydro-3-quinolinecarbonitrile; (P)-4-(2-chlorophenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-qumolinecarbonitrile; 4-(2-chloro-5-hydroxyphenyl)-7-(4-methyl-13-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diaz^piro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(2,3-difluorophenyl)-7-(4-methyl-l, 3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbomtrile; 4-(2-fluoro-5-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6’dihydro-3-quinolinecarbonitrile; 4-(2-fluoro-6-methylphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; (P)-4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6"yl)"5,6-dihydrO"3-quinoiinecarbonitriie; 4-(2-fluorophenyl)-7-(4-(methoxymethyl)-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(3-fiuoro-2-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; 4-(3-hydroxyphenyl)-7-(4-methyl-l ,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6’dihydro-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-7-(4-(hydroxymethyl)-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile; (7R)-4-(3-fluoro-2-pyridinyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile or (7S)-4-(3-fluoro-2-pyridinyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; (7S)-4-(3-fluoro-2-pyridinyl)-7-(4-methyl-l, 3-thiazol-5-y 1)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(2-chloro-5-(difluoromethyl)phenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3 / 4]octan-6-yl)-5,6 J,8-tetrahydro-l,7-naphthyridine~3-carbonitrile; (6R)-4-(5-methyl-lH-indazol-4-yl)-6-(2-propanyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile or (6S)-4-(5-methyl -1 H-indazol-4-yl)-6-(2-propanyl)-2-(2-(2-propenoyl)-2,6-diazaspiro [3.4] octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridme-3-carbonitrile; (P)-l-(6-(3-ethenyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(3-fluoro-7-methoxy-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6”(3-diloro-4-(5-methyl”lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one; l-(6-(7-chloro-8-(5-methyl-lH-indazol-4-yl)-3,4-dihydro-2H-chromen-6-yr)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 4-(2-fluoro-3-hydroxyphenyl)-7-(4-methyl-l,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-l,7-naphthyridine-3-carbonitrile; (P)-1 -(6-(4-( 1,6-dimethyl-l H-indazol-7-y4)-3-methyl-7-(3-methyl-3-oxetanyl)-5,6,7,8-tetrahydro-l J-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-7,7-dimethyl-4-(5-methyl-lH-mdazol-4-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; l-(6-(4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 8-(5-methyl-lH-indazol-4-yl)-2-phenyl-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)imidazo[ 1,2-a]pyridine-7-carbonitrile; 7-methoxy-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-7’methyl-4’(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile; (7)-2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(5,6-dimethyl-l H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)- 3-quinolinecarbonitrile; or 4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diaz^piro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile. Provided herein as Embodiment 84 is the compound according to Embodiment 1 or a pharmaceutically acceptable salt thereof, wherein the compound is l-(6-(4-(3-hydroxy-l-naphthalenyl)-3,7,7-trimethyi-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1 -(6-(5-0 uoro-6-(3-hydroxy-1 -naphthalenyl)-10,10-dimethyl-3- azatricyclo[7.1 J .02, Jundeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(3-chloro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(3-cliloro-5-hyd.roxy-2-methylphenyl)-3,7,7-trimethyl-7,8-diliydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(5-methyl-6-(l,5,6-trimethyl-lH-indazol-7-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one; 1 -(6-(5-fluoro-10,10-dimethyl-6-(5-methyl-1 H-mdazol-4-yl)-3- azatricyclo[7d J.02’']undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yr)-2-propen-l-one; l-(6-(3-fluoro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2’propen-l’One; l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3-fluoro-7-(3-oxetanyl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; or 1-(6-(4-(2,4-difluorophenyl)-7-(l,4-dimethyl-lH-pyrazol-5-yr)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. Provided herein as Embodiment 85 is the compound according to Embodiment 1 or a pharmaceutically acceptable salt thereof, wherein the compound is (M)-l-(6-(4-(3-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-((lR,9R)-5-tluoro-6-(3-hydroxy-l-naphthalenyl)-10,10-dimethyl-3- azatricyclo[7.1.1.02’ / ]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-1 -(6-( 3-chloro-4-(3-hydroxy-1 -naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3,4]octan-2-yl)-2-propen-l-one; (M)-l-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l -one; (M)-1-(6-((1 S,8R)-5-methyl-6-(l ,5,6-trimethyl- lH-indazol-7-yl)-3- azatricyclo[6.2.1.02’']undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyri din-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-1 -(6-((1 R,9R)-5-fluoro-10,10-dimethyl-6-(5-methyl- lH-indazol-4-yl)-3 - azatricyclo[7J.1.02’ / ]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(3-fluoro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-blpyridin-2-yl)-2,6-diazaspiro[3,41octan-2-yl)-2-propen-l-one; (M)-l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3-fluoro-7-(3-oxetanyl)- 5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; or l-(6-((7R)-4-(2,4-difluorophenyl)-7-(l,4-dimethyl-lH-pyrazol-5-yl)-3-methyl- 5,6,7,8-tetrahydro-2-quinolinyr)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. Provided herein as Embodiment 86 is the compound according to Embodiment 1 or a pharmaceutically acceptable salt thereof, wherein the compound is (P)-l-(6-(4-(3-hydroxy-1 -naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3- b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-1 -(6-((1 R,9R)-5-fluoro-6-(3my droxy-1 -naphthalenyl)-10,10-dimethyl-3- azatricyclo[7.1.1.0z’ / ]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-1 -(6-(( 1 S,9S)-5-fluoro-6-(3-hydroxy-1 -naphthalenyl)-10,10-dimethyl-3- azatricyclo[7.1.1.02’ / ]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-1 -(6-((1 S,9S)-5-fluoro-6-(3-hydroxy-1 -naphthalenyl)-10,10-dimethyl-3- azatricyclo[7.1.1.02’']undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-l-(6-(3-chloro-4-(3-hydroxy-l-naphthalenyl)-?,7-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyri din-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-l-(6-((lS,8R)-5-methyl-6-(l,5,6-trimethyl-lH-indazol-7-yl)-3- azatricyclo[6.2.1.0z’7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-1 -(6-((1 R,8S)-5-methyl-6-(l ,5,6-trimethyl-lH-indazol-7-yl)-3- azatricyclo[6.2.1.02’ / ]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-1 -(6-(( 1 R,8S)-5 -methyl-6-( 1,5,6-trimethyl-1 H-indazol-7-yl)-3- azatricyclo[6.2.1.02’']undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-l-(6-(4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro- 5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3,4]octan-2-yl)-2-propen-l-one; (P)-1 -(6-(( 1 R,9R)-5-fluoro-10,10-dimethyl-6-(5-methyl- lH-indazol-4-yl)-3- azatricyclo[7J4 A)2, / ]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-1 -(6-( (1 S,9S)-5-fluoro-10,10-dimethyl-6-(5-methyl-1 H-indazol-4-yl)-3- azatricyclo[7.1.1.0z’7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-1 -(6-((1 S,9S)-5-fluoro-10,10-dimethyl-6-(5-methyl-1 H-mdazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one; (M)-l-(6-(3-fluoro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H- pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one; (P)-l-(6-(4-(5-chloro-l,6-dimethyl-lH-mdazol-7-yl)-3-fluoro-7-(3-oxetanyl)-5,6,7,8-tetrahydro-l,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; or l-(6-((7S)-4-(2,4-difluorophenyl)-7-(l,4-dimethyl-lH-pyrazol-5-yl)-3-methyl- 5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one. Provided herein as Embodiment 87 is a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1 at each occurrence independently is H, Ci ^alkoxy, -(CH2)-CMdialkylamino, aziridin-1 -yl-methyl, azetidin-1 -yl-methyl, pyrrolidine-1 -yl-methyl, piperidin-1 -yl-methyl, or morpholin-1 -yl-methyl; R2 is H, halogen, -CN, Cwalkyl, Ci^haloalkyl, -CFLCN, -CH2OH, Cwalkoxy, or Ci. 4haloalkoxy; wherein, optionally, one R1 and Rz together with the carbon atoms to -which they are |     __pi attached form a *         group; R3 at each occurrence independently is H, halogen, CN, OH, C Malkyl, Ci-4haloalkyl, -CH2CN, -CH2OH, Cwalkoxy, or Ci-4haloalkoxy, wherein two substituents R3 attached to the same carbon atom optionally form together with said carbon atom a C3-6cycloalkyl or a carbonyl group; A at each occurrence independently is CR3R3 or absent; R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl, wherein the aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from OH, halogen, -CN, NH2, Cwalkyl, CiJialoalkyl, Ci-4alkoxy, or Cwhaloalkoxy; X! is C IC or N; X2 is CH, CF, or N; X3 is C or N; X4isCorN; R5 is H, halogen, CN, Chalky!, Ci.4haloalkyl, Cwalkoxy, CiJialoalkoxy, C3. scycloalkyl, CXscyclohaloalkyl, or Cs-sheterocycloalkyl; B together with the atoms to which it is attached forms a 4 to 7 membered fully saturated, fully unsaturated, or partially unsaturated carbocyclic or heterocyclic ring system, wherein the heterocyclic ring system comprises 1 to 5 heteroatoms independently selected from N, O, and S, wherein the ring system is optionally substituted with 1 to 5 substituents R6; R6 at each occurrence independently is halogen, OH, -CN, -NH2, Cuealkyl, Ci. ehaloalkyl, Cwalkoxy, Cwhaloalkoxy, Cj-scycloalkyl, Cs-scyclohaloalkyl, phenyl, or 5 to 6 membered heteroaryl, wherein the Ci-ealkyl is optionally substituted with -CO(Ci-4alkylamino) or -CO(Ci-4dialkylamino), wherein the phenyl is optionally substituted with 1 to 3 independently selected halogens, wherein the heteroaryl is optionally substituted "with 1 to 3 substituents selected from halogen, Ci^alkyl, and CMhaloalkyl, wherein two substituents R6 together optionally form a -(CH2)n- group creating a ring together with the ring atom or ring atoms to "which the two substituents R6 are attached, wherein the -(CH?),,- group optionally has one -CH2-group substituted with one heteroatom selected from N, O, and S; and n is 1, 2, 3, or 4. Provided herein as Embodiment 88 is the compound according to Embodiment 87 or a pharmaceutically acceptable salt thereof, wherein R4 is not 2-fluoro-5-cyano-phenyl, 2-methyl’5-hydroxymethyl-phenyl, 2-chloro-5-(difluoromethoxy)phenyl, 2-methyl-5-(difluoromethyl)-phenyl, 6-amino-3-methyl-pyridin-2-yl, 6-hydroxy-2-methyl-naphthalen-l-yl, isoquinolin-4-yl, or 6-hydroxy-8-quinolinyl; or Rb is not 3-chlorophenyl or 8-methylnaphthalen-l-yl. Provided herein as Embodiment 89 is the compound according to Embodiment 87 or a pharmaceutically acceptable salt thereof, wherein the compound is not l-(6-(4-(2-fluorophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-fluorophenyl)-8-methyl-5,6,7,8-tetrahydropyrido[2,3’d]pyrimidin-2-yl)- 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(7-methyl-4-(5-methyl-lH-indazol-4-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)prop-2-en-l-one; l-(6-(4-(2-fluorophenyl)-7-(8-methyl~l-naphthalenyl)-6,7~dihydro-5H-pyrrolo[2,3" d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-4-(5-cyano-2-fluorophenyl)quinoline-3-carbonitrile; l-(6-(4-(2-chloro-5-(difluoromethoxy)phenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-fluorophenyl)-7-(8-methylnaphthalen-l-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)prop-2-en-l-one; l-(6-(4-(4-isoquinolinyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-(difluoromethyl)-2-methylphenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4] octan-2-yl)-2-propen-1 -one; i-(6-(4-(5-(hydroxymethyl)-2-methylphenyl)-5,6,7,8-tetrahydro-2-quinazolmyl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)- 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1 -(6-(4-(5-methyl-1 H-indazol-4-yl)pyrido[3,2-d]pynmidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-amino-3-methyl-2-pyridinyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-2-methyl-l-naphthalenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4] octan-2-yl)-2-propen-1 -one; l-(6-(4-(6-hydroxy-8-quinolinyl)-5,6,7,8-tetTahydro-2-quinazolinyl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-1 -one; or l-(6-(8-(3-chlorophenyl)-4-(2-fluorophenyl)-5,6,7,8-tetrahydropyrido[2,3- d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. Provided herein as Embodiment 90 is the compound according to Embodiment 87 or a pharmaceutically acceptable salt thereof, wherein the compound has an IC50 of less than 10 pM in the 2h coupled exchange assay or the 20h coupled exchange assay. Provided herein as Embodiment 91 is the compound according to any one of Embodiments 87-90 or a pharmaceutically acceptable salt thereof, wherein Rl is at each occurrence independently H or -(CH2)-Ci-4dialkylamino. Provided herein as Embodiment 92 is the compound according to any one of Embodiments 87-91 or a pharmaceutically acceptable salt thereof, wherein one R1 is H and the other R1 is -(CHij-NtCHs)?. Provided herein as Embodiment 93 is the compound according to any one of Embodiments 87-91 or a pharmaceutically acceptable salt thereof, wherein each R1 is H. Provided herein as Embodiment 94 is the compound according to any one of Embodiments 87-90 or a pharmaceutically acceptable salt thereof, wherein one Rl and R2 together with the carbon atoms to which they are attached form a j = R1 *          group. Provided herein as Embodiment 95 is the compound according to any one of Embodiments 87-93 or a pharmaceutically acceptable salt thereof, wherein R2 is H. Provided herein as Embodiment 96 is the compound according to any one of Embodiments 87-95 or a pharmaceutically acceptable salt thereof, wherein R’ at each occurrence independently is H, halogen, Cwhaloalkyl, or two substituents R3 attached to the same carbon atom form together with said carbon atom a carbonyl group. Provided herein as Embodiment 97 is the compound according to any one of Embodiments 87-95 or a pharmaceutically acceptable salt thereof, wherein 5           R3 at each occurrence independently is H, F, CHF2, or two substituents R3 attached to the same carbon atom form together with said carbon atom a carbonyl group. Provided herein as Embodiment 98 is the compound according to any one of Embodiments 87-97 or a pharmaceutically acceptable salt thereof, wherein one A is absent and the other A is CR’Rv 10           Provided herein as Embodiment 99 is the compound according to any one of Embodiments 87-97 or a pharmaceutically acceptable salt thereof, wherein both A are absent. Provided herein as Embodiment 100 is the compound according to any one of Embodiments 87-95 or a pharmaceutically acceptable salt thereof, wherein Provided herein as Embodiment 101 is the compound according to any one of Embodiments 87-95 or a pharmaceutically acceptable salt thereof, wherein Provided herein as Embodiment 102 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl, wherein the aryl is optionally substituted with 1 to 2 substituents independently selected from OH, halogen, or Cwalkyl. Provided herein as Embodiment 103 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl, wherein the aryl is optionally substituted with 1 to 2 substituents independently selected from OH, F, Cl, or methyl. Provided herein as Embodiment 104 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 6 or 10 membered aryl, wherein the aryl is optionally substituted with OH. Provided herein as Embodiment 105 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 2-fluorophenyl, 2-fluoro-5-hydroxyphenyl, 2,3-dichlorophenyl, 2-chloro-5-hydroxyphenyl, 2-chloro-3-methylphenyl, 2,3-dimethylphenyl, 5-hydroxy-2-methylphenyl, 3-hydroxynaphthalen-1 -yl, 6-hydroxy-1 -naphthalenyl, 8-methyl-1 -naphthalenyl, 8-chloro-1 -naphthalenyl, or 2-methyl-1 -naphthalenyl. Provided herein as Embodiment 106 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 3-hydroxynaphthalen-l-yl. Provided herein as Embodiment 107 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 5 to 10 membered heteroaryl, wherein the heteroaryl is optionally substituted with 1 to 2 substituents independently selected from NH2 or C1.4a.lkyi. Provided herein as Embodiment 108 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 5 to 10 membered heteroaryl, wherein the heteroaryl is optionally substituted with 1 to 2 substituents independently selected from NH2, methyl, ethyl, or isopropyl. Provided herein as Embodiment 109 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 5 to 10 membered heteroaryl, wherein the heteroaryl is optionally substituted with 1 or 2 methyl substituents. Provided herein as Embodiment 110 is the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 5-methyl-lH-indazol-4-yl, 5-ethyl-lH-indazol-4-yl, 6-methyl-lH-indazol-7-yl, l,6-dimethyl-lH-indazol-7-yl, 3,5-dimethyl-lH-indazol-4-yl, 5,6-dimethyl-lH-indazol-4-yl, 5-(2-propanyl)-lH-indazol-4-yl, or 2-amino-l,3-benzothiazol-4-yl. Provided herein as Embodiment Illis the compound according to any one of Embodiments 87-101 or a pharmaceutically acceptable salt thereof, wherein R4 is 5-methyl-lH-indazol-4-yl or 5,6-dimethyl-lH-indazol-4-yl. Provided herein as Embodiment 112 is the compound according to any one of Embodiments 87-111 or a pharmaceutically acceptable salt thereof, wherein Xs is CR5. Provided herein as Embodiment 113 is the compound according to any one of Embodiments 87-111 or a pharmaceutically acceptable salt thereof, wherein Xs is N. Provided herein as Embodiment 114 is the compound according to any one of Embodiments 87-113 or a pharmaceutically acceptable salt thereof, wherein X2 is CH. Provided herein as Embodiment 115 is the compound according to any one of Embodiments 87-113 or a pharmaceutically acceptable salt thereof, wherein X2isN. Provided herein as Embodiment 116 is the compound according to any one of Embodiments 87-115 or a pharmaceutically acceptable salt thereof, wherein X3 is C. Provided herein as Embodiment 117 is the compound according to any one of Embodiments 87-115 or a pharmaceutically acceptable salt thereof, wherein X3 is N. Provided herein as Embodiment 118 is the compound according to any one of Embodiments 87-117 or a pharmaceutically acceptable salt thereof, wherein X4 is C. Provided herein as Embodiment 119 is the compound according to any one of Embodiments 87-117 or a pharmaceutically acceptable salt thereof, wherein X4 is N. Provided herein as Embodiment 120 is the compound according to any one of Embodiments 87-111 or a pharmaceutically acceptable salt thereof, wherein Xs is N, X2 is N, X3 is C, and X4 is C; or X1 is CR5, X2 is N, X3 is C, and X4 is C; or Xs is CR5, X2 is CH, X3 is C, and X4 is C; or X! is CR5, X2 is CH, X3 is N, and X4 is C; or X; is CR5, X2 is CH, X3 is C, and X4 is N. Provided herein as Embodiment 121 is the compound according to any one of Embodiments 87-112 and 120 or a pharmaceutically acceptable salt thereof, wherein R5 is H, CN, Ci-4alkyl, or Cs-scycloalkyl. Provided herein as Embodiment 122 is the compound according to any one of Embodiments 87-112 and 120 or a pharmaceutically acceptable salt thereof, wherein R5 is H, CN, methyl, or cyclopropyl. Provided herein as Embodiment 123 is the compound according to any one of Embodiments 87-112 and 120 or a pharmaceutically acceptable salt thereof, wherein R5 is CN. Provided herein as Embodiment 124 is the compound according to any one of Embodiments 87-115 and 121-123 or a pharmaceutically acceptable salt thereof, wherein B together with the atoms to which it is attached forms a ring system selected from NH hn O HN wherein the ring system is optionally substituted w'ith 1 to 5 substituents R6. Provided herein as Embodiment 125 is the compound according to Embodiment 124 or a pharmaceutically acceptable salt thereof, wherein B together with the atoms to which it is attached forms a ring system selected irom and wherein the ring system is optionally substituted with 1 to 5 substituents R6. Provided herein as Embodiment 126 is the compound according to Embodiment 125 or a pharmaceutically acceptable salt thereof, wherein B together with the atoms to which it is attached forms a ring system selected from Provided herein as Embodiment 127 is the compound according to any one of Embodiments 87-115 and 121-125 or a pharmaceutically acceptable salt thereof, wherein wherein the ring system is optionally substituted with 1 to 2 substituents R6; R6 at each occurrence independently is halogen, Cnealkyl, CMalkoxy, or phenyl, wherein the Ci-ealkyl is optionally substituted with -CO(Ci-4alkylamino). Provided herein as Embodiment 128 is the compound according to any one of Embodiments 87-115 and 121-125 or a pharmaceutically acceptable salt thereof, wherein wherein the ring system is optionally substituted with 1 to 2 substituents R6; R6 at each occurrence independently is F, Cl, methyl, methoxy, phenyl, or -CHiCH CH(CH-H(Cn COXHCH ). Provided herein as Embodiment 129 is the compound according to any one of Embodiments 87-115 and 121-125 or a pharmaceutically acceptable salt thereof, wherein wherein the ring system is optionally substituted with 1 to 2 substituents R6; R6 at each occurrence independently is methyl or methoxy. Provided herein as Embodiment 130 is the compound according to Embodiment 87 or a pharmaceutically acceptable salt thereof, wherein the compound is l-(6-(4-(3-hydroxynaphthalen-l-yl)-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6- diazaspiro[3.4]octan-2-yl)prop-2-en-l-one; 3-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-l-(5-methyl-lH-mdazol-4-yl)-2-naphtho-nitrile; 4-(5-methyl-lH-mdazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile; 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]oc tan-6-yl)imidazo[l,2-a]pyridine-7-carbonitrile; 8-methyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; l-(6-(4-(8-methyl-l-naphthalenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (P)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 1 -(6-(4-(8-chloro-1 -naphthaleny 1)-5,6,7,8-tetrahydro-2"quinazoliny 1)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; (M)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; l-(6-((7)-7-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-qumazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1-(6-(4-(2-methyl-l-naphthalenyl)-5,6,7,8-tetrahydro-2-quinazoliny 1)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 8-fluoro-2-((8)-8-fluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarbonitrile; 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propynoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; l-(6-((8)-8-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-methyl-lH-indazol-7-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(5-methyl-lH-mdazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-chloro-5-hydroxyphenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-((5S)-5-(difluoromethyl)-6-(4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1 -(6-(9-methyi-6-(5-metliyl-1 H-indazol-4-yl)-9H-purin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(6-hydroxy-l-naphthalenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(3-hydroxy-l-naphthalenyl)-7-methylpyrido[3,2-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-amino-l,3-benzothiazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1-(6-(4-(2,3-dichlorophenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1 -(6-(4-(1,6-dimethyl-lH-mdazol-7-yl)-5,6,7,8-tetrahydro-2-qumazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 1-(6-(4-(2,3-dimethylphenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6- diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(2-chloro-3-methylphenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(8-methyl-4-(8-methyl-l-naphthalenyl)-7,8-dihydro-6H-pyrimido[5,4-b][l,4]oxazin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 8-(5-hydroxy-2-methylphenyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)imidazo[l,2-a]pyridine-7-carbonitrile; 1-(6-(7,7-dimethyl-4-(8-methyl-l-naphthalenyl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(3-liydroxy-l-naphthalenyl)-7,7-dimethyl-5,6,7,8-tetraliydro-2-quinazolinyl)-2,6-diazaspiro[3,4] octan-2-yl)-2-propen-1 -one; l-(5-methyl-lH-indazol-4-yl)-3-(6-(2-propenoyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-naphthalenecarbonitrile; l-(6-(4-(5-(2-propanyl)-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(3,5-dimethyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 3-methyl-8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)imidazo[ 1,2-a]pyridine-7-carbonitrile; 8-(5-methyl-lH4ndazol-4-yl)-2-phenyl-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)imidazo[ 1,2-a]pyridine-7-carbonitrile; 2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-8-fluoro-4-(5-methyl-lH-indazol-4-yl)-3-qumolinecarbonitrile; 1-(6-(7-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(7-methoxy-4-(5-methyl-lH-indazol-4-yl)-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; l-(6-(4-(8-methyl~l -naphthalenyl)-7,8-dihydro-6H-pyrano[3,2-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 2-(5,5-difluoro-2-(2-propenoyl)-2,7-diazaspiro[3,5]nonan-7-yl)-8-fluoro-4-(5-methyl-1 H-indazol-4-yl)-3-quinolinecarbonitrile; 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(5-oxo-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 7-methoxy-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 2-(2-((2E)4-(dimethylamino)-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-8-fluoro-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarbonitrile; 1 -((5R)-5-(difluoromethyl)-6-(4-(3-hydroxy-1 -naphthalenyl)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile; 4-(6-methyl-lH-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-amino-l,3-benzothiazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(3-hydroxy-l-naphthalenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 2-(8,8-difluoro-2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(5,6-dimethyl-lH-indazol’4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 4-(2-fluorophenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; 4-(2-fluoro-5-hydroxyphenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; l-(6-(3-methyl-7-(5-methyl-lH-indazol-4-yl)furo[3,2-b]pyridin-5-yl)-2,6-diazaspiro[3.4]octan-2-yl)prop-2-en-l-one; 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-4-(5-ethyl-lH-indazol-4-yl)quinoline-3-carbonitrile; l-(6-(3-cyclopropyl-4-(5-methyl-lH-indazol-4-yl)quinolin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)prop-2-en-l-one; l-methyl-4-(5-methyl-lH-indazol’4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1 H-benzimidazole-5-carbonitrile; l-(6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)quinolm-2-yl)-2,6-diazaspiro[3.4joctan-2-yl)prop-2-en-1 -one; (S)-3-(2-(2-acryloyl-2,6- diazaspiro[3.4]octan-6-yl)-4-(2-fluorophenyl)-5,6-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,5-dimethylhexanamide; (S)-3-(2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-4-(2-fluorophenyl)-6,7-dihydropyrido[2,3-d]pyrimidin-8(5H)-yr)-N,5-dimethylhexanamide; or (S)-3-(2-(2-acryloyl-2,6- diazasprro[3.4]octan-6-yl)-4-(2-fluorophenyl)-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-N,5-dimethylhexanamide. Provided herein as Embodiment 131 is the compound according to Embodiment 87 or a pharmaceutically acceptable salt thereof, wherein the compound is (P)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; l-(6-(4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one; 7-methoxy-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6- diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5-methyl-lH-indazol-4-yl)- 5,6,7,8-tetrahydroquinoline-3-carbonitrile; 2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5- methyl-lH-mdazol-4-yl)-5,6,7,8-tetrahydro-3-qumolinecarbonitrile; 4-(5,6-dimethyl-lH-indazol”4-yl)-2-(2-(2-propenoy 1)-2,6-diazaspiro[3.4]octan-6-yl)- 3-quinolinecarbonitrile; or 4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)- 5,6,7,8-tetrahydro-3-quinolinecarbonitrile. The foregoing merely summarizes certain aspects of this disclosure and is not intended, nor should it be construed, as limiting the disclosure in any way. FORMULATION AND ROUTE OF ADMINISTRATION While it may be possible to administer a compound disclosed herein alone in the uses described, the compound administered normally will be present as an active ingredient in a pharmaceutical composition. Thus, in one embodiment, provided herein is a pharmaceutical composition comprising a compound disclosed herein in combination with one or more pharmaceutically acceptable excipients and, if desired, other active ingredients. See, e.g., Remington: The Science and Practice of Pharmacy, Volume 1 and Volume II, twenty-second edition, edited by Loyd V. Allen Jr., Philadelphia, PA, Pharmaceutical Press, 2012; Pharmaceutical Dosage Forms (Vol. 1-3), Liberman et al., Eds., Marcel Dekker, New York, NY, 1992; Handbook of Pharmaceutical Excipients (3rd Ed.), edited by Arthur H. Kibbe, American Pharmaceutical Association, Washington, 2000; Pharmaceutical Formulation: The Science and Technology of Dosage Forms (Drug Discovery), nrst edition, edited by GD Tovey, Royal Society of Chemistry, 2018. In one embodiment, a pharmaceutical composition comprises a therapeutically effective amount of a compound disclosed herein. The compound(s) disclosed herein may be administered by any suitable route in the form of a pharmaceutical composition adapted to such a route and in a dose effective for the treatment intended. The compounds and compositions presented herein may, for example, be administered orally, mucosally, topically, transdermally, rectally, pulmonarily, parentally, intranasally, intravascularly, intravenously, intraarterial, intraperitoneally, intrathecally, subcutaneously, sublingually, intramuscularly, intrastemally, vaginally or by infusion techniques, in dosage unit formulations containing conventional pharmaceutically acceptable excipients. The pharmaceutical composition may be in the form of, for example, a tablet, chewable tablet, minitablet, caplet, pill, bead, hard capsule, soft capsule, gelatin capsule, granule, powder, lozenge, patch, cream, gel, sachet, microneedle array, syrup, flavored syrup, juice, drop, injectable solution, emulsion, microemulsion, ointment, aerosol, aqueous suspension, or oily suspension. The pharmaceutical composition is typically made in the form of a dosage unit containing a particular amount of the active ingredient. Provided herein as Embodiment 132 is a pharmaceutical composition comprising the compound according to any one of Embodiments 1-131 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Provided herein as Embodiment 133 is a compound according to any one of Embodiments 1-131 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 132 for use as a medicament. METHODS OF USE As discussed herein (see Section entitled “Definitions”), the compounds described herein are to be understood to include all stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Accord ingly, the scope of the methods and uses provided in the instant disclosure is to be understood to encompass also methods and uses employing all such forms. Besides being useful for human treatment, the compounds provided herein may be useful for veterinary treatment of companion animals, exotic animals, and farm animals, including mammals, rodents, and the like. For example, animals including horses, dogs, and eats may be treated with compounds provided herein. In one embodiment, the disclosure provides methods of using the compound s or pharmaceutical compositions of the present disclosure to treat disease conditions, including but not limited to conditions implicated by KRAS G12C mutation (e.g., cancer). See, e.g., U.S. Patent No. 10,519,146 B2, issued December 31, 2019; specifically, the section from column 198, line 1, to column 201, line 36, which is herewith incorporated by reference. Without wishing to be bound by any particular theory', the following is noted: AMG 510 is a small molecule that - similarly to the compounds disclosed herein - specifically and irreversibly inhibits KRASG12l (Hong et al., 2020, at 1208). Hong et al. report that “[p]reclinical studies showed that [AMG 510] inhibited nearly all detectable phosphorylation of extracellular signal-regulated kinase (ERK), a key down-stream effector of KRAS, leading to durable complete tumor regression in mice bearing KRAS p.G12C tumors.” (id, see also Section entitled “Biological Evaluation” below, Canon et al., 2019, and Lanman et al., 2020). AMG 510 was evaluated in a Phase 1 dose escalation and expansion trial with 129 subjects having histologically confirmed, locally advanced or metastatic cancer with the KRAS G12C mutation identified by local molecular testing on tumor tissues, including 59 subjects with non-small cell lung cancer, 42 subjects with colorectal cancer, and 28 subjects with other tumor types (Hong et al., 2020, at page 1208-1209). Hong et al. report a disease control rate (95% CI) of 88.1% for non-small cell lung cancer, 73.8% for colorectal cancer and 75.0% for other tumor types (Hong et al., 2020, at page 1213, Table 3). In conclusion, the cancer types showing either stable disease (SD) or partial response (PR) as reported by Hong et al. were non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma (Hong et al., 2020, at page 1212, (Figure A), and Supplementary Appendix (page 59 (Figure S5) and page 63 (Figure S6)). KRAS G12C mutations occur with the alteration frequencies shown in the table below (Cerami et al., 2012; Gao et al., 2013). For example, the table shows that 11.6% of subjects with non-small cell lung cancer have a cancer, wherein one or more cells express KRAS G12C mutant protein. Accordingly, the compounds provided herein, which specifically and irreversibly bind to KRASG12C (see Section entitled “Biological Evaluation” below) are useful for treatment of subjects having a cancer, including, but not limited to the 5 cancers listed in the table below. Cancer Type Alteration Frequency Non-Small Cell Lung Cancer 11.6 Small Bowel Cancer 4.2 Appendiceal Cancer 3.6 Colorectal Cancer 3.0 Cancer of Unknown Primary 2.9 Endometrial Cancer 1.3 Mixed Cancer Types 1.2 Pancreatic Cancer 1.0 Hepatobiliary Cancer 0.7 Small Cell Lung Cancer 0.7 Cervical Cancer 0.7 Germ Cell Tumor 0.6 Ovarian Cancer 0.5 Gastrointestinal Neuroendocrine Tumor 0.4 Bladder Cancer 0.4 Myelodysplastic / Myeloproliferative Neoplasms 0.3 Head and Neck Cancer 0.3 Esophagogastric Cancer 0.2 Soft Tissue Sarcoma 0.2 Mesothelioma 0.2 Thyroid Cancer 0.1 Leukemia 0.1 Melanoma 0.1 Provided herein as Embodiment 134 is a compound according to any one of Embodiments 1-131 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 132, for use in treating cancer. Provided herein as Embodiment 135 is a compound according to any one of 10 Embodiments 1-131 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 132 for use in treating cancer, wherein one or more cells express KRAS G12C mutant protein. Provided herein as Embodiment 136 is the compound or pharmaceutical composition for use of Embodiment 134 or 135, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma. Provided herein as Embodiment 137 is a use of the compound according to any one of Embodiments 1-131 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 132 in the preparation of a medicament for treating cancer. Provided herein as Embodiment 138 is a use of the compound according to any one of Embodiments 1-131 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Embodiment 132 in the preparation of a medicament for treating cancer, wherein one or more cells express KRAS G12C mutant protein. Provided herein as Embodiment 139 is the use according to Embodiment 137 or 138, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma. Provided herein as Embodiment 140 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of to any one of Embodiments 1-131 or a pharmaceutically acceptable salt thereof. Provided herein as Embodiment 141 is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of to any one of Embodiments 1-131 or a pharmaceutically acceptable salt thereof, wherein one or more cells express KRAS G12C mutant protein. Provided herein as Embodiment 142 is the method according to Embodiment 140 or 141, wherein the cancer is non-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma. Provided herein as Embodiment 143 is the method according to Embodiment 140 or 141, wherein the cancer is non-small cell lung cancer, colorectal cancer, pancreatic cancer, appendiceal cancer, endometrial cancer, esophageal cancer, cancer of unknown primary, ampullary cancer, gastric cancer, small bowel cancer, sinonasal cancer, bile duct cancer, or melanoma. Provided herein as Embodiment 144 is the method according to Embodiment 143, wherein the cancer is non-small cell lung cancer. Provided herein as Embodiment 145 is the method according to Embodiment 143, wherein the cancer is colorectal cancer. Provided herein as Embodiment 146 is the method according to Embodiment 143, wherein the cancer is pancreatic cancer. Provided herein as Embodiment 147 is the method according to anyone of Embodiments 140-146, wherein the subject has a cancer that was determined to have one or more cells expressing the KRAS G12C mutant protein prior to administration of the compound or a pharmaceutically acceptable salt thereof. Combination Therapy The present disclosure also provides methods for combination therapies in which an agent known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a compound of the present disclosure or a pharmaceutically acceptable salt thereof. In one aspect, such therapy includes but is not limited to the combina tion of one or snore compounds of the disclosure with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide, for example a synergistic or additive therapeutic effect. See, e.g., U.S. Patent No. 10,519,146 B2, issued December 31, 2019; specifically, the sections from column 201 (line 37) to column 212 (line 46) and column 2,19 (line 64) to column 2,20 (line 39), which are herewith incorporated by reference. Provided herein as Embodiment 148 is the method according to anyone of Embodiments 140-147, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor, AKT inhibitor, arginase inhibitor, CDK4 / 6 inhibitor, ErbB family inhibitor, ERK inhibitor, FAK inhibitor, FGFR inhibitor, glutaminase inhibitor, IGF-1R inhibitor, KIF18A inhibitor, MCL-1 inhibitor, MEK inhibitor, mTOR inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PI3K inhibitor, Raf kinase inhibitor, SHP2 inhibitor, S0S1 inhibitor, Src kinase inhibitor, or one or more chemotherapeutic agent. In one embodiment, the second compound is administered as a pharmaceutically acceptable salt. In another embodiment the second compound is administered as a pharmaceutical composition comprising the second compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. Aurora Kinase A Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor. Exemplary Aurora kinase A inhibitors for use in the methods provided herein include, but are not limited to, alisertib, cenisertib, danusertib, tozasertib, LY3295668 ((2R,4R)-l-[(3-chloro-2-fluorophenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-lH-pyrazol-3-yl)amino]pyridin-2-yl]methyl]-2-methylpiperidine-4-carboxylic acid), ENMD-2076 (6-(4-methylpiperazin-1 -yl)-N-(5-methyl-1 H-pyrazol-3-yl)-2- [(E)-2-phenyl ethenyl]pyrimi din-4-amine), TAK-901 (5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(l-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7~carboxamide), TT-00420 (4-[9-(2-chlorophenyl)-6-methyl-2,4,5,8,12-pentazatricyclo[8.4.0.03,7]tetradeca-l(14),3,6,8,10,12-hexaen-13-yl]morpholine), AMG 900 (N-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1 -amine), MLN8054 (4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4- d][2]benzazepin-2-yl]ammo]benzoic acid), PF-03814735 (N-[2-[(lR,8S)-4-[[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-l 1- azatricyclo[6.2.1.02’ / ]undeca-2(7),3,5-trien-l l-yl]-2-oxoethyl]acetamide), SNS-314 (1-(3-chlorophenyl)-3-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-l,3-thiazol-2-yl]urea), CYC116 (4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-l,3-thiazol-2-amine), TAS-119, BI 811283, and TTP607. AKT Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an AKT inhibitor. Exemplary AKT inhibitors for use in the methods provided herein include, but are not limited to, afuresertib, capivasertib, ipatasertib, uprosertib, BAY! 125976 (2-(4-(1 -aminocyclobutyl)phenyl]-3-phenylimidazo[l,2-b]pyridazine-6-carboxamide), ARQ 092 (3-[3-[4-(l-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine), MK2206 (8- [4-( 1 -aminocyclobutyl)phenyl]-9-pheny 1-2H-[ 1,2,4]triazolo[3,4-f][l,6]naphthyridin-3-one), SR13668 (indolo[2,3-b]carbazole-2,10-dicarboxylic acid, 5,7-dihydro-6-methoxy-, 2,10-diethyl ester), ONC201 (1 l-benzyl-7-[(2-methylphenyl)methyl]-2,5,7,1 l-tetrazatricyclo[7.4.0.02,6jtrideca-l(9),5-dien-8-one), ARQ 751 (N-(3-aminopropyl)-N-[(lR)-l-(3-anilino-7-chloro-4-oxoquinazolin-2-yl)but-3-ynyl]-3-chloro-2-fluorobenzamide), RX-0201, and LY2780301. Arginase Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an arginase inhibitor. Exemplary arginase inhibitors for use in the methods provided herein include, but are not limited to, numidargistat and CB 280. CDK4 / 6 Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a CDK4 / 6 inhibitor. The term “CDK 4 / 6” as used herein refers to cyclin dependent kinases (“CDK”) 4 and 6, which are members of the mammalian serine / threonine protein kinases. The term “CDK 4 / 6 inhibitor” as used herein refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzymatic activity of CDK 4 and / or 6. Exemplary CDK 4 / 6 inhibitors for use in the methods provided herein include, but are not limited to, abemaciclib, palbociclib, ribociclib, trilaciclib, and PF-06873600 ((pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(difluoromethyl)-8-[(lR,2R)-2-hydroxy-2-methylcyclopentyl]-2-[[l-(methylsulfonyl)-4-piperidinyl]amino]). In one embodiment, the CDK4 / 6 inhibitor is palbociclib. ErbB Family Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an ErbB family inhibitor. The term “ErbB family” as used herein refers to a member of a mammalian transmembrane protein tyrosine kinase family including: ErbBl (EGFR HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). The term “ErbB family inhibitor” as used herein refers to an agent, e.g., a compound or antibody, that is capable of negatively modulating or inhibiting all or a portion of the activity of at least one member of the ErbB family. The modulation or inhibition of one or more ErbB tyrosine kinase may occur through modulating or inhibiting kinase enzymatic activity of one or more ErbB family member or by blocking homodimerization or heterodimerization of ErbB family members. In one embodiment, the ErbB family inhibitor is an EGFR inhibitor, e.g., an anti-EGFR antibody . Exemplary anti-EGFR antibodies for use in the methods provided herein include, but are not limited to, zalutumumab, nimotuzumab, matuzumab, necitumumab, pamtumumab, and cetuximab. In one embodiment, the anti-EGFR antibody is cetuximab. In one embodiment, the anti-EGFR antibody is panitumumab. In another embodiment the ErbB family inhibitor is a HER2 inhibitor, e.g., an anti-HER2 antibody. Exemplary anti-HER-2 antibodies for use in the methods provided herein include, but are not limited to, pertuzumab, trastuzumab, and trastuzumab emtansine. In yet another embodiment the ErbB family inhibitor is a HER3 inhibitor, e.g., an anti-HER3 antibody, such as HMBD-001 (Hummingbird Bioscience). In one embodiment, the ErbB famil y inhibitor is a combination of an anti-EGFR antibody and anti-HER2 antibody. In one embodiment, the ErbB family inhibitor is an irreversible inhibitor. Exemplary irreversible ErbB family inhibitors for use in the methods provided herein include, but are not limited to, afatinib, dacomitinib, canertinib, poziotinib, AV 412 ((N-[4-[(3-chloro-4-f]uorophenyl)amino]-7-[3-methyl-3-(4-methyl-l-piperazinyl)-l-butyn-l-yl]-6-quinazolinyl]-2-propenamide)), PF 6274484 ((N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-2-propenamide), and HKI 357 ((E)-N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide). In one embodiment, the irreversible ErbB family inhibitor is afatinib. In one embodiment, the irreversible ErbB family inhibitor is dacomitinib. In one embodiment, the ErbB family inhibitor is a reversible inhibitor. Exemplary reversible ErbB family inhibitors for use in the methods provided herein include, but are not limited to erlotinib, gefitinib, sapitinib, varlitinib, tarloxotinib, TAK-285 (N-(2-(4-((3-chloro-4-(3-(trifluoromethyl)phenoxy)phenyl)amino)’5H-pyrrolo[3,2-d]pyrimidin-5-yl)ethyl)-3-hydroxy-3-methylbutanamide), AEE788 ((S)-6-(4-((4-ethylpiperazin-l-yl)methyl)phenyl)-N-(T-phenylethyl)-7H“pyiTolo[2,3-d]pyrimidin-4-amine), BMS 599626 ((3S)-3-morpholinylmethyl-[4-[[l-[(3-fluorophenyl)methyl]-lH-indazol-5-yl]amino]-5-methylpyrrolo[2,l-f][l,2,4]triazin-6-yl]-carbamate), and GW 583340 (N-[3-chloro-4-[(3-fluorophenyi)methoxy]phenyl]-6-[2”[(2-methylsulfonylethylamino)methyl]-l,3”thiazol”4-yl]quinazolin-4-amine). In one embodiment, the reversible ErbB family inhibitor is sapitinib. In one embodiment, the reversible ErbB family inhibitor is tarloxotinib. ERK Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an ERK inhibitor. Exemplary ERK inhibitors for use in the methods provided herein include, but are not limited to, ulixertinib, ravoxertinib, CC-90003 (N-[2-[[2-[(2-methoxy-5-methylpyridin-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-5-methylphenyl]prop-2-enamide), LY3214996 (6,6-dimethyl-2-[2-[(2-methydpyrazol-3-yl)aminolpyrimidin-4-yd]-5-(2-morpholin’4-ylethyl)thieno[2,3-c]pyrrol-4’one), KO-947 (l,5,6,8-tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-7H-pyrazolo[4,3-g]quinazolin-7-one), ASTX029, LTT462, and JSI-1187. FAK Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a FAK inhibitor. Exemplary FAK inhibitors for use in the methods provided herein include, but are not limited to, GSK2256098 (2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]ammo]-N-methoxybenzamide), PF-00562271 (N-methyl-N-[3-[[[2-[(2-oxo-l,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]pyridin-2-yl]methanesulfonamide), VS-4718 (2-[[2-(2-methoxy-4-morpholin-4-ylanilmo)-5-(trifluoromethyl)pyridm-4-yl]amino]-N-methylbenzamide), and APG-2449. FGFR Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an FGFR inhibitor. Exemplary' FGFR inhibitors for use in the methods provided herein include, but are not limited to, futibatinib, pemigatinib, ASP5878 (2-[4-[[5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidin-2-yl]amino]pyrazol-l-yl]ethanol), AZD4547 (N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-lH-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-l- yl]benzamide), debio 1347 ([5-amino-l-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(lH-indol-2-yl)methanone), INCB062079, H3B-6527 (N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-l-yl)phenyl]prop-2-enamide), ICP-105, CPL.304110, HMPL-453, and HGS1036. Glutaminase Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a glutaminase inhibitor. Exemplary glutaminase inhibitors for use in the methods provided herein include, but are not limited to, telaglenastat, IPN60090, and OP 330. IGF-1R Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an IGF-1R inhibitor. Exemplary IGF-1R inhibitors for use in the methods provided herein include, but are not limited to, cixutumumab, dalotuzumab, linsitinib, ganitumab, robatumumab, BMS-754807 ((2S)-l’[4-[(5-cyclopropyl-lH’pyrazol-3-yl)amino]pyrrolo[2,l-f][l,2,4]triazin-2-yl]-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide), KW-2450 (N-[5-[[4-(2-hydroxyacetyl)piperazin-1 -yl]methyl]-2- [(E)-2-( 1 H-indazol-3-yl)ethenyl jpheny 1]-3 -methylthiophene-2-carboxamide), PL225B, AVE 1642, and BIIB022. KIF18A Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a KIF18A inhibitor. Exemplary KTF18A inhibitors for use in the methods provided herein include, but are not limited to, the inhibitors disclosed in US 2020 / 0239441, WO 2020 / 132649, WO 2020 / 132651, and WO 2020 / 132653, each of which is herewith incorporated by reference in its entirety. MCL-1 Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an MCL-1 inhibitor. Exemplary MEK inhibitors for use in the methods provided herein include, but are not limited to, murizatoclax, tapotoclax, AZD 5991 ((3aR)-5-chloro-2,ll,12,24,27,29-hexahydro-2,3,24,33-tetramethyl-22H-9,4,8-(metheniminomethyno)-14,20:26,23-dimetheno-10H,20H-pyrazolo[4,3-l][2,l 5,22,18,19] benzoxadithiadiazacyclohexacosine-3 2-carboxylic acid), MIK 665 ((aR)-a-[[(5S)-5-[3-Chloro-2-methyl-4-[2-(4-methyl-l-piperazinyl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy]-2-[[2-(2-methoxyphenyl)-4-pyrimidinyl]methoxy]benzenepropanoic acid), and ABBV-467. In one embodiment, the MCL-1 inhibitor is murizatoclax. In another embodiment, the MCL-1 inhibitor is tapotoclax. MEK Inhibitors Provided herein is the method according to any one of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is MEK inhibitor. Exemplary MEK inhibitors for use in the methods provided herein include, but are not limited to, trametinib, cobimetinib, selumetinib, pimasertib, refametinib, PD-325901 (N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide), AZD8330 (2-(2-fluoro-4-iodoanilino)-N-(2-hydroxy ethoxy)-!,5-dimethyl-6-oxopyridine-3-carboxamide), GDC-0623 (5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[l,5-a]pyridine-6-carboxamide), RO4987655 (3,4-difluoro-2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide), TAK-733 (3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione), PD0325901 (N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide), CI-1040 (2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide), PD318088 (5-bromo-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide), PD98059 (2-(2-amino-3-methoxyphenyl)-4H-chromen-4-one), PD334581 (N-[5-[3,4-Difluoro-2-[(2- fluoro-4-iodophenyl)amino]phenyl]-l,3,4-oxadiazol-2-yl]-4-morpholineethanamine), FCN-159, CS3006, HL-085, SHR 7390, and WX-554. In one embodiment, the MEK inhibitor is trametinib. mTOR Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an mTOR inhibitor. Exemplary mTOR inhibitors for use in the methods provided herein include, but are not limited to, everolimus, rapamycin, zotarolimus (ABT-578), ridaforolimus (deforolimus, MK-8669), sapanisertib, buparlisib, pictilisib, vistusertib, dactolisib, Torin-1 (1-(4-(4-propionylpiperazin-l-yl)-3-(trifluoromethyl)cyclohexyl)-9-(quinolin-3-yl)benzo[h][l,6]naphthyridin-2(lH)-one), GDC-0349 ((S)-l-ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidm-2-yl)phenyl)urea), and VS-5584 (SB2343, (5-(8-methyl-2-morphoUn-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine). In one embodiment, the mTOR inhibitor is everolimus. PD-1 Inhibitors Provided herein is the method according to any one of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a PD-1 inhibitor. Exemplary PD-1 inhibitors for use in the methods provided herein include, but are not limited to, pembrolizumab, nivolumab, cemiplimab, spartalizumab (PDR001), camrelizumab (SHR1210), sintilimab (IBI308), tislelizumab (BGB-A317), toripalimab (JS 001), dostarlimab (TSR-042, WBP-285), INCMGA00012 (MGA012), AMP-224, AMP-514, and the anti-PD-1 antibody as described in US 10,640,504 B2 (the “Anti-PD-1 Antibody A,” column 66, line 56 to column 67, line 24 and column 67, lines 54-57), which is incorporated herein by reference. In one embodiment, the PD-1 inhibitor is pembrolizumab. In another embodiment the PD-1 inhibitor is the Anti-PD-1 Antibody A. PD-L1 Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a PD-L1 inhibitor. Exemplary PD-L1 inhibitors for use in the methods provided herein include, but are not limited to, atezolizumab, avelumab, durvalumab, ZKAB001, TG-1501, SHR-1316, MSB23H, MDX-1105, KN035, IMC-001, HLX20, FAZ053, CS1001, CK-301, CBT-502, BGB-A333, BCD-135, and A167. In one embodiment, the PD-L1 inhibitor is atezolizumab. PI3K Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a PI3K inhibitor. Exemplary PI3K inhibitors for use in the methods provided herein include, but are not limited to, idelalisib, copanlisib, duvelisib, alpelisib, taselisib, perifosine, buparlisib, umbralisib, pictilisib, dactolisib, voxtalisib, sonolisib, tenalisib, serabelisib, acalisib, CUDC-907 (N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide), ME-401 (N-[2-methyl-l-(2-(1-methylpiperidin-4-yl)pheny4]propan-2-yl]-4-(2-methylsulfonylbenzimidazol-l-yl)-6-morpholin-4-yl-l,3,5-triazin-2-amine), IPI-549 (2-amino-N-[(lS)-l-(8-(2-(1 -methylpyrazol-4-yl)ethynyl]-l-oxo-2-phenylisoqumolin-3-yl]ethyl]pyrazolo[l,5-a]pyrimidine-3-carboxamide), SF1126 ((2S)-2-[[(2S)-3-carboxy-2-[[2-[((2S)-5-(diaminomethylideneamino)-2-[[4-oxo-4-([4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate), XL 147 (N-[3-(2,1,3-benzothiadiazol-5-ylamino)quinoxalin-2-yl]-4-methylbenzenesulfonamide), GSK1059615 ((5Z)-5-[(4-pyridin-4-ylqumolin-6-yl)methylidene]-l ,3-thiazolidine-2,4-dione), and AMG 319 (N-[(lS)-l-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7H-purin-6-amine). Raf Kinase Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a Raf kinase inhibitor. The term “RAF kinase” as used herein refers to a member of a mammalian serine / threonine kinases composed of three isoforms (C-Raf, B-Raf and A-Raf) and includes homodimers of each isoform as well as heterodimers between isoforms, e.g., C-Raf / B-Raf heterodimers. The term “Raf kinase inhibitor” as used herein refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzy matic activity of one or more member of the Raf family kinases, or is capable of disrupting Raf homodimer or heterodimer formation to inhibit activity. In one embodiment, the Raf kinase inhibitor includes, but is not limited to, encorafenib, sorafenib, lifirafenib, vemurafenib, dabrafenib, PLX-8394 (N-(3-(5-(2-cyclopropylpyrimidin-5-yl)-3a,7a-dihydro-lH-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-3-fluoropyrrolidine-l-sulfonamide), Raf-709 (N-(2-methyl-5,-morpholino-6’-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide), LXH254 (N-(3-(2-(2-hydroxyethoxy)-6- morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide), LY3009120 (1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea), Tak-632 (N-(7-cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide), CEP-32496 (1 -(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(l,l,l-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea), CCT196969 (l-(3-(tert-butyl)-l-phenyl-lH-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea), and RO5126766 (N-[3-fluoro-4-[[4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2H-l-benzopyran-3-yl]methyl]-2-pyridinyl]-N'-methyl-sulfamide). In one embodiment, the Raf kinase inhibitor is encorafenib. In one embodiment, the Raf kinase inhibitor is sorafenib. In one embodiment, the Raf kinase inhibitor is lifirafenib. SHP2 Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is a SHP2 inhibitor. Exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to, SHP-099 (6-(4-amino-4-methylpiperidin-l-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine dihydrochloride), RMC-4550 ([3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol), TNO155, (3S,4S)-8-[6-amino-5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine), and RMC-4630 (Revolution Medicine). In one embodiment, the SHP inhibitor for use in the methods provided herein is RMC-4630 (Revolution Medicine). In another embodiment, exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to, 3-[(lR,3R)-l-amino-3-methoxy-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-methyl-2-pyrazinemethanol (CAS 2172651-08-8), 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-methyl-2-pyrazinemethanol (CAS 2172652-13-8), 3-((35,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-[[3-chloro-2-(3-hydroxy-l-azetidinyl)-4-pyridinyl]thio]-5-methyl-2-pyrazinemethanol (CAS 2172652-38-7), and 6-[(2-amino-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-methyl-2-pyrazinemethanol (CAS 2172652-48-9). In another embodiment, exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to, 1-(5-(2,3-dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl]-4-methyl-4-piperidinamine (CAS 2240981 -75-1), (lR)-8-[5-(2,3-dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl]-8-azaspiro(4.5]decan-l-amine (CAS 2240981-78-4), (3S,4S)-8-[7-(2,3-dichlorophenyl)-6-methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (CAS 2240982-45-8), (3S,4S)-8-[7-[(2-amino-3-chloro-4-pyridinyl)thio]pyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4,5]decan-4-amine (CAS 2240982-57-2), 4-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-7-(2,3-dichlorophenyl)-6-methyl-pyrazolo[l,5-a]pyrazine-2-methanol (CAS 2240982-69-6), 7-[(2-amino-3-chloro-4-pyridinyl)thio]-4-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]dec-8-yl]-6-methyl-pyrazolo[ 1,5-a]pyrazine-2-methanol (CAS 2240982-73-2), and (3S,4S)-8-[7-[(2-ammo-3-chloro-4-pyridinyl)thio]-6-methylpyrazolo[l,5-a]pyrazin-4-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (CAS 2240982-77-6). In one embodiment, the SHP inhibitor for use in the methods provided herein is (1R)-8-(5-(2,3-dichlorophenyl)-6-methylimidazo[l,5-a]pyrazin-8-yl]-8-azaspiro[4.5]decan-l-amine (CAS 2240981-78-4). In another embodiment, exemplary SHP2 inhibitors for use in the methods provided herein include, but are not limited to 3-[(lR)-l -amino-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-hydroxy-2-pyridinemethanol (CAS 2238840-54-3), 3-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-hydroxy-2-pyridinemethanol (CAS 2238840-56-5), 5-[(lR)-l-ammo-8-azaspiro[4.5]dec-8-yl]-2-(2,3-dichlorophenyl)-3-pyridinol (CAS 2238840-58-7), 3-((1R)-l -amino-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-methyl-2-pyridinemethanol (CAS 2238840-60-1), (lR)-8-[6-(2,3-dichlorophenyl)-5-methyl-3-pyridinyl]-8-azaspiro[4.5]decan-l-amine (CAS 2238840-62-3), 3-((1 R)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-methyl-2-pyridinemethanol (CAS 2238840-63-4), (lR)-8-[6-((2,3-dichlorophenyl)thio]-5-methyl-3-pyridmyl]-8-azaspiro[4.5]decan-l-amine (CAS 2238840-64-5), 5-(4-amino-4-methyl-l-piperidinyl)-2-[(2,3-dichlorophenyl)thio]-3-pyridinol (CAS 2238840-65-6), 5-((1 R)-l-amino-8-azaspiro[4.5]dec-8-yl]-2-[(2,3-dichlorophenyl)thio]-3-pyridinol (CAS 2238840-66-7), 6-((2-amino-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-hydroxy-2-pyridinemethanol (CAS 2238840-67-8), 3-(4-amino-4-methyl-l-piperidinyl)-6-(2,3-dichlorophenyl)-5-hydroxy-2-pyridinemethanol (CAS 2238840-68-9), 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-methyl-2-pyridinemethanol (CAS 2238840-69-0), 6-[(2-amino-3-chloro-4-pyridinyl)thio]-3-[(3S,4S)-4-amino-3-mefnyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-methyl-2-pyridinemethanol (CAS 2238840-70-3), 3-(4-ammo-4-methyl-l-piperidinyl)-6-(2,3-dichlorophenyr)-5-methyl-2-pyridinemethanol (CAS 2238840-71 -4), 6-[(2-amino-3-chloro-4-pyridinyl)thio]-3-(4-amino-4-methyl-l-piperidinyl)-2-pyridinemethanol (CAS 2238840-72-5), 5-[(2-amino-3-chloro-4-pyridinyl)thio]-2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-methyl-3-pyridinemethanol (CAS 2238840-73-6), 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-5-(2,3-dichlorophenyl)-6-methyl-3-pyridinemethanol (CAS 2238840- 74-7), 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-y 11-6-(2,3-dichlorophenyl)-5-hydroxy-2-pyridinemethanol (CAS 2238840-75-8), and 2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-5-[(3S,4S)-4-amino-3- methyl-2-oxa-8-azaspiro[4,5]decan-8-yl]-6-(hydroxymethyl)pyridin-3-ol. In one embodiment, the SHP inhibitor for use in the methods provided herein is 3-[(lR)-l-amino-8-azaspiro[4.5]dec-8-yl]-6-[(2,3-dichlorophenyl)thio]-5-hydroxy-2-pyridinemethanol (CAS 2238840-56-5). In one embodiment, the SHP2 inhibitor for use in the methods provided herein is an inhibitor disclosed inUS 10,590,090 B2, US 2020 / 017517 Al, US 2020 / 017511 Al, or WO 2019 / 075265 Al, each of which is herewith incorporated by reference in its entirety. SOS1 Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an S0S1 inhibitor. Exemplary S0S1 inhibitors for use in the methods provided herein include, but are not limited to, BI 3406 (N-[(lR)-l-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-7-methoxy-2-methyl-6-[(3S)-oxolan-3-yl]oxyquinazolin-4-amine), and Bl 1701963. Sre Kinase Inhibitors Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, "wherein the second compound is a Src kinase inhibitor. The term “Src kinase” as used herein refers to a member of a mammalian nonreceptor tyrosine kinase family including: Src, Yes, Fyn, and Fgr (SrcA subfamily ); Lek, Hck, Blk, and Lyn (SrcB subfamily), and Frk subfamily. The term “Src kinase inhibitor” as used herein refers to a compound that is capable of negatively modulating or inhibiting all or a portion of the enzymatic activity of one or more member of the Src kinases. Exemplary Src kinase inhibitors for use in the methods provided herein include, but are not limited to, dasatinib, ponatinib, vandetanib, bosutinib, saracatinib, KX2-391 (N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide), SU6656 ((Z)-N,N- dimethyl-2-oxo-3-((4,5,6,7-tetrahydro-lH-indol-2-yl)methylene)mdoline-5-sulfonaimde), PP 1 (l-(tert-butyl)-3-(p-tolyl)-lH-pyrazolo[3,4-d]pyrimidin-4-amine), WH-4-023 (2,6-dimethylphenyl(2,4-dimethoxyphenyl)(2-((4-(4-methylpiperazin-l-yl)phenyl)ammo)pyrimidin-4-yl)carbamate), and KX-01 (N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide). In one embodiment, the Src kinase inhibitor is dasatinib. In one embodiment, the Src kinase inhibitor is saracatinib. In one embodiment, the Src kinase inhibitor is ponatinib. In one embodiment, the Src kinase inhibitor is vandetanib. In one embodiment, the Src kinase inhibitor is KX-01. Chemotherapeutic Agents Provided herein is the method according to anyone of Embodiments 54-61, which further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is one or more chemotherapeutic agent. Exemplary chemotherapeutic agents for use in the methods provided herein include, but are not limited to, leucovorin calcium (calcium folinate), 5-fluorouracil, irinotecan, oxaliplatin, cisplatin, carboplatin, pemetrexed, docetaxel, paclitaxel, gemcitabine, vinorelbine, chlorambucil, cyclophosphamide, and methotrexate. DEFINITIONS The following definitions are provided to assist in understanding the scope of this disclosure. Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification or claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the standard deviation found in their respective testing measurements. As used herein, if any variable occurs more than one time in a chemical formula, its definition on each occurrence is independent of its definition at every other occurrence. If the chemical structure and chemical name conflict, the chemical structure is determinative or the identity of the compound. Stereoisomers The compounds of the present disclosure may contain, for example, double bonds, one or more asymmetric carbon atoms, and bonds with a hindered rotation, and therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers (E / Z)), enantiomers, diastereomers, and atropoisomers. Accordingly, the scope of the instant disclosure is to be understood to encompass all possible stereoisomers of the illustrated compounds, including the stereoisomerically pure form (for example, geometrically pure, enantiomerically pure, diastereomericaHy pure, and atropoisomerically pure) and stereoisomeric mixtures (for example, mixtures of geometric isomers, enantiomers, diastereomers, and atropoisomers, or mixture of any of the foregoing) of any chemical structures disclosed herein (in whole or in part), unless the stereochemistry is specifically identified. If the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. If the stereochemistry of a structure or a portion of a structure is indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing only the stereoisomer indicated, unless otherwise noted. For example, NH represents NH and NH . Similarly, for example, the chemical name (4R)-4-methoxy-5-methyl-4,5,6,7-tetrahydro-2H-isoindole represents (4R,5R)-4-methoxy-5-methyl-4,5,6,7-tetrahydro-2H-isoindole and (4R,5S)-4-methoxy-5-methyl-4,5,6,7"tetrahydro-2H-isoindole. l-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3*d]pyrimidine-2>4(lH,3H)-dione represents (M)-7-chloro-6-fluoro-l-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine- 2,4( lH,3H)-di one and (P)-7-chloro-6-fluoro-l-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidme-2,4(lH,3H)-dione. In certain instances, a bond drawn with a wavy line may be used to indicate that both stereoisomers are encompassed. This is not to be confused with a wavy line drawn perpendicular to a bond which indicates the point of attachment of a group to the rest of the molecule. The term “stereoisomer” or “stereoisomerically pure” compound as used herein refers to one stereoisomer (for example, geometric isomer, enantiomer, diastereomer and atropoisomer) of a compound that is substantially free of other stereoisomers of that compound. For example, a stereoisomerically pure compound having one chiral center will be substantially free of the mirror image enantiomer of the compound and a stereoisomerically pure compound having two chiral centers will be substantially free of the other enantiomer and diastereomers of the compound. A typical stereoisomerically pure compound comprises greater than about 80% by weight of one stereoisomer of the compound and equal or less than about 20% by weight of other stereoisomers of the compound, greater than about 90% by weight of one stereoisomer of the compound and equal or less than about 10% by weight of the other stereoisomers of the compound, greater than about 95% by weight of one stereoisomer of the compound and equal or less than about 5% by weight of the other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and equal or less than about 3% by weight of the other stereoisomers of the compound. This disclosure also encompasses the pharmaceutical compositions comprising stereoisomerically pure forms and the use of stereoisomerically pure forms of any compounds disclosed herein. Further, this disclosure also encompasses pharmaceutical compositions comprising mixtures of stereoisomers of any compounds disclosed herein and the use of said pharmaceutical compositions or mixtures of stereoisomers. These stereoisomers or mixtures thereof may be synthesized in accordance with methods well known in the art and methods disclosed herein. Mixtures of stereoisomers may be resolved using standard techniques, such as chiral columns or chiral resolving agents. See, for example, Jacques et a!., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725; Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions, page 268 (Eliel, Ed., Univ, of Notre Dame Press, Notre Dame, IN, 1972). Tautomers As known by those skilled in the art, certain compounds disclosed herein may exist in one or more tautomeric forms. Because one chemical structure may only be used to represent one tautomeric form, it will be understood that for convenience, referral to a compound of a given structural formula includes other tautomers of said structural formula. example, the chemical name (4R,5R)-4-methoxy-5-methyl-4,5,6,7-tetrahydro-lH-indazole represents (4R,5R)-4-methoxy-5-methyl-4,5,6,7-tetrahydro-lH-indazole and (4R,5R)-4-methoxy-5-methyl-4,5,6,74etrahydro-2H-indazole. Accordingly, the scope of the instant disclosure is to be understood to encompass all tautomeric forms of the compounds disclosed herein. IsotopicaHy-Labelled Compounds Further, the scope of the present disclosure includes all pharmaceutically acceptable isotopically-labelled compounds of the compounds disclosed herein, such as the compounds of Formula I, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds disclosed herein include isotopes of hydrogen, such as ZH and 3H, carbon, such as "C, S3C and 14C, chlorine, such as 36C1, fluorine, such as 18F, iodine, such as 123I and 125I, nitrogen, such as i3N and l5N, oxygen, such as 1SO, L'O and 18O, phosphorus, such as 32P, and sulphur, such as 35S. Certain isotopically-labelled compounds of Formula I, for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotopes tritium (3H) and carbon-14 (i4C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with isotopes such as deuterium (2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be advantageous in some circumstances. Substitution with positron emitting isotopes, such as “C, 18F, 15O and i3N, can be useful in Positron Emission Topography (PET) studies, for example, for examining target occupancy. Isotopically-labelled compounds of the compounds disclosed herein can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying General Synthetic Procedures and Examples using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed. Miscellaneous Definitions This section will define additional terms used to describe the scope of the compounds, compositions and uses disclosed herein. The term “2h coupled exchange assay” or “20h coupled exchange assay” as used herein refers to the assay described in the Section entitled “BIOLOGICAL EVALUATION.” The term “6 or 10 membered aryl” as used herein refers to a phenyl or naphthyl ring. The term “C2-4alkenyl” as used herein refers to a saturated hydrocarbon containing 2 to 4 carbon atoms having at least one carbon-carbon double bond. Alkenyl groups include both straight and branched moieties. Representative examples of C2-4alkenyl include, but are not limited to, 1-propenyl, 2-propenyl, 2-methyl-2-propenyl, and butenyl. The terms “CMalkyl” and “Cnealkyl” as used herein refer to a straight or branched chain hydrocarbon containing from 1 to 4 and 1 to 6 carbon atoms, respectively. Representative examples of CMalkyl or Cuealkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, and hexyl. The term “CMalkoxy” as used herein refers to OR#, wherein R# represents a Cj. 4alkyl group as defined herein. Representative examples of CMalkoxy include, but are not limited to, methoxy, ethoxy, propoxy, iso-propoxy, and butoxy. The term “Cs-scycloalkyl” and “C3.6cycloalkyl” as used herein refers to a saturated carbocyclic molecule wherein the cyclic framework has 3 to 5 and 3 to 6 carbon atoms, respectively. Representative examples of Cwscycloalkyl or C3.6cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term “deutero” as used herein as a prefix to another term for a chemical group refers to a modification of the chemical group, wherein one or more hydrogen atoms are substituted with one or more deuterium atoms. For example, the term “CMdeuteroalkyl” refers to a CMalkyl as defined herein, wherein one or more hydrogen atoms are substituted with one or more deuterium atoms. Representative examples of CMdeuteroalkyl include, but are not limited to, -CH2D, -CHD2, -CD3, -CH CD:. -CDHCD3, -CD2CD3, -CH(CD. y. -CD(CHD2)2, and -CH(CH2D)(CD3). The term “Cu4dialkylamino” as used herein refers to -NR*R**, wherein R* and R** independently represent a CMalkyl as defined herein. Representative examples of Ci-4dialkylamino include, but are not limited to, -N(CH3)2, -N(CH2CH3)2, -N(CH3)(CH2CH3), -N(CH2CH2CH3)2, and MCHR H3)2)2. The term “CMalkylamino” as used herein refers to -NHR*, wherein R* represents a CMalkyl as defined herein. Representative examples of CMalkylamino include, but are not limited to, -XH(Ci I c -NH(CH2Cf U -NH(CH2CHCH3), and Xi RCHfCH Ci. The term “halogen'’ as used herein refers to -F, -CI, -Br, or -I. The term “halo” as used herein as a prefix to another term for a chemical group refers to a modification of the chemical group, wherein one or more hydrogen atoms are substituted with one or more halogen atoms as defined herein. The halogen is independently selected at each occurrence. For example, the term “Ci-draloalkyl” refers to a Ci^alkyl as denned herein, wherein one or more hydrogen atoms are substituted with a halogen. Representative examples of CMhaloalkyl include, but are not limited to, -CH2F, -CHF2, -CF3, -CHFC1, -CH2CF3, -CFHCF3, -CF2CF3, -CH(CF3)2, -CF(CHF2)2, and -CH(CH2F)(CF3). Further, for example, the term “CMhaloalkoxy” for example refers to a Cwalkoxy as defined herein, wherein one or more hydrogen atoms are substituted with a halogen. Representative examples of Ci^haloalkoxy include, but are not limited to, -OCH2F, -OCHF2, -OCF3, -OCHFC1, -OCH2CF3, -OCFHCF3, -OCF2CF3, -OCH(CF3)2, -OCF(( HF )•. and -OCH(CH2F)(CF3). The terms “5 to 6 membered heteroaryl” and ‘‘5 to 10 membered heteroaryl” as used herein refer to a mono or bicyclic ring aromatic ring system containing 1 to 5 and 1 to 10 heteroatoms, respectively, at each occurrence independently selected from N, O, and S "with the remaining ring atoms being carbon. Representative examples of 5 to 6 or 5 to 10 membered heteroaryls include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, triazolyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, benzofuranyl, benzimidazolyl, benzoi sox azol yl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzothiophenyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quiazolinyl, thiadiazolopyrimidyl, and thienopyridyl. The term “Cs-sheterocycloalkyl” as used herein refers to a saturated carbocyclic molecule wherein the cyclic framework has 3 to 5 carbon atoms and wherein one carbon atom is substituted with a heteroatom selected from N, O, and S. Representative examples of Cj-sheterocycloalkyl include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, and pyrrolidinyl. The term “C3-6heterocycloalkyl” as used herein refers to a saturated carbocyclic molecule wherein the cyclic framework has 3 to 6 carbon atoms and wherein one or two carbon atoms are substituted with one or two heteroatoms independently selected from N, O, and S. Representative examples of Cj-sheterocycloalkyl include, but are not limited to, azindinyi, azetidmyl, oxetanyl, pyrrolidmyl, piperidmyl, ptperazmyl, morpholmyl, and thiomorpholinyl. The term “pharmaceutically acceptable” as used herein refers to generally recognized for use in subjects, particularly in humans. The term “pharmaceutically acceptable salt” as used herein refers to a salt of a compound that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, for example, an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, dicyclohexylamine, and the like. Additional examples of such salts can be found in Berge et a!., J. Pharm. Sci. 66(1):1-19 (1977). See also Stahl et al., Pharmaceutical Salts: Properties, Selection, and Use, 2nd Revised Edition (2011). The term “pharmaceutically acceptable excipient” as used herein refers to a broad range of ingredients that may be combined with a compound or salt disclosed herein to prepare a pharmaceutical composition or formulation. Typically, excipients include, but are not limited to, diluents, colorants, vehicles, anti-adherants, glidants, dis integrants, flavoring agents, coatings, binders, sweeteners, lubricants, sorbents, preservatives, and the like. The term “subject” as used herein refers to humans and mammals, including, but not limited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits, rats, and mice. In one embodiment the subject is a human. The term “therapeutically effective amount” as used herein refers to that amount of a compound disclosed herein that will elicit the biological or medical response of a tissue, a system, or subject that is being sought by a researcher, veterinarian, medical doctor or other clinician. GENERAL SYNTHETIC PROCEDURES The compounds provided herein can be synthesized according to the procedures described in this and the following sections. The synthetic methods described herein are merely exemplary, and the compounds disclosed herein may also be synthesized by alternate 5 routes utilizing alternative synthetic strategies, as appreciated by persons of ordinary skill in the art. It should be appreciated that the general synthetic procedures and specific examples provided herein are illustrative only and should not be construed as limiting the scope of the present disclosure in any manner. Generally, the compounds of Formula I can be synthesized according to the 10 following schemes. Any variables used in the following scheme are the variables as defined for Formula I, unless otherwise noted. All starting materials are either commercially available, for example, from Sigma-Aldrich, Inc., or known in the art or may be synthesized by employing known procedures using ordinary skill. Starting material may also be synthesized via the procedures disclosed herein. Suitable reaction conditions, such as, 15 solvent, reaction temperature, and reagents, for the Schemes discussed in this section, may be found in the examples provided herein. Scheme 1 warhead installation Step 2 Ar reagent coupling catalyst Step 1 Scheme 2 warhead installation Step 1 i. N-deprotection II. acylating agent Step 3 Ar reagent coupling catalyst Step 2 As can be appreciated by the skilled artisan, the above synthetic schemes and representative examples are not intended to comprise a comprehensive list of all means by 5 which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds. Purification methods for the compounds described herein are known in the art and 10 include, for example, crystallization, chromatography (for example, liquid and gas phase), extraction, distillation, trituration, and reverse phase HPLC. The disclosure further encompasses “intermediate” compounds, including structures produced from the synthetic procedures described, whether isolated or generated in-si tu and not isolated, prior to obtaining the finally desired compound. These intermediates are 15 included in the scope of this disclosure. Exemplary embodiments of such intermediate compounds are set forth in the Examples below. EXAMPLES This section provides specific examples of compounds of Formula I and methods of making the same. List of Abbreviations 5 Table 1. AcOH or HOAc acetic acid Ac2O acetic anhydride aq or aq. aqueous Bn benzyl BOC or Boc tert-butyloxycarbonyl CAN ceric ammonium nitrate DAST di ethylaminosulfur trifluoride DBU l,8-diazabicyclo[5.4.0]undec-7-ene DCE 1,2-dichloroethane DCM dichloromethane DEAD diethyl azodicarboxylate DMA N,N-dimethylaceta mid e DMAP 4-dim ethyl am inopyri din e DMF N,N-dimethylformamide DMSO dimethyl sulfoxide Dppf, DPPF or dppf 1,1 ’“bis(diphenylphosphmo)ferrocene EDC or EDCI l-ethyl-3-(3-dimethylaminopropyl)carbodiimide ESI or ES electrospray ionization Et ethyl EtOH ethanol Et2O diethyl ether EtOAc ethyl acetate g gmrnts) h hour(s) HATU l-[bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate HC1 hydrochloric acid HPLC high pressure liquid chromatography iPr isopropyl iPrOH isopropyl alcohol iPrzNEt or DIPEA or DIEA N-ethyl diisopropylamine (Hunig’s base) [Ir(l,5-COD)(OMe)]2 (1,5-Cyclooctadiene)(methoxy)iridium(I) dimer KOAc potassium acetate K PO. potassium phosphate LC MS, LCMS, LC-MS or LC / MS liquid chromatography mass spectroscopy LDA lithium diisopropylamide I HMDS or MHMDS lithium bis(trimethylsilyl)amide m / 'z mass divided by charge Me methyl MeCN acetonitrile MeOH methanol uL microliter / h-CPBA 3-chlorobenzene-1 -carboperoxoic acid mg milligrams min minutes mL or ml milliliters MS mass spectra MTBE methyl tert-butyl ether NBS A-bromosuccinimide NCS A7-chlorosuccinimide NESI y-fluorobenzenesulfonimide NIS / V-iodosuccinimide NsCl 4-nitrobenzenesulfonyl chloride NMP N-methyl- 2 -pyrroli dinone NMR nuclear magnetic resonance PE petroleum ether Pdz(dba)3 tris(dibenzylideneacetone)dipalladium(O) Pd(dppf)Ch [LE- bis(diphenylphosphino)ferrocene]dichloropalladium(II) Pd(PPh3)4 tetrakis(triphenylphosphine)palladium(0) PEPPSI-Ipent [l,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)dichloropalladium(II) Ph phenyl PPh3 triphenylphosphine PPTS pyridinium p-toluenesulfonate RBF round bottomed flask RP reverse phase RT or rt or r.t. room temperature RuPhos 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl RuPhosPd G4 methanesulfonato(2-dicyclohexylphosphino-2 ’ ,6 ’ - di-i-propoxy-1,1’ -biphenyl)(2 ’ -methylamino-1,1’- biphenyl-2-yl)palladium(II) sat. or satd saturated SFC supercritical fluid chromatography SPhosPd G3 (2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl) [2-(2'-amino-1 ,r-biphenyl)]palladium(II) methanesulfonate T3P propylphosphonic anhydride TEA or Et3N triethylamine TEA trifluoroacetic acid Tf2O trifluoromethanesulfonic anhydride THF tetrahydrofuran XPhos Pd G2 chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'- biphenyl)[2-(2'-amino-l,r-biphenyr)]palladium(II) General Analytical and Punhcation Methods Provided in this section are descriptions of the general analytical and purification methods used to prepare the specific examples provided herein. Chromatography; Unless otherwise indicated, crude product-containing residues were purified by passing the crude material or concentrate through either a Biotage or ISCO brand silica gel column pre-packed with flash silica (SiCh), or reverse phase flash silica (Cl 8) and eluting the product off the column with a solvent gradient as indicated. For example, a description of (330 g SiO2, 0-40% EtOAc / hexanes) means the product was obtained by elution from the column packed with 330 grams of silica, with a solvent gradient of 0% to 40% EtOAc in hexanes. Preparative HPLC Method: Where so indicated, the compounds described herein were purified via reverse phase HPLC using Waters FractionLynx semi-preparative HPLC-MS system utilizing one of the following two HPLC columns: (a) Phenomenex Gemini column (5 pm, C18, 150x30 mm) or (b) Waters X-select CSH column (5 pm, Cl8, 100x30 mm). A typical run through the instrument included: eluting at 45 mL / min with a linear gradient of 10% (v / v) to 100% MeCN (0.1% v / v formic acid) in water (0.1% formic acid) over 10 minutes; conditions can be varied to achieve optimal separations. Preparative SFC Method: Where so indicated, the compounds described herein were purified via SFC using Chiral SFC-80 (Thar, Waters) in an AD (20x250mm, 10pm) (Daicel) column. Proton NMR Spectra: Unless otherwise indicated, all 'H NMR spectra were collected on a Bruker NMR Instrument at 300, 400 or 500 MHz. Where so characterized, all observed protons are reported as parts-per-million (ppm) downfield from tetramethylsilane (TMS) using the internal solvent peak as reference. Mass Spectra (MS) Unless otherwise indicated, all mass spectral data for starting materials, intermediates and / or exemplary compounds are reported as mass / charge (m / z), having an [M+H]+ molecular ion. The molecular ion reported was obtained by electrospray detection method 5 (commonly referred to as an ESI MS) utilizing a Waters Acquity UPLC / MS system. Compounds having an isotopic atom, such as bromine and the like, are generally reported according to the detected isotopic pattern, as appreciated by those skilled in the art. Compound Names The compounds disclosed and described herein have been named using the IUPAC 10 naming function provided with JChem for Excel 18.22.1.7 from ChemAxon Ltd. Specific Examples Provided in this section are the procedures to synthesize specific examples of the compounds provided herein. All starting materials are either commercially available from Merck Sigma-Aldrich Inc., unless otherwise noted, or known in the art and may be 15 synthesized by employing known procedures using ordinary skill. Synthesis of Examples Method 1. Example 1-1: l-(6-(4-(3-hydroxynaphthalen-l-yl)-5,6,7,8-tetrahydroquinazolin-2-yl)- 2,6-diazaspiro [3.4] octan-2-yl)prop~2-en~l-one Step 1 HCI dioxane Step 3 Acryloyl chloride Et3N, DCM Step 4 Step 1: 4-(2-chloro-5,6,7,8-tetrahydroquinazolin-4-yI)naphthaIen-2-ol (A-l) To a degassed solution of 2,4-dichloro-5,6,7,8-tetrahydroquinazoline (0.5 g, 2.462 mmol, Combi-Blocks), 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)naphthalen-2-ol (0.665 g, 2.462 mmol, CAS: 2043962-01-0) and K2CO3 (0.681 g, 4.92 mmol) in 1,4-dioxane 10   (6 mL) and water (1.5 ml), was added PdC12(dppf)-DCM adduct (0.201 g, 0.246 mmol, Hindustan platinum). The reaction mixture was heated to 90 °C for 16 h. Upon completion, the reaction was allowed to cool to rt and was filtered through celite (washed with EtOAc). The filtrate was washed with water, brine solution, separated, dried over Na^-SCfi, filtered and concentrated in vacuo. The residue was farther purified by silica gel chromatography eluting 15 with a gradient of 40% to 50% EtOAc in PE, to provide 4-(2-chloro-5,6,7,8-tetrahydroquinazolin-4-yl)naphthalen-2-ol A-l (0.250 g, 0.804 mmol, 33% yield) as alight yellow liquid, m / z (ESI): 311.1 (M+H)+. Step 2: tert-butyl 6-(4-(3-hydroxynaphthalen-l-yI)-5,6,7,8-tetrahydroquinazolm-2-yI)-2,6-diazaspiro[3.4]octane-2-carboxylate (B-l) A solution of 4-(2-chloro-5,6,7,8-tetrahydroquinazolin-4-yl)naphthalen-2-ol A-l (0.25 g, 0.804 mmol), tert-butyl 2,6-diazaspiro[3.4]octane-2-carboxylate (0.124 g, 0.585 mmol, PharmaBlock), and DIPEA (0.281 mL, 1.61 mmol) in DMA (1.5 mL) was heated to 90 °C for 16 h. Upon completion, the reaction mixture was allowed to cool to rt. The mixture was diluted with water and extracted with EtOAc. The organic extracts were washed with brine solution, separated, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with a gradient of 70% to 90% EtOAc in hexanes, to provide tert-butyl 6-(4-(3-hydroxynaphthalen-l-yl)-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6-diazaspiro[3.4] octane-2-carboxylate B-l (0.200 g, 0.411 mmol, 52% yield) as a light yellow' solid, m / z (ESI): 486.9 (M+H)’. Step 3: 4-(2-(2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)naphthaIen-2-oi hydrochloride (C-l) To a solution of tert-butyl 6-(4-(3-hydroxynaphthalen-l-yl)-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate B-l (0.200 g, 0.411 mmol) in 1,4-dioxane (2 mL) wras added 4.0 M HC1 in 1,4-dioxane (2 mL, 65.8 mmol) at 0 °C. The reaction mixture was allowed to stir for 6 h at rt. The reaction mixture was concentrated under reduced pressure and triturated with Et2O to afford 4-(2-(2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)naphthalen-2-ol hydrochloride C-l (0.170 g, 0.402 mmol, 98% yield) as light yellow' solid, m / z (ESI): 387.9 (M+H)+. Step 4: l-(6-(4-(3-Hydroxynaphthalen-l-yI)-5,6,7,8-tetrahydroquinazoIin-2-yl)-2,6-diazaspiro [3.4] octan-2-yl)prop-2-en-l-one (Example 1-1) To a solution of 4-(2-(2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinazolin-4-yl)naphthalen-2-ol hydrochloride C-l (0.15 g, 0.355 mmol) and TEA (0.48 mL, 3.55 mmol) in DCM (2 mL) was added acryloyl chloride (0.021 mL, 0.284 mmol) at -78 °C. The resulting reaction mixture was stirred at rt for 10 min. The reaction mixture was then diluted with water and extracted with DCM. The combined organic extracts were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Gemini C18 column, 150x30 mm, 10-100% 0.1% TFA in MeCN / H2O) to afford 1 -(6-(4-(3-hydroxynaphthalen-1 -yl)-5,6,7,8-tetrahydroquinazoliii-2-yl)-2,6- diazaspiro[3.4]octan-2-yl)prop-2-en-l-one Example 1-1 (0.025 g, 0.057 mmol, 16% yield) as a white solid, m / z (ESI): 440.9 (M+H)+. ‘H NMR (400 MHz, DMSO->) 8 ppm 7.77 (d, >8.3 Hz, 1 H), 7.39 - 7.42 (m, 1 H), 7.31 (d, >8.3 Hz, 1 H), 7.17 - 7.24 (m, 2 H), 6.95 (d, >2.4 5 Hz, 1 H), 6.30 (dd, >17.0, 10.3 Hz, 1 H), 6.10 (dd, >17.1, 2.3 Hz, 1 H), 5.66 (dd, >10.2, 2.3 Hz, 1 H), 4.10 4.27 (m, 2 H), 4.07 4.11 (m, 2 H), 3.89 3.93 (m, 2 H), 3.66 3.69 (m, 2 H), 2.76 --2.79 (m, 2 H), 2.16 -- 2.22 (m, 3 H), 2.05 - 2.09 (m, 1 H), 1.77 - 1.81(m, 2 H), 1.57-1.61 (m, 2 H). 10 Table 2: Examples 1-2 to 1-54 were prepared following the procedure described in Method 1, Steps 1-4, above as follows: Ex.# Chemical Structure Name Method changes Reagent 1-2 z \ / o / =\ \= / 3-(2-acryloyl-2,6-diazaspiro[3.4]o ctan-6-yl)-1-(5-methyl-lH-indazol-4-yl)-2-naphtho-nitrile See below for alternative Step 2 Step 1: Intermediate 18 and (5-methyl-lH-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-3 M° N—, XKa crn V / n-nh 4-(5-methyl- 1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-6,7- dihydro-5H-cyclopenta[b]pyr idine-3-carbonitrile Step 1: Intermediate 3 and (5-methyl-177-indazol-4-yDboronic acid (CAS: 124581610-7, Combi-Blocks). Ex.# Chemical Structure Name Method changes Reagent 1-4 M° N—, c’c n-nh 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolmecarboni trile Step 1: Intermediate 4 and (5-methyl-l / Y-indazol-4-yDboronic acid (CAS: 124581610-7, Combi-Blocks). 1-5 M° N-, J^CN ui ^-N V 1 n-nh 8-(5-methyl- 1H-indazol-4-yl)-6-(2-(2- ' propenoyl)-2,6-diazaspiro[3.4]o ctan-6- yl)imidazo[l,2-aJpyridine-7-carbonitrile Step 1: Intermediate 17 and (5-methyl-l / Z-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-6 M° N—, 4c n-nh 8-methyl-4-(5-methyl-lH-indazol-4-vl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolinecarboni trile Step 1: Intermediate 5 and (5-methyl-1 / / -indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-7 % N^N 7. if 1. I| 1-(6-(4-(8-methyi-i -naphthalenvD- 5,6,7,8-^ ' tetrahydro-2-quinazolinyl)- 2,6- ’ diazaspiro[3.4]o Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and (8-methylnaphthalen-l-yl)boronic acid Ex.# Chemical Structure Name Method changes Reagent ctan-2-yl)-2-propen-l-one (CAS: 948592-914). 1-8 M° N—, XXX “XxO / X / n-nh (P)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-5,6,7,8-tetrahydro-3-qu inolin ecarboni trile, stereochemistry arbitrarily assigned [1st eluting atropisomer] See below for atropisomer separation conditions Step 1: Intermediate 6 and (5-methyl-177-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-9 ■x O M % X c \ JL.X X J 1-(6-(4-(8-chloro-1-naphthalenyl)- 5,6,7,8-tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-5,6,7,8-te trahy dr oqui n azo 1 i ne (CAS: 1127-851, Combi-Blocks) and (8-chloronaphthalen-l-yl)boronic acid (CAS: 230502253-9, Enamine). 1-10 M° K m-X / CN XXX |        [ M [1       | /         A ' n-nh (M)-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarboni trile, stereochemistry arbitrarily-assigned See below for atropisomer separation conditions Step 1: Intermediate 6 and (5-methyl-177-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Ex.# Chemical Structure Name Method changes Reagent [2nd eluting atropisomer] 1-11 M° N-^ N^N । 7¾ n-nh 1-(6-((7)-7-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: Intermediate 11 and (5-methyl-l / Z-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-12 M° N-, N^N । COO O' 1-(6-(4-(2-methyl-1-naphthalenyl)- 5,6,7,8-" tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichl oro-5,6,7,8-tetrahydroq uinazo li ne (CAS: 1127-851, Combi-Blocks) and (2-methylnaphthalen-l-yl)boronic acid (CAS: 103989-840, Combi-Blocks). 1-13 M° F n-nh 8-fluoro-2-((8)-8-fluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarboni trile Step 1: Intermediate 4 and (5-methyl-lH-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Step 2: Amine 1. Ex.# Chemical Structure Name Method changes Reagent 1-14 0 - n-nh 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propynoyl)-2,6-diazaspiro[3.4]o c ran- 6 -yl) - 3 -quinolinecarboni trile See below for alternative Step 4 Step 1: Intermediate 4 and (5-methyl-lZ / -indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-15 M° N-, N^N । w n-nh 1-(6-((8)-8-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: Intermediate 9 and (5-methyl-lH-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-16 w 0 M N-, N^N । 000 HN 1-(6-(4-(6-methyl-lH-indazol-7-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one See additional Step la (Example 125) for the synthesis of boronic ester Step 1: 2,4-dichl oro-5,6,7,8-tetr ahydr oq uinazo li ne (CAS: 1127-851, Combi-Blocks ) and 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- IH-indazole. Ex.# Chemical Structure Name Method changes Reagent 1-17 M° N—, N^N । n-nh 1-(6-(4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and (5-methyl-lZZ-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-18 M° N-, N^N Cl OH 1-(6-(4-(2-chloro-5-hydr oxypheny 1) - 5,6,7,8- ” tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and (2-chloro-5-hydroxyphenyl)bor onic acid (CAS: 913835-71-9, Combi-Blocks). 1-19 z Q ,zTV o / \ l-((5S)-5- . (difluoromethyl) -6-(4-(3-hydroxy-1 -naphthalenyl)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one, stereochemistry arbitrarily assigned See below for stereoisomer separation conditions of intermediate Step 1: Intermediate 10 and Step 2: Amine 2. Ex.# Chemical Structure Name Method changes Reagent 1-20 M° N—, N^N । n-nh l-(6-(9-methyl-6-(5-methyl-lH-indazol-4-yl)-9H-purin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)~2-propen-l-one Step 1: 2,6-dichloro-9-methyl-9H-purine (CAS: 2382-10-7, Combi-Blocks) and (5-methyl-1 / / -indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-21 M° N-, N^N if COO c* OH 1-(6-(4-(6-hydroxy-1-naphthalenvD- 5,6,7,8-" ' tetrahydro-2-quinazolinyl)-. 2’6" ' diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one See below for additional Step la for the synthesis of borons c ester Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-2-ol. 1-22 V d5 Cube IJUk OH 1-(6-(4-(3- hydroxy-1-naphthalenyl)-7-me thy Ipyr ido [ 3, 2-d]pvrimidin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one See below' for additional Steps la and 3a for the synthesis of boronic ester and latestage derivatizatio n Step 1: Intermediate 16. 1-23 M° d T nh2 N^N N=f 6¼5 1-(6-(4-(2- amin 0-1,3 -benzothiazol-4-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o See below' for additional Steps la-lb for the synthesis of boronic acid Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and (2-((tert-butoxycarbonyl)am ino)benzo[d]thiazol -4-vl)boronic acid. Ex.# Chemical Structure Name Method changes Reagent ctan-2-yl)~2-propen-l-one 1-24 ., O M 7? N^N Cl 1-(6-(4-(2,3-dichlorophenyl)- 5,6,7,8- tetrahydro-2-quinazolinyl)-. 2’6" ' diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and (2,3-    ' di chlorophenyl)bor onic acid (CAS: 151169-74-3, Combi-Blocks). 1-25 z fi—A 1 \   / ^x       \ / \          / —z o \ / z 1-(6-(4-(1,6-dimethyl-lH-indazol-7-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one See below for additional Steps la and 3a for the synthesis of boronic ester and latestage derivatizatio n Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indazole. 1-26 Eb N^N । 1-(6-(4-(2,3-dim ethylphenyl) -5,6,7,8- " tetrahydro-2-quinazolinyl)- . 2’6" ' diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and 2,3-dimethylphenylbor onic acid (CAS: 183158-34-1, Combi-Blocks). Ex.# Chemical Structure Name Method changes Reagent 1-27 M° N^N Cl 1-(6-(4-(2-chloro-3- methylphenyl)-5^6,7,8-^ tetrahydro-2-quinazolinyl)- 2,6- * diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and (2-chloro-3-me thy Iph enyl)boro nic acid (CAS: 915070-53-0, Combi-Blocks). 1-28 ... o M A N^N YA l if r ij l-(6-(8-methyl-4-(8-methyl-l-naphthalenyl)-7,8-dihydro-6H-pyrimido[5,4-b]n.4]oxazin-2-' > 1)-2.6- diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: Intermediate 13 and (8-methylnaphthalen-l-yl)boronic acid (CAS: 948592-914)- 1-29 M° A UJU 8-(5-hydroxy-2-methylphenyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)imidazo[l,2-a]pyridine-7-carbonitrile Step 1: Intermediate 17 and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2 -dioxaborolan-2-yl)phenol (CAS: 1196985-65-5). 1-30 /          z=<   > 1-(6-(7,7-dimethyl-4-(8- methyl-1-naplithalenyl)- 5,6,7,8-tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: Intermediate 10 and (8-methylnaphth al en-l-yl)boronic acid (CAS: 948592-914). Ex.# Chemical Structure Name Method changes Reagent 1-31 M° A N^N J 'll ^OH 1-(6-(4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)- 2,6- Step 1: Intermediate 10. diazaspiro[3.4]o ctan-2-yl)-2- propen-1-one 1-32 'N jf J F 0 1-(6-(4-(2-flu orop h eny 1)-7 -methyl-7H-pyrrolo[2,3-dlpyrimidin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Reagent (CAS: 90213-66-4) was methylated prior to Step 1 See below for details. Step 1: 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-dlpyrimidine (CAS: 90213-67-5) and (2-fluorophenyl)boron ic acid (CAS: 1993-03-9, Combi-Blocks). 1-33 JJ             / 'N J F 0 1-(6-(4-(2-fluorophenyl)-8-m ethyl-5,6,7,8-tetrahydropyrido P,3-d]pyrimidin-2- J yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Intermedia! e 15 was methylated prior to Step 1 See below for details. Step 1: 4-chloro-8-methyl-2-(methylthio)-5,67,8-tetrahydropyrido [2, 3-d]pyrimidine and ' ’ (2-fluorophenyl)boron ic acid (CAS: 1993-03-9, Combi-Blocks). Ex.# Chemical Structure Name Method changes Reagent 1-34 N n-nh 1-(5-methyl- 1H-indazol-4-yl)-3-(6-(2-propenoyl)-2,6-diazaspiro[3.3]h eptan-2-yl)-2-naphthalenecarb onitrile See below for alternative Step 2 Step 1: Intermediate 18 and (5-methyl-L¥-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Step 2: tert-butyl 2,6-     " diazaspiro [3.3]hept ane-2-carboxylate (CAS: 104102670-3). 1-35 M° N—J N^N 'V JI T 1 mn V / n-nh 1.(6-(4.(5-(2-propanyl)-lH-indazol-4-yl)- 5,6,7,8- ' tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one See below for additional Step la~lb for the synthesis of boronic ester Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and 5-isopropyl-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5’,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- IH-indazole. 1-36 w 0 M N-, N^N । Ji JI 1 ¢00 n-nh 1-(6-(4-(3,5-dimethyl-lH-indazol-4-yl)-5,6,7,8- ’ tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one See below for additional Step la-le for the synthesis of boronic ester Step 1: 2,4-dichloro-5,6,7,8-tetrahydroquinazoli ne (CAS: 1127-851, Combi-Blocks) and 3,5-dimethyl-1 -(tetrahydro-2H-pyran-2-yl)-4-' (4,4,5’,5 -tetramethyl-1,3,2-dioxaborolan-2-yl)- IH-indazole. Ex.# Chemical Structure Name Method changes Reagent 1-37 M° N—? J^CN zOQ V / n-nh 3-methyl-8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)imidazo[l,2-a]pyridine-7-carbonitrile Step 1: Intermediate 19 and (5-methyl-l H-indazol-4-yljboronic acid (CAS: 124581610-7, Combi-Blocks). 1-38 M° N-^ N^ O^CN ,00¾. Xju Ph      V / n-nh 8-(5-methyl- 1H-indazol-4-yl)-2-phenyl-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)imidazo[l,2-a]pyridine-7- carbonitrile Step 1: Intermediate 8 and (5-methyl-lH-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-39 M° XN Si n-nh 2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-8-fluoro-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarboni trile Step 1: Intermediate 4 and (5-methyl-UZ-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Step 2: tert-butyl 8,8-difluoro-2,6-diazaspiro[3.4] octa ne-2-carboxylate (CAS: 213799774-9, PharmaBlock). Ex.# Chemical Structure Name Method changes Reagent 1-40 K\    O M N-^ N^N । 4¾ n-nh l-(6-(7-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-7-methylquinazoline (CAS: 25171-19-1) and (5-methyl-lH-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-41 M° ¾ N^N । n-nh 1-(6-(7-methoxy-4-(5-methyl-lH-indazol-4-yl)-2-quinazolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 2,4-dichloro-7-methoxyquinazolin e (CAS: 62484-315) and (5-methyl-l / T-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-42 M° A 1-(6-(4-(8-methyl-1-naphthalenyl)-7,8-dihydro-6H-pyrano[3,2-d]pyrimidin-2- J yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: Intermediate 14 and (8-methylnaphth al en-l-yl)boronic acid (CAS: 948592-914). Ex.# Chemical Structure Name Method changes Reagent 1-43 N F< j ^n^ ' A n-nh 2,-(5,5-difluoro-2-(2-propenoyl)-2,7-diazaspiro[3.5]n onan-7-yl)-8-fluoro-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarboni trile Step 1: Intermediate 4 and (5-methyl-L¥-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Step 2: 2,7- D i azaspiro [3.5] non ane - 2 - c a r b oxy lie acid, 5,5-difmoro-, 1,1 -dimethylethyl ester (CAS: 2007920-32-1). 1-44 M° N-, 0 N 'A n-nh 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(5-oxo-2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolinecarboni trile See below for alternative Step 2 Step 1: Intermediate 4 and (5 -methyl-1 H-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Step 2: 2,6-diazaspirop .41 octa ne-2-carboxyIic acid, 5-oxo-, 1,1-dimethylethyl ester (CAS: 133076539-3). 1-45 . .A n-nh 7-meth oxy-4-(5 -methyl- 1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolinecarboni trile Step 1: Intermediate 7 and (5-methyl-l / / -indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Ex.# Chemical Structure Name Method changes Reagent 1-46 Me2N       Q A N-NH 2-(2-((2E)-4-(dimethylamino) -2-butenoyl)-2,6- " ' diazaspiro[3.4]o ctan-6-yl)-8-fluoro-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarboni trile See below for alternative Step 4 Step 1: Intermediate 4 and (5-methyl-lH-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). 1-47 '% O __ / N v Ya / n==\ f HO     \_ / l-((5R)-5-(difluoromethyl) -6-(4-(3- ’ hydroxy-1-naphthalenyl)-7,7-dimethyl- 5,6,7,8-^ tetrahydro-2-quinazolinyl)- 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one, stereochemistry arbitrarily assigned See below for stereoisomer separation conditions of intermediate Step 1: Intermediate 10 and Step 2: Amine 2. 1-48 AL J^CN O v / n-nh 8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)[l,2,4]triazolo [l,5-a]pyridine-7-carbonitrile See below for A lternate Step 2. Step 1: intermediate 53. Ex.# Chemical Structure Name Method changes Reagent 1-49 M° N—, / ^n^ n-nh 8-fluoro-2-(5-(fluoromethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarboni idle Step 1: Intermediate 4 and (5-methyl-L¥-indazol-4-yl)boronic acid (CAS: 124581610-7, Combi-Blocks). Step 2: tert-butyl 5-(fluoromethy 1)-2,6-diazaspiro[3.4]octa ne-2-carboxylate (LabNetwork). 1-50 M° N—, nV| 11 JL 1 v / n-nh l-methyl-4-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-lH-pyrrolo[2,3-b]pyridine-5-carbonitrile Alternative Step 2 done in analogous manner to Example 144, Step 3: TFA, DCM instead of HC1, dioxane Step 4: DIPEA replaced TEA. Step 1: Intermediate 39 and (5-methyl-1-(tetrahydro-2H-pyran-2-y 1)-1H-indazol-4-yl)boronic acid (PharmaBlock). 1-51 v° Br "j ■4: n-nh 2-(2-(2 -bromo-2-propenoyl)-2,6-diazaspiro[3.4]o c ran- 6 -y 1) - 8 -fluoro-4-(5-methyl-lH-indazol-4-yl)-3-quinolinecarboni idle See alternate Step 4 from Example 146 Step 1: Intermediate 4 and (5-methyl-17 / -indazol-4-yl)boronic acid (Combi-Blocks). Step 4: 2-bromoacrylic acid (CAS#10443-65-9) Ex.# Chemical Structure Name Method changes Reagent 1-52 M° N n l ( 1 n-nh 8-(5-methyl- 1H-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-(l-pyrrolidinyl)imi dazo[l,2-a]pyridine-7- carbonitrile Alternative Step 2 done in analogous manner to Example 144. Step 3: TFA, DCM instead of HO, dioxane Step 4: DIPEA replaced TEA. Step 1: Intermediate 111 and (5-methyl-1-(tetrahydro-2H-pyran-2-yl)-lH-indazol-4-yl)boronic acid (PharmaBlock). 1-53 M° % NM ~~jfj v i n-nh 8-(5-methyl-lH-indazol-4-yl)-3-(4-methyl-l-piperazinyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)imidazo[l,2-a]pyridine-7-carbonitrile Alternative Step 2 done in analogous manner to Example 144. Step 3: TFA, DCM instead of HC1, dioxane Step 4: DIPEA replaced TEA. Step .1: Intermediate 112 and (5-methyl-1-(tetrahydro-2H-pyran-2-y 1)-1H-indazol-4-yl)boronic acid (PharmaBlock). 1-54 x\ O M N-^ A™, A ju N=\     V j^xs n-nh 8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-2-(l,3-thiazol-2-yl)imidazo[l,2-a]pyridine-7-carbonitrile Alternative Step 2 done in analogous manner to Example 144. Step 3: TFA, DCM instead of HC1, dioxane Step 4: DIPEA replaced TEA. Step 1: Intermediate 113 and (5-methyl-1-(tetrahydro-2H-pyran-2-yl)-lH-indazol-4-yl)boronic acid (PharmaBlock). Step 2a prior to acrylamide installation for Examples 1-19 and 1-47. Peak-1                             Peak-2 Ex. 1-19 Ex. 1-47 Step 2a: tert-butyl 7-(difluoromethyl)-6-(4-(3-hydroxynaphthalen-l~yl)~7,7-dimethyI-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxyIate A solution of 4-(2-diloro-7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-4-yl)naphthalen-2-ol (obtained by arylation of Intermediate 10 as in Method 1, step 1) (0.30 g, 0.885 mmol), tertbutyl 7-(difluoromethyl)-2,6-diazaspiro[3.4]octane-2-carboxylate (0.279 g, 1.062 mmol) and DIPEA (0.464 mL, 2.66 mmol) in DMA (1 mL) was heated at 120 °C for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was purified on a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 80-100% EtOAc in PE to provide tert-butyl 7-(difluoromethyl)-6-(4-(3-hydroxynaphthalen-l-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (0.25 g, 0.443 mmol, 50% yield) as a white solid. !H NMR (400 MHz, DMSO-A): 8 ppm 9.94 (s, 1 H), 7.78 (d, . / 8 4 Hz, 1 H), 7.37 - 7.47 (m, 1 H), 7.13 - 7.31 (m, 3 H), 7.00 (s, 1 H), 6.43 (t, >54.8 Hz, 1 H), 4.28 - 4.52 (br m, 1 H), 3.80 (br s, 6 H), 2.58 (s, 2 H), 1.93 -- 2.43 (m, 6 H), 1.37 (s, 9 H), 0.97 (br s, 6 H). m / z (ESI): 564.8 The racemic mixture (0.25 g) was separated by Lux C4 Chiral column (250x50mm, 5g) using 75% Liquid CO2 and 25% MeOH:MeCN (1:1) to provide tertebutyl (S)-7-(difluoromethyl)-6-(4-(3-hydroxynaphthalen-l-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (0.10 g) as Peak 1 and tert-butyl (2?)-7-(difluoromethyl)-6-(4-(3-hydroxynaphthalen-l-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (0.10 g) as Peak 2. The stereochemistry of structures was arbitrarily assigned and are not established. Peak 1: ‘H NMR (400 MHz, DMSO-<) 8 ppm 9.95 (br s, 1 H), 7.78 (d, 7==8.3 Hz, 1 H), 7.37 - 7.47 (m, 1 H), 7.16 -- 7.31 (m, 3 H), 7.00 (s, 1 H), 6.43 (br t, 7=58.0 Hz, 1 H), 4.26 - 4.53 (br m, 1 H), 3.80 (br s, 6 H), 2.58 (s, 2 H), 1.92 - 2.44 (m, 6 H), 1.37 (s, 9 H), 0.97 (s, 6 H). 19F NMR (377 MHz, DMSO-J6) 8 ppm -12.3.12 (d, 7=281.3 Hz), -133.79 (d, 7=282.0 Hz). m / z (ESI): 564.8 (M+H)+. Peak 2: H NMR (400 MHz, DMSO-<) 8 ppm 9.94 (s, 1 H), 7.78 (d, 7==8.3 Hz, 1 H), 7.37 3.45 (m 1 H), 7.17 - 7.33 (m, 3 H), 7.00 (d, 7=2.5 Hz, 1 H), 6.43 (br t, 7=58.0 Hz, 1 H), 4.26 - 4.51 (br m, 1 H), 3.80 (br s, 6 H), 2.58 (s, 2 H), 1.87 - 2.44 (m, 6 H), 1.37 (s, 9 H), 0.97 (s, 6 H). 19F NMR (377 MHz, DMSO-76) 8 ppm -123.12 (d, 7=281.2 Hz), -133.79 (d, 7=282.3 Hz), m / z (ESI): 564.8 (M+H)\ Additional Step la prior to Suzuki coupling for Example 1-21. Step 1a Step la: 5-(4,4,5,5-tetramethyl~l,392~dioxab0roIan-2-yI)naphtiiaIen-2-ol To a degassed solution of 5-bromonaphthalen-2-ol (1.5 g, 6.7 mmol, synthesized according to ACIE 2019, 58, 4596), bis(pinacolato)diboron (2.56 g, 10.1 mmol) and potassium acetate (1.980 g, 20.2 mmol) in DMF (15 mL) was added PdCb(dppf)-DCM adduct (0.110 g, 0.134 mmol) and the mixture was heated at 100 °C at for 16 h. Then the reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified on a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0-10% EtOAc in hexanes to provide 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)naphfnalen-2-ol (1.5 g, 83% yield) as an off-white solid. lH NMR (400 MHz, CDCh) 8 ppm 8.65 - 8.75 (m, 1 H), 7.95 (dd, 7=6.9, 1.4 Hz, 1 H), 7.79 (dt, 7=8.3, 1.2 Hz, 1 H), 7.39-7.49 (m, 1 H), 7.14-7.21 (m, 2 H), 1.44 (s, 12 H). m / z (ESI): 271.1 (M+H)+. Synthesis of boronic ester (Step la) and additional Step 3a for Example 1-22. Step la: 2-(3-methoxynaphthaIen-l-yI)-4,4,5,5-tetramethyH,3?2-dioxaborolane To a solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)naphthalen-2-ol (1,0 g, 3,7 5 mmol) and K2CO3 (1.54 g, 11,1 mmol) in DMF (10 mL) was added methyl iodide (0.347 mL, 5.55 mmol). The resulting mixture was stirred at rt for 2 h before it was diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to provide 2-(3-methoxynaphthalen-l-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (1.0 g, 95% yield) which 10 was taken to the next step without purification. 'H NMR (400 MHz, DMSO-rA) 5 ppm 8.54 (dd, . / 8.4. 1.3 Hz, 1 H), 7.84 (dd, . / 8.2. 1.5 Hz, 1 H), 7.56 (d, . / 2.8 Hz, 1 H), 7.44 7.50 (m, 2 H), 7.38 - 7.42 (m, 1 H), 3.88 (s, 3 H), 1.37 (s, 12 H). Step 3a: 4-(7-methyI-2-(2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)naphthaIen-2-oI 15 To a solution of tert-butyl 6-(4-(3-methoxynaphthalen-l-yl)-7-methylpyrido[3,2-d]pyrimidin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (0.14 g, 0.274 mmol) in DCM (0.7 mL) -was added BBrj (IM solution in DCM) (0.82 mL, 0.82 mmol, Sigma-Aldrich) at -78 °C. The reaction mixture was warmed up to rt and stirred for 1 h before it wras quenched with satd NaHCOs and extracted with 10% MeOH in DCM. The organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to provide 4-(7-methyl-2-(2,6-diazaspiro[3.4]octan-6-yl)pyrido[3,2-d]pyrimidin-4-yl)naphthalen-2-ol which was taken to the next step without purification, m / z (ESI): 398.0 (M+H)+. Additional Steps la - lb prior to Suzuki coupling for Example 1-23. Br BOC2O, DMAP TEA, DCM Step 1 a Br NaH, n-BuLi B(OMe)3, THF Step 1 b HO. ,OH B Step la: tert-butyI(4-bromobenzo[d]thiazol-2-yI)carbamate To a solution of 4-bromobenzo[d]thiazol-2-amine (5.0 g, 21.8 mmol, Combi-Blocks) in DCM (50 mL) were added DMAP (2.67 g, 21.8 mmol), TEA (9.13 mL, 65.5 mmol) and (Boc)zO (5.57 mL, 24.01 mmol). The reaction mixture was stirred at rt for 15 h before it was diluted with water and extracted with DCM. The organic extracts were washed with brine, separated, dried over Na2SO4, filtered and concentrated. The residue was purified on a RediSep pre-packed silica gel column (40 g), eluting with 10-20% EtOAc in hexanes to afford tert-butyl (4-bromobenzo[d]thiazol-2-yl)carbamate (1.5 g, 21% yield) as an off-white solid. ‘H NMR (400 MHz, DMSO-ri6) 8 ppm 12.14 (s, 1 H), 7.96 (dd, . / 7 9. 1.1 Hz, 1 H), 7.64 (dd, . / 7.8. 1.1 Hz, 1 H), 7.19 (t, 7==7.9 Hz, 1 H), 1.51 (s, 9 H). m / z (ESI): 330.8 Step lb: (2-((tert-butoxycarbonyl)amino)benzo[d]thiazol-4-yl)boronic add To a solution of tert-butyl (4-bromobenzo[d]thiazol-2-yl)carbamate (1.0 g, 3.04 mmol) in THF (15 mL) was added sodium hydride (0.20 g, 4.56 mmol) and stirred for 10 min. Then the reaction mixture was cooled to -78 °C and n-BuLi (1.82 mL, 4.56 mmol, 2.5 M solution in hexanes) was added dropwise. Then the reaction mixture was stirred for 30 min before triisopropyl borate (2.12 mL, 9.11 mmol) was added dropwise. Then the reaction mixture was slowly warmed up to rt over 30 min before it was quenched with a satd aqueous solution of NH4CI and extracted with EtOAc. The combined organic extracts were washed with water and brine, separated, dried over Na2SO4, filtered and concentrated. The residue was purified on a Redi-Sep pre-packed silica gel column (24 g), eluting with 80% EtOAc in PE to afford (2-((tert-butoxycarbonyl)amino)benzo[d]thiazol-4-yl)boronic acid (0.3 g, 34% yield) as an off white solid. !H NMR (400 MHz, DMSO-O 8 ppm 11.98 (s, 1 H), 8.60 (s, 2 H), 8.03 (d, . / ST Hz, 1 H), 7.81 (d, . / 2.8 Hz, 1 H), 7.31 (t, 7==8.8 Hz, 1 H), 1.53 (s, 9 H). m / z (ESI): 295.0 (MH). Additional Step la (prior to Suzuki coupling) and Step 3a (late-stage derivatization) for Example 1-25. Step 1a Step la: 6-methyI-7-(4,4,5,5-tetramethyI-l,3,2-dioxaboroIan-2-yl)-lH-indazole To a degassed solution of 7-bromo-6-methyl-lH-indazole (3.0 g, 14.21 mmol, BLD Pharma), bis(pmacolato)diboron (5.41 g, 21.3 mmol) and potassium acetate (4.19 g, 42.6 mmol) in 1,4-dioxane (30 ml) was added PdCLtdppfl-DCM adduct (0.87 g, 1.07 mmol) and the mixture was heated at 100 °C for 16 h. Then the reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified on a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 0-10% EtOAc in hexanes to provide 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (2.2 g, 60% yield) as an off-white solid. lH NMR (400 MHz, DMSO-J6) 5 ppm 12.16 (s, 1 H), 8.03 (s, 1 H), 7.75 (d, 7=8.2 Hz, 1 H), 6.98 (d, 7=8.2 Hz, 1 H), 2.61 (s, 3 H), 1.37 (s, 12 H). m / z (ESI): 259.0 (Mln. Step 3a: tert-butyl 6-(4-(1,6-dimethyI-lH-indazoI-7-yI)-5,6,7,8-tetrahydroquinazoIin-2-yI)-2,6-diazaspiro[3.4]octane-2-carboxy!ate To a solution of tert-butyl 6-(4-(6-methyl-lH-indazol-7-yl)-5,6,7,8-tetrahydroquinazolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (0.20 g, 0.421 mmol) in acetone (10 mL) were added KOH (0.071 g, 1.26 mmol) and methyl iodide (0.053 mL, 0.84 mmol) at 0 °C. The resulting mixture was stirred at rt for 12 h before it was diluted with water and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified on a Redi-Sep pre-packed 5 silica gel column (12 g), eluting with a gradient of 0-40% EtOAc in PE to provide tert-butyl 6-(4-( 1,6-dimethyl-1 H-indazol-7-y 1)-5,6,7,8-tetrahydroquinazolin-2-y 1)-2,6- diazaspiro[3.4]octane-2-carboxylate as a yellow solid, m / z (ESI): 489.9 (M+H)L Step la prior to Suzuki coupling for Example 1-32. 10 Step la: 2,4-dichloro~7-methyl-7H-pyrrolo[2,3-d]pyrimidine To a solution of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (CAS: 90213-66-4,1.50 g, 7.98 mmol) and CS2CO3 (2.60 g, 7.98 mmol) in DMF (20 mL) was added iodomethane (2.27 g, 15.96 mmol). The reaction was allowed to stir for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts 15 -were dried over anhydrous Na2SO4, concentrated and purified by silica gel column chromatography through a Redi-Sep pre-packed silica gel column (40 g), eluting with 0-15% EtOAc in PE to provide 2,4-dichloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (1.40 g, 87% yield) as white solid, m / z (ESI): 202.0 (M+H)+. Step la prior to Suzuki coupling for Example 1-33. Mel, NaH DMF Step 1a SMe Intermediate 15 Step la: 4-chloro-8-methyl-2-(methylthio)-5,6,7,8-tetrahydropyrido[2,3-d]pyriimdine To a stirred solution of 4-chloro-2-(methylthio)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine (Intermediate 15, 1.0 g, 4.64 mmol) in DMF (20 mL) was added sodium hydride (0.278 g, 6.95 mmol) at 0 °C. The reaction was stirred for 20 min. Then, iodomethane (0.722 mL, 11.59 -nmol) was added drop wise at 0 °C and stirred for 3 h. Upon completion, the reaction mixture was slowly quenched with ice. The reaction was extracted with EtOAc (2 x 75 mL), washed with water (100 mL), brine (TOO mL), dried over Na2SO4 and concentrated in vacuo to provide 4-chloro-8-methyl-2-(methyhhio)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine (1.0 g, 94% yield) as an off-white solid, m / z (ESI): 230.1 (M+H)1. Steps la-lb for the synthesis of boronic ester for Example 1-35. Step la: 4-bromo-5-isopropyI-l-(tetrahydro-2H-pyran-2-yI)-lH-indazoIe A solution of 4-bromo-3,5-dimethyl-lH-indazole (4.0 g, 16.73 mmol, synthesized according to the procedure described in WO2017201161), 3,4-dihydropyran (6.12 mL, 66.9 mmol) and PPTS (0.84 g, 3.35 mmol, Spectrochem) in DCM (50 mL) was stirred at rt for 16 h. Then the reaction mixture was diluted with water and extracted with DCM. The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified on a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 10-15% EtOAc in hexanes to provide 4-bromo-5-isopropyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole (4.00 g, 74% yield), m / z (ESI): 322.8 (M+H)'. Step lb: 5-isopropyM-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxabortdan-2-yI)-lH-mdazole 5 To a degassed solution of 4-bromo-5-isopropyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole (4.0 g, 12.4 mmol), bis(pinacolato)diboron (3.14 g, 12.4 mmol, Spectrochem) and potassium acetate (1.22 g, 12.4 mmol) in 1,4-dioxane (50 mL) was added PdCh(dppf)-DCM adduct (1.0 g, 1.24 mmol, Chempure) and the mixture was heated at 90 °C for 16 h. Then the reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was 10 concentrated under reduced pressure and the residue was purified on a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 10-15% EtOAc in hexanes to provide 5-isopropyl-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)-TH-indazole (3.0 g, 66% yield), m / z (ESI): 371.0 (M+H)+. Steps la-le for the synthesis of boronic ester for Example 1-36. 15 Step 1e Step la: l-(2-bro>mo-6-nuoro-3-methyIphenyI)ethan-l-oI To a solution of 2-bromo-6-fluoro-3-methylbenzaldehyde (12.0 g, 55.3 mmol, Combi-Blocks) in THF (150 mL) was dropwise added methyl magnesium bromide (3.0 M solution in EtjO) (36.9 mL, 111 mmol, Symax) at -20 °C and the reaction mixture was stirred at 0 °C for 2 h. Then the reaction mixture was quenched with a satd aqueous solution of NH4CI and extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified on a Redi-Sep pre-packed silica gel column (120 g), eluting with a gradient of 10-15% EtOAc in hexanes to provide l-(2-bromo-6-fluoro-3-methylphenyl)ethan-l-ol (12.0 g, 93% yield). 'H NMR (400 MHz, DMSO-O 8 ppm 7.29 (dd, / =8.4, 5.7 Hz, 1 H), 7.11 (dd,. / I1.0, 8.4 Hz, 1 H), 5.31 (dd, / =20.7, 5.9 Hz, 1 H), 2.34 (s, 3 H), 1.43 (dd, / =6.6, 1.2 Hz, 3 H). Step lb: l-(2-bromo~6-fluoro-3-methyIphenyI)ethan-l-one To solution of l-(2-bromo-6-fluoro-3-methylphenyi)ethan-l-ol (12.0 g, 51.5 mmol) in DCM (150 mL) was added Dess-Martin periodinane (32.8 g, 77.0 mmol, Chempure) and the reaction mixture was stirred at 0 °C for 1 h. Then the reaction mixture was quenched with a satd aqueous solution of sodium carbonate and extracted with DCM. The combined organic extracts were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified on a Redi-Sep pre-packed silica gel column (120 g), eluting with a gradient of 5-10% EtOAc in hexanes to provide l-(2-bromo-6-fluoro-3-methylphenyl)ethan-l-one (10.0 g, 84% yield) as a light-yellow oil. ‘H NMR (400 MHz, CDCI3) 8 ppm 7.26 (dd, / =7.5, 6.0 Hz, 1 H), 7.01 (t, / =8.5 Hz, I H), 2.59 (s, 3 H), 2.41 (s, 3 H). Step 1c: 4-bromo-3,5-dimethyHH-indazoIe To a solution of l-(2-bromo-6-fluoro-3-methylphenyl)ethan-l-one (9.0 g, 39.0 mmol) in DMSO (10 mL) was added hydrazine hydrate (9.75 g, 195 mmol, Spectrochem) and the reaction mixture was heated at 110 °C for 16 h. The reaction mixture was quenched with icecold water and the precipitated solid was filtered, washed with water and EtzO, and dried to provide 4-bromo-3,5-dimefnyl-lH-indazole (4.5 g, 51% yield). 'HNMR (400 MHz, DMSO-ds) 8 ppm 12.81 (s, 1 H), 7.37 (d, / =8.4 Hz, 1 H), 7.26 (d, / =8.4 Hz, 1 H), 2.67 (s, 3 H), 2.42 (s, 3 H). m / z (ESI): 224.9 (M+H)+. Step Id: 4-bromo-3,>(Mmethyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole A solution of 4-bromo-3,5-dimethyl-lH-indazole (4.5 g, 20.0 mmol), 3,4-dihydropyran (1.83 mL, 20.0 mmol) and PPTS (5.0 g, 20.0 mmol, Spectrochem) in DCM (100 ml) was stirred at rt for 16 h. Then the reaction mixture was diluted with 'water and extracted with DCM. The combined organic extracts were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified on a Redi-Sep pre-packed silica gel column (40 g), eluting with a gradient of 5-10% EtOAc in hexanes to provide 4-bromo-3,5-dimethyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole (4.0 g, 65% yield), m / z (ESI): 309.8 (M+H)+. Step le: 3,5-dimethyl-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaboroIan-2-yi)-lH-indazo>le To a degassed solution of 4-bromo-3,5-dimethyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole (4.0 g, 12.94 mmol), bis(pinacolato)diboron (3.94 g, 15.5 mmol, Spectrochem) and potassium acetate (1.90 g, 19.40 mmol) in 1,4-dioxane (50 mL) was added PdC12(dppf)-DCM adduct (1.06 g, 1.29 mmol, Chempure) and the mixture was heated at 90 °C for 16 h. Then the reaction mixture was filtered through a pad of celite and washed with EtOAc. The filtrate was concentrated trader reduced pressure and the residue was purified on a Redi-Sep prepacked silica gel column (40 g), eluting with a gradient of 10-15% EtOAc in hexanes to provide 3,5-dimethyl-l-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazole (3.0 g, 65% yield), m / z (ESI): 357.0 Alternative Step 2 for Example 1-44. Step 2: tert-butyl 6-(3-Cyano-8-niioro-4-(5-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazoI-4-yl)quinolin-2-yI)-5-oxo-2,6-diazaspiro[3.4]octane-2-carboxyIate To a solution of 2-chloro-8-fluoro-4-(5-methyl-l -(tetrahydro-2H-pyran-2-yl)-l H-indazol-4-yl)quinoline-3-carbonitrile (200 mg, 0,475 mmol), tert-butyl 5-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate (129 mg, 0.57 mmol), CS2CO3 (464 mg, 1.43 mmol) and 1,4-dioxane (5 mL) was added Pd?(dba)3 (43.5 mg, 0.048 mmol) and RuPhos (44.4 mg, 0.095 mmol). The system was evacuated and then refilled with N2- The reaction was stirred at 120°C for 3 h. Upon completion, the reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 50 mL). The organic extract was washed with brine (3 x 15 mL), dried over NaiSCh, and concentrated in vacuo. The crude material was absorbed onto a plug of silica gel and purified by chromatography through a Redi-Sep pre-packed silica gel column (12 g), eluting with a gradient of 0-70% EtOAc in PE, to provide tert-butyl 6-(3-cyano-8-fluoro-4-(5-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-4-yl)quinolin-2-yl)-5-oxo-2,6-diazaspiro[3.4]octane-2-carboxylate (60 mg, 21% yield) which was used in the following step as is. Alternative Step 4 for Example 1-46. Step 4: (E)-2-(2~(4-(dimethyIami!io)but~2“enoyI)~2,6-diazaspiro[3.4]octan-6~yI)~8-fluoro-4-(5-methyHH-indazoI-4-yl)qumolme-3-carb(mitriIe A solution of 8-fluoro-4-(5-methyl-lH-indazol“4-yl)-2-(2,6-diazaspiro[3.4]octan-6-yl)quinoline-3-carbonitrile (80 mg, 0.194 mmol), (E)-4-(dimethylamino)but-2-enoic acid (35.1 mg, 0.272 mmol), HATU (118 mg, 0.31 mmol) and DIPEA (102 pL, 0.582 mmol) in DMF (2 mL) was stirred at ri for 2 h. Upon completion, the reaction was diluted with water and EtOAc. The mixture was separated and the water phase was extracted with EtOAc twice. The combined organic layers were washed by brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by Prep-HPLC (Phenomenex Gemini CIS column, 150x30 mm, 10-100% 0.1% TFA in MeCN / H2O) to give (E)-2-(2-(4-(dimethylamino)but-2-enoyl)-2,6-diazaspiro[3.4]octan-6-yl)-8-fluoro-4-(5-methyl-lH-indazol-4-yl)quinoline-3-carbonitrile 5    (70 mg, 69 % yield), m / z (ESI): 524.2 (MHT)+. Alternative Step 2 for Examples 1-2 and 1-34. RuPhos Pd G4, Cs2CO3, dioxane:H2O Step 2 Step 2: tert-butyl 6-(3-cyano-4-(5-methyI-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-4-yl)naphthalen-2-yI)-2,6-diazaspiro[3.4]octane-2-carboxylate 10 A mixture of 3-chloro-1 -(5-methyl-1 -(tetrahydro-2H-pyran-2-yl)-lH-indazol-4-yl)-2-naphthonitrile (220 mg, 0.547 mmol), RuPhos Pd G4 (30 mg, 0.05 mmol, Greenchem), CS2CO3 (535 mg, 1.642 mmol), and tert-butyl 2,6-diazaspiro[3.4]octane-2-carboxylate (139 mg, 0.657 mmol) in 1,4-dioxane (5 mL) was stirred at 130 °C for 3 h under microwave irradiation. The reaction was extracted with DCM (50 mL x 2). The organic phase was 15 washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude material was purified by silica gel flash chromatography (EtOAc : PE = 5:1, v / v) to afford the title compound (202 mg, 63% yield) as a yellow solid, m / z (ESI): 578.3 (M+H)+. Alternative Step 4 for Example 1-14. OH EDCI, DIPEA DMF Step 4 Step 4: 8-fl«oro-4-(5-methyI-lH-indazol-4-yI)-2-(2-propioIoyl-2,6-diazaspiro[3.4]octan-6-yI)quinoIine-3-carbonitrile 5 To a solution of 8-fhioro-4-(5-methyl-lH-indazol-4-yl)-2-(2,6-diazaspiro[3.4]octan-6-yl)quinoline-3-carbonitrile (70 mg, 0.17 mmol) in DMF (2 mL) was added DIPEA (89 pL, 0.51 mmol), 3-(((ethylimino)methylene)amino)-N,N-dimethylpropan-l-amine (81 mg, 0.424 mmol), and propiolic acid (24 mg, 0.339 mmol). The mixture was stirred at room temperature for 2 h. Upon completion, the reaction was diluted with water and EtOAc. The layers were 10 partitioned and the water layer was extracted with EtOAc twice. The combined organic extracts were washed "with brine, dried over MgSO4, and concentrated in vacuo. The crude material was purified by Prep-HPLC (Phenomenex Gemini C18 column, 150x30 mm, 10100% 0.1% TFA in MeCN / H2O) to give 8-fluoro-4-(5-methyl-lH-indazol-4-yl)-2-(2-propioloyl-2,6-diazaspiro[3.4]octan-6-yl)quinoline-3-carbonitrile (60.0 mg, 76% yield), m / z 15 (ESI): 465.1 (M+H)1. Atropisomer separation conditions for Examples 1-8 and 1-10. n-nh Atropisomer separation: The racemic mixture was separated by Chiral SFC-80 (Thar, Waters) in an AD (20x250mm, 10pm) (Daicel) column using liquid CO2 : MeOH (0.5% NH3) and EtOH (70:30) at 35°C with a flow rate of 80 g / min to provide the respective P and M isomers of 7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6"yl)"5,6,7,8-tetrahydro”3-quinolinecarbonitrile (110 mg, 0.229 mmol, 39% yield ). The stereochemistry of structures was arbitrarily assigned and is not established. I3' eluting atropisomer assigned as the P isomer and 2"° eluting atropisomer assigned as the M isomer, m / z (ESI): 481.2 (M+H)+. Alternative Step 2 for Example 1-48 n-nh A mixture of tert-butyl 2,6-diazaspiro[3.41octane-2-carboxyiate (19.84 mg, 0.093 mmol), 6-bromo-8-(5-methyl-lH-indazol-4-yl)-[l,2,4]triazolo[l,5-a]pyridine-7-carbonitrile (30mg, 0.085 mmol), sodium tert-butoxide (16.33 mg, 0.170 mmol), BINAP (5.29 mg, 8.49 pmol), and Pd3(dba)3 (7.78 mg, 8.49 nmol) in 1,4-dioxane was stirred for 16h at 90°C in a RBF under N2. LC-MS suggests complete conversion. The reaction mixture was filtered through a pad of Celite and rinsed with EtOAc, and the filtrate was concentrated in vacuo, purified by HPLC to give the desired product tert-butyl 6-(7-cyano-8-(5-methyl-lH-indazol-4-yl)-[l,2,4]triazolo[l,5-a]pyridin-6-yl)-2,6-diazaspiro[3.4]octane-2-cafboxylate (10 mg, 24.3% yield) as a white solid. Method 2. Example 2-1: 2-(2-acryIoyI-2,6-diazaspiro[3.4]octan-6-yI)-7-methyI-4-(5-methyHH- indazoI-4-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile C-2                                        Example 2-1 5 Step h tert-butyl 6-(4-chioro-3-cyano-7-methyl-5,6,7,8-tetrahydroquinolin-2-yI)-2,6-diazaspiro [3.4] octane-2-carboxy late (A-2) tert-Butyl 2,6-diazaspiro[3.4]octane-2-carboxylate (1.06 g, 4.98 mmol, PharmaBlock) was added to a stirred mixture of 2,4-dichloro-7-methyl-5,6,7,8-tetrahydroquinoline-3-carbonitrile Intermediate 1 (1.0 g, 4.15 mmol) in DMA (10 mL) at 10    140°C. The reaction mixture was stirred at 140 °C for 2 h. The reaction was then cooled to room temperature, diluted with water (50 mL), and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine (2 x 50 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was absorbed onto a plug of silica gel and purified by column chromatography (silica gel, 20-30% EtOAc in petroleum ether) to give tert-butyl 6- (4-chioro-3-cyano-7-methyl-5,6,7,8-tetrahydroquinolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate A-2 (197 mg, 11 % yield) as a yellow solid, m / z (ESI): 361.0 (M+H)1. Step 2: tert-butyl 6-(3-cyano-7-methyl-4-(5-methyI-lH-indazol-4-yI)-5,6,7,8-tetrahydroquinoIin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxyIate (B-2) tert-Butyl 6-(4-chloro-3-cyano-7-methyl-5,6,7,8-tetrahydroquinolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate A-2 (197 mg, 0.472 mmol), (5-methyl-lrt-indazol-4-yl)boronic acid (125 mg, 0.71 mmol), K2CO3 (163 mg, 1.18 mmol), and PdfPPh^ (54.6 mg, 0.047 mmol) were mixed in 1,4-di oxane (2 mL) and water (0.5 mL). The reaction mixture was purged with nitrogen for 10 min. The mixture was allowed to stir at 110 °C for 3 h. The reaction mixture was cooled to room temperature, diluted with water (20 mL), and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (2 x 20 mL), dried over NazSCA, and concentrated in vacuo. The resulting residue was absorbed onto a plug of silica gel and purified by column chromatography (silica gel, 40-50% EtOAc in PE) to give tert-butyl 6-(3-cyano-7-methyl-4-(5-methyl-1 H-indazol-4-yl)-5,6,7,8-tetrahydroquinolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate B-2 (110 mg, 45% yield) as a yellow' solid, m / z (ESI): 513.1 (M+H)’. Step 3: 7-methyI-4-(5-methyl-lH-indazol-4-yl)-2-(2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile (C-2) TEA (83 pL, 1.073 mmol) was added to a mixture of tert-butyl 6-(3-cyano-7-methyl-4-(5-methyl-lH-indazol-4-yr)-5,6,7,8-tetrahydroqumolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate B-2 (110 mg, 0.215 mmol) in DCM (3 mL). The reaction mixture w'as allowed to stir at room temperature for 1 h. The reaction mixture w’as filtered, and the filtrate was concentrated in vacuo to give the crude TEA salt of 7-methyl-4-(5-methyl-lH-indazol-4-yl)-2-(2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile C-2 (88 mg, 98% yield) as a yellow solid, which was used directly in the next step, m / z (ESI): 413.0 (M-rH)+. Step 4: 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5-methyl-lH-indazoI-4-yl)-5,6,7,8-tetrahydroquinoIine-3-carbonitrile (Example 2-1) The crude TEA salt of 7-methyl-4-(5-methyl-lH-indazol-4-yl)-2-(2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile C-2 (88 mg, 0.21 mmol), DIPEA (186 pL, 1.07 mmol), and acryloyl chloride (17.3 pL, 0.213 mmol) were mixed in DCM (10 mL) at -60 °C. The reaction mixture was allowed to stir at -60 °C for 1 h. The reaction was warmed to room, temperature and diluted with water (20 mL). The organic extract was separated, and the aqueous layer was extracted with DCM (2 x 20 mL). The 5 combined organic extracts were washed with brine (2 x 20mL), dried over Na2SO4, and concentrated in vacuo. The resulting residue was purified by reverse phase preparative chromatography (XBridge Prep C18 10 pm, 19 x 250 mm; 40-70% (10 mMNHJICOs in ■water) in MeCN with a flow rate of 30 mL / min) to give 2-(2-actyloyl-2,6-diazaspiro[3.4]octan-6-yl)-7~methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8- 10 tetrahydroquinoline-3-carbonitrile Example 2-1 (15 mg, 14% yield) as a white solid. m / z (ESI) 467.2 (M+H)L 'H NMR (400 MHz, DMSO-A) 8 13.15 (d, 7=6.6 Hz, 1 H), 7.52 (d, 7=8.8 Hz, 2 H), 7.33 (d, 7=8.5 Hz, 1 H), 6.31 (dd, 7=16.9, 10.3 Hz, 1 H), 6.09 - 6.08 (m, 1 H), 5.67 (dd, 7=10.3, 2.3 Hz, 1 H), 4.28 - 4.26 (m, 1 H), 4.17 - 4.15 (m, 1 H), 3.96 (d, 7=10.2 Hz, 1 H), 3.90 - 3.83 (m, 3 H), 3.72 (t, 7=6.7 Hz, 2 H), 2.90 - 2.84 (m, 1 H), 2.50 - 2.38 (m, 1 15    H), 2.19 - 2.16 (m, 2 H), 2.11 (s, 3 H), 2.00 (dt, 7=30.8, 13.1 Hz, 2 H), 1.86 - 1.84 (m, 1 H), 1.65 (d, 7=12.3 Hz, 1 H), 1.18 (dd, 7=15.5, 8.4 Hz, 1 H), 1.00 (d, 7=6.5 Hz, 3 H). Table 3: Examples 2-2 to 2-111 were prepared following the procedure described in Method 2, Steps 1-4, above as follows: Ex.# Chemical Structure Name Method changes Reagent 2-2 K\ O M N-^ N nVi COO HN 4-(6-methyl-lH-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolinecarboni tale Step 1: 2,4-di chloroquinolin e-3-carbonitrile (CAS: 69875-543, eNovation Chemicals LLC) and Step 2: 6- Methyl-7- (4,4,5,5-tetramethyl-1,3,2-“ dioxaborolan-2-yl)-lH-indazole (As synthesized for Example 1 -25). Ex.# Chemical Structure Name Method changes Reagent 2-3 M° N—. nVcn JI .1 GOO S h2n 4-(2-amino-l,3-benzothiazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolinecarboni trile Step 1: 2,4-dichloroquinolin e-3-carbonitrile (CAS: 69875-54 3, eNovation Chemicals LLC) and Step 2: (2-((tert-butoxycarbonyl)a mino)benzo[d]thi azol-4-yl)boronic acid (As synthesized for Example 1-23), 2-4 n-Vcn Oy 4-(3-hydroxy-l-naphthalenyl)-2 -(2-(2- ' propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolinecarboni trile Step 1: 2,4-dichloroquinolin e-3-carbonitrile (CAS: 69875-543, eNovation Chemicals LLC) and Step 2: 2-(3-methoxynaphthal en-l-yl)-4,4,5,5-tetramethyl-1,3,2-“ dioxaborolane (As synthesized for Example 122). 2-5 M° A n-nh 2-(8,8-difluoro-2-(2-propenoyl)-. 2’6" diazaspiro[3.4]o ctan-6-y 1)-7-methyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarboni trile Step 1: tert-butyl 8,8-difluoro-2,6-diazaspiro[3.4]oc tane-2-carboxylate (CAS: 213799774-9, PharmaBlock) and Intermediate 1. Ex.# Chemical Structure Name Method changes Reagent 2-6 M° • n-nh 4-(5,6-dimethyl-lH-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-quinolinecarboni trile See below for synthesis of boronic ester Step 1: 2,4-di chloroquinolin e-3-carbonitrile (CAS: 69875-543, eNovation Chemicals LLC) and Step 2: 5,6-dimethyl-1-(tetrahydro-2H-pyran-2-vl)-4-(4,4,5^,5-tetramethyl-1,3,2-" dioxaborolan-2-yl)-lH-indazole 2-7 M N—, n^cn Cun 4-(2-fluorophenyl)-2-(2-(2- ' propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarboni trile Step 1: Intermediate 2 and Step 2: (2-fluorophenyl)bor onic acid (CAS: 1993-03-9, Combi-Blocks). 2-8 M° N-^ ori OjQ V / n-nh 4-(5-methyl-lH-indazol-4-yl)-2-(2-(2- ' propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-5,6,7,8-tetrahydro-3-quinolmecarboni trile Step 1: Intermediate 2. Ex.# Chemical Structure Name Method changes Reagent 2-9 M° n\cn i J Xj 4-(2-fluoro-5-hvdroxyphenyl)- ' 2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)- 5,6,7,8- tetrahydro-3-quinolinecarboni trile Step 1: Intermediate 2 and Step 2: (2-fluoro-5-hydroxyphenyl)b oronic acid (CAS: 115011452.-5, Combi-Blocks). 2-10 o ( h Z / --J. / x— / V-z2j ±0=0 T V V 4-(5-methyl- 1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)- 6,7,8,9-tetrahydro-5H-cycloh epta[b]pyr idine-3-carboni trile Step 1: 3 eq DIPEA and Step 2: PdCl2 (dppf) Step 1: Intermediate 119 and Step 2: 5-methyl-1-(tetrahydro-2H-pyran-2-yl)-4-" (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock). 2-11 o / \ < y—z / -~J / \—zjj "O / \ z^\ /  \ 1 / =\ Z~J \__ I V V (P)-l-(6-(3,7,7-trimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting peak) See below for Alternative Step 1. Step 2: SPhos Pd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: 5-methyl-l-(oxan-2-yl)-4-(4,4,5,5 -tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock). Ex.# Chemical Structure Name Method changes Reagent 2-12 J ) N' V jfl M || J V / n-nh (M)- 1-(6-(3,7,7-trimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-I-one (1st eluting peak) Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: 5-methyl-l-(oxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock). 2-13 N— N' bT jO Qr OH 1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 1: Intermediate 36. Step 2: Intermediate 65. 2-14 J \— N' N' Ox M || J Qi (M)-1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-qumolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting peak) Alternative Step 1 performed in analogous manner to Example 2-11. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: Intermediate 65. OH Ex.# Chemical Structure Name Method changes Reagent 2-15 N—, x’XX (P)-1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting peak) Alternative Step 1 performed in analogous manner to Example 2-11. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: Intermediate 65. H T OH 2-16 % jjQl Xs h2n 4-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-'     2,6- diazaspiro[3,4]o ctan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile Alternative Step 1 performed in analogous manner to Example 2-11. Step 1: Intermediate 36. Step 2: (2-(( tertbutoxy c arb onyl) a mino)-7-flu orobenzo [d ]thi azol -4-yl)boroni c acid (PliarmaBlock) 2-17 % jCjCx n / ^f Xs h2n (P)-4-(2-amino-7-fluoro-l,3-benzothiazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile (1st eluting peak) Alternative Step 1 performed in analogous manner to Example 2-11. See below for atropisomer separation conditions. Step 1: Intermediate 36. Step 2: (2-((tert-butoxycarbonyl)a mino)-7-fluorobenzo[d]thi azol-4-yl)boronic acid (PliarmaBlock) Ex.# Chemical Structure Name Method changes Reagent 2-18 Xja T m T J h2n (M)-4-(2-amino-7-fluoro-l,3-benzothiazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)- 2,6- ’ diazaspiro[3.4]o ctan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile (2nd eluting peak) Alternative Step 1 performed in analogous manner to Example 2-11. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: (2-((tert-butoxycarbonyl)a mino)-7-fluorobenzo [d ]thi azol-4-yl)boronic acid (PharmaBlock) 2-19 N-^ XN aXa TA 1-(6-(4-(1,6-dimethyl-lH-indazol-7-yl)-3.7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3; K3PO4. N-methylation performed after Step 2 using conditions described below. Step 1: Intermediate 36. Step 2: 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-20 . / aKa T m T j (M)-1-(6-(4-(1,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting isomer) Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3; K3PO4. N-methylation performed using procedure from Example 2-19 after step 2. See below for atropisomer Step 1: Intermediate 36. Step 2: 6-methyl-7-(4,4,5,5-teframethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) Ex.# Chemical Structure Name Method changes Reagent separation conditions 2-21 J N—, aXa (P)-1-(6-(4-( 1,6-dimetliyl-lH-indazol-7-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3; K3PO4. N-methylation performed using procedure from Example 2-19 after step 2. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-" dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-22 % N iT^ F AUkxX / CF3 xJ LT OH 1-(6-(4-(2-fluoro-5-hydroxy-3-(trifluoromethyl) phenyl)-3,7,7-trimethyl- 5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 1: Intermediate 36. Step 2: (2-fluoro-5-hydroxy-3-(trifluoromethyl) phenyljboronic acid (Combi- Blocks) 2-23 J N-, Y aXa jjO Hhlf 1-(6-(3,7,7-trimethyl-4-(6-methyl-lH-indazol-7-yl)-5,6,7,8- ' tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 36. Step 2: 6-methyl-7-(4,4,5,5-teframethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) Ex.# Chemical Structure Name Method changes Reagent 2-24 2 \ / ' )---( 0- z r—8 / \   1 U 7¼ / / A 1 i"7             > \ / (P)-1-(6-(3,7,7-trimethyl-4-(6-methyl-lH-indazol-7-yl)-5,6,7,8-tetraliydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting peak) Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-25 N-, XjCi T mJ J HN (M)-1-(6-(3,7,7-trimethyl-4-(6-methyl-lH-indazol-7-yl)-5,6,7,8- ' tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting peak) Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 36. Step 2: 6m ethyl-7-(4,4,5,5-tetramethyl-1,3,2-* dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-26 % N |7 F OH 1-(6-(4-(2,3-difluoro-5-hydroxyphenyl)-3,7,7-trimethyl- 5,6,7,8- ’ tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 36. Step 2: (5-((tert-butyldim ethyls! ly l)oxy)-2,3-difluorophenyl)b oronic acid (Combi-Blocks) Ex.# Chemical Structure Name Method changes Reagent 2-27 ok I o 003 .   z-^ /            \    / 1-(6-(4-(3-hydroxy-1 -naphthalenyl)-3.7,7-trimethyl- 5,6,7,8- tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 36. Step 2: 3-hydr oxynaph tha 1 ene-1 -boronic acid (eNovation Chemicals LLC) 2-28 J N—, Oju / n-nh 1-(6-(3,7,7-trimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8- ’ tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 36. Step 2: 5-methyl-l-(oxan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PhannaBlock) 2-29 N Cl 0k n-nh 1-(6-(4-(5-chloro-lH-indazol-4-yl)-3-methyl-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1 used 3 eq of DIEA. Step 2: SPhos Pd G3, K3PO4 Step 1: 2,4-dichloro-3-methylquinoline (Combi-Blocks) Step 2: Intermediate 52 Ex.# Chemical Structure Name Method changes Reagent 2-30 r1' o XO' b A^cn 7,7-dimethyl-4-(i -methyl- 1H-indol-7-yl)-2-(2-(2-propenoyl)-2,6- ’ diazaspiro[3.4]o ctan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile Step 1: 3 eq DIEA. Step 2: SPhos Pd G3, Additional N-methylation performed using procedure from Example 2-19 after step 2. Step 1: Intermediate 20. Step 2: indole-7-boronic acid (Combi-Blocks) 2-31 r 0 2 A<CNcf T । 3 m N-NH (1R,9R)-1O,1O-dimethyl-4-(2-(2-propenoyl)-2,6- ’ diazaspiro[3.4]o ctan-6-yl)-6-(5-(trifluoromethyl) -lH-indazol-4- yl)-3-azatricyclo[7.1.1 .02,']undeca-2,4,6-triene-5-carbonitrile Step 1: 3 eq DIEA. Step 2: SPhos Pd G3, k3po4. Step 1: Intermediate 21. Step 2: 1-(tetrahydro-2h-pyran-2-yl)-5-(tri fluorom ethy 11 H-indazol-4-ylboronic acid (Apollo Scientific) 2-32 ft 't A "cr J 1-(6-(4-(5-chloro-1 -methyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1:3 eq DIEA. Step 2: SPhos Pd G3, K:PO: Additional N-methylation performed using procedure from Example 2-19 after step 2. Step 1: Intermediate 22. Step 2: 7-bromo-5-chloro-1 H-indazole (Combi-Blocks) Ex.# Chemical Structure Name Method changes Reagent 2-33 % _r Tmt j - / 0      jT (M)-l-(6-(4-(5-chloro-1 -methyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)~ * 2,6- ' diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2ndeluting isomer) Step 1: 3 eq DIEA. Step 2: SPhos Pd G3, K3PO4. Additional N-methylation performed using procedure from Example 2-19 after step 2. See below for atropisomer separation conditions Step 1: Intermediate 22. Step 2: 7-bromo-5-chloro-1 H-indazole (Combi-Blocks) 2-34 JUC^ci r t pY Y - / 0 (P)-1-(6-(4-(5-chloro-1 -methyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (lsl eluting isomer) Step 1: 3 eq DIEA. Step 2: SPhos Pd G3, K3PO4. Additional N-m ethylation performed using procedure from Example 2-19 after step 2. See below for atropisomer separation conditions Step 1: Intermediate 22. Step 2: 7-bromo-5-chloro-1 H-indazole (Combi-Blocks) 2-35 Cl JL I ZjTj 'r0 Yr OH 1-(6-(4-(2-chloro-5-hydroxyphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)- * 2,6- ' diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used Step 1: Intermediate 22. Step 2: (2-chloro-5-hydroxyphenyl)b oronic acid (Synnovator) Ex.# Chemical Structure Name Method changes Reagent 2-36 3b r y it Ct n-nh 1-(6-(4-(6-chloro-5-methyl-lH-indazol-4- yl)-3,7,7-trimetliyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)~2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos PdG3 and K3PO4 used Step 1: Intermediate 22. Step 2: 6-chloro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-4-“ (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-37 M° A n\cn JU (!R,8S)-6-(5-hydroxy-2 -methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[6.2.1 .02,']undeca-2,4,6-triene-5-carbonitrile (IS, 8R)-6-(5-hydroxy-2 -methylphenyl)-4-(2-(2-^ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[6.2.1 ,0z-']undeca-2,4,6-triene-5-carbonitrile Step 1: See step 2 of intermediate 54. Step 2: SPhos Pd G3 and K3PO4 used Step 2: Intermediate 54, step 1. Step 2: (5-hydroxy-2-methylphenyljbo ronic acid (Combi-Blocks). 2-38 M % n\cn u Ju cu (lR,8S)-6-(3-hydroxy-1-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo [6.2.1 .02’7]undeca-2,4,6-triene-5- Step 1: See step 2 of intermediate 54. Step 2: SPhos Pd G3 and K3PO4 used Step 1: Intermediate 54, step 1. Step 2: 3-hydroxynaphthal ene-l-boronic acid (eNovation Chemicals LLC). Ex.# Chemical Structure Name Method changes Reagent carbonitrile (IS, 8R)-6-(3-hydroxy-1-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[6.2.1 .02-7]undeca-2,4,6-triene-5-carbonitrile 2-39 L n\cn CypYj (P)-(lR,8S)-6-(3-hydroxy-1-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[6.2.1 .02-7]undeca-2,4,6-triene-5-carbonitrile (3IB eluting isomer) Step 1: See step 2 of intermediate 54. Step 2: SPhosPd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 54, step 1. Step 2: 3" h ydr ox ynaphth al ene-l-boronic acid (eNovation Chemicals LLC). 2-40 % n\cn .OH m y V a (M)-(lR,8S)-6-(3-hydroxy-1-n aph thaleny 1 )-4(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[6.2.1 2,4,6-triene-5-carbonitrile (4th eluting isomer) Step 1: See step 2 of intermediate 54. Step 2: SPhos Pd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 54, step 1. Step 23-hydroxynaphthal ene-l-boronic acid (eNovation Chemicals LLC). Ex.# Chemical Structure Name Method changes Reagent 2-41 z=\ / \ / \= / o ^ / \ z o I (lR,9R)-6-(6-hydroxy-8-isoquinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[ 7.1.1 .02-7]undeca- 2,4,6-triene-5-carbonitrile Step 1: 2 eq pyridine. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 35 and Intermediate 72 2-42 I o 0=0 OO (lR,9R)-6-(7“ hydroxy-5-quinolinyl)-10,10-dimethyl-' 4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02-7]undeca-2,4,6-triene-5-carbonitrile Step 1: 2 eq pyridine. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 35 and Intermediate 73 2-43 I o Z \ / X. o >—\   / \_ /  2=7 (lR,9R)-6-(6-hydroxy-8-quinolinyl)-10,10-dimethyl-' 4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .OA / ]undeca-2,4,6-trieiie-5-carbonitrile Step 1: 2 eq pyridine. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 35 and Intermediate 74 Ex.# Chemical Structure Name Method changes Reagent 2-44 I o z  \__ /  \\ o )—\   / (M)-(lR,9R)-6-(6-hydroxy-8-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02-7]undeca- 2,4,6-triene-5-carbonitrile (1st eluting isomer) Step 1: 2 eq pyridine. Step 2: SPhosPd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 35 and Intermediate 74 2-45 A        r—z"^0 y / ^r / =z vx Z \=< O / \ z o I (P)-(lR,9R)-6-(6-hydroxy-8-quinolinyl)-10,10-dimethyl- 4-(2-(2- ’ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02l']undeca-2,4,6-triene-5-carbonitrile (2nd eluting isomer) Step 1: 2 eq pyridine. Step 2: SPhos Pd G3 and K dhh used. See below' for atropisomer separation conditions Step 1: Intermediate 35 and Intermediate 74 2-46 o On 9 1 .CN N Y -Myo (P)-(lR,9R)-6-(7-hydroxy-5-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,7]undeca-2,4,6-triene-5-carbonitrile (1st eluting isomer) Step 1: 2 eq pyridine. Step 2: SPhos Pd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 35 and Intermediate 73 Ex.# Chemical Structure Name Method changes Reagent 2-47 A        r— / =\ s / \ <\ M 2 o I (M)-(lR,9R)-6-(7-hydroxy-5-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .027]undeca-2,4,6-triene-5-carbonitrile (2nd eluting isomer) Step 1: 2 eq pyridine. Step 2: SPhosPd G3 and K3PO4 used. See below for atropisomer separation conditions Step 1: Intermediate 35 and Intermediate 73 2-48 q / 7=\ x—\ Z-z z^\ / \ ' / =\ \__ i v / / 1-(6-(7-methoxy-3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 3 eq. DIPEA. Step 2: PdCl2(dppf) replaced Pd(PP113)4. Step 4: 5 eq. K2CO3 Step 1: 2,4-dichloro-7-methoxy-3-methylquinoline (Aurum Pharmatech) 2-49 o \\ a z z^~L / —( / y- z । I   \_ / x / - 1-(6-(7-methoxy-3-methyl-4-(6-methyl-lH-indazol-7-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 3 eq. DIPEA. Step 2: RuPhos Pd G4, K3PO4 replaced Pd(PPh3)4 and k2co3. Step 1: 2,4-dichloro-7-m ethoxy-3-methylquinoline (Aurum Pharmatech) Step 2: 6m ethyl -7(4,4,5,5-tetramethyl-1,3,2-’ dioxaborolan-2-yl)-l H-indazole (PharmaBlock) Ex.# Chemical Structure Name Method changes Reagent 2-50 / =\ \\ z / —L I Mj-zy X?- 1-(6-(4-(1,6-dimetbyl-lH-indazol-7-yl)-7-methoxy-3-methyl-2-qumolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 3 eq. DIPEA. Step 2: RuPhos Pd G4, K3PO4 replaced Pd(PPh3)4 and K2CO3. Additional N-methylation performed using procedure from Example 2-19 after step 2. Step 1: 2,4-dichloro-7-methoxy-3-methylquinoline (Aurum Pharmatech) Step 2: 6-methyl-7-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-51 ,4 N-, - / ¾ n-nh 1-(6-(7-methoxy-3-methyl-4-(5-methyl-lH-indazol-4-yl)-1,5-naphthyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 3 eq. DIPEA. Step 2: PEPPSI-iPr and K3PO4 replaced Pd(PPh3)4 and K2CO3. Step 1: Intermediate 75 2-52 T O Z \_ / o  2—\ / 8-(3-hydroxy-l-naphthalenyl)-6-(2-(2- ’ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile Alternative Step 1 see below. Step 2: SPhos Pd G3, K3PO4 replaced Pd(PPh3)4 and K2CO3. Step 4: DIPEA replaced TEA. Step 1: Intermediate 79. Step 2: 4(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthol (Combi-Blocks) Ex.# Chemical Structure Name Method changes Reagent 2-53 / \ L >=\ o / \ z o I (P)-8-(3-hydroxy-1 -naphthalenyl)-6-(2-(2- ’ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile (1st eluting isomer) Alternative Step 1 performed in analogous manner to Example 2-52. Step 2: SPhos Pd G3, K3PO4 used. Step 4: DIPEA replaced TEA. See below for atropisomer separation conditions Step 1: Intermediate 79. Step 2: 4(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-naphthol (Combi-Blocks) 2-54 / —\ . O— / =\ s / \ Z >=< o / \ z MJ o I (M)-8-(3-hydroxy-1-naphth al eny 1)- 6 -(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile (2nd eluting isomer) Alternative Step 1 performed in analogous manner to Example 2-52. Step 2: SPhos Pd G3, K3PO4 used. Step 4: DIPEA replaced TEA. See below for atropisomer separation conditions Step 1: Intermediate 79. Step 2: 4(4,4,5,5-tetramethyl-1,3,2-" dioxaborolan-2-yl)-2-naphthol (Combi-Blocks) 2-55 .4 N—, xXa 030 c / n-nh (P)-l -(6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting isomer) Step 1: 3 eq. DIPEA. Step 2: SPhos Pd G3, K3PO4 used. Step 4: 5 eq. K2CO3. See below' for atropisomer separation conditions Step 1: 2,4-dichloro-3-methylquinoline (Combi-Blocks) Ex.# Chemical Structure Name Method changes Reagent 2-56 N—, Y JuOk O7O A / n-nh (M)-1-(6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Step 1: 3 eq. DIPEA. Step 2: SPhos Pd G3, K3PO4 used. Step 4: 5 eq. K2CO3. See below for atropisomer separation conditions Step 1: 2,4- dichloro-3-methylquinoline (Combi-Blocks) 2-57 N—, xXa OjQ / n-nh 1-((58)-5-methyl-6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)~2-propen-l-one Step 1: 3 eq. DIPEA. Isomer separation after Step 1,see below for conditions. Peak 1 used. Step 2: PdCl2(dppf) used. Step 4: 5 eq. K2CO3 Step 1: 2,4-dichloro-3-methylquinoline (Combi-Blocks) and tert-butyl 5-methyl-2,6-diazaspiro[3.4]oc tane-2-carboxylate (Enamine) 2-58 -n                 1 / =\ \ \\ z / -"J. I zjj / \ Z~J \__ I V V 1-((58)-6-(7-fluoro-3-methyl-4-(5-methyl- 1H-indazol-4-yl)~2-quinolinyl)-5-methyl-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 3 eq. DIPEA. Isomer separation after Step 1, see below for conditions. Peak 1 used. Step 2: PdCl2(dppf) used. Step 4: 5 eq. K2CO3 Step 1: 2,4-dichloro-7-fluoro-3-methylquinoline (see J. Med. Chern. 2012, 55, 17,7667-7685) and tert-butyl 5-methyl-2,6- diazaspiro[3.4]oc tane-2-carboxylate (Enamine) Ex.# Chemical Structure Name Method changes Reagent 2-59 / =\     \ r-z'""' \\ n z            / / zjj / \ Z-J \__ I V 'Z l-((5R)-6-(7-fluoro-3-methyl-4-(5-methyl- 1H-indazol-4-yl)-2-quinolinyl)-5-methyl-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: 3 eq. DIPEA. Isomer separation after Step 1, see below for conditions. Peak 2 used. Step 2: PdCl2(dppf) used. Step 4: 5 eq. K2CO3 Step 1: 2,4- dichloro-7- fluoro-3-methylquinoline (see J. Med. Chem. 2012, 55, 17,7667-7685) and tert-butyl 5-methyl-2,6- diazaspiro[3.4]oc tane-2- carboxylate (Enamine) 2-60 N—, j^Yi jO^Yj f^^ Ci n-nh (M)-1-((5 S)-6-(7-fluoro-3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-5-methyl-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Step 1: 3 eq. DIPEA. Isomer separation after Step .1, see below for conditions. Peak 1 used Step 2: PdCl2(dppf) replaced Pd(PPh3)4. Step 4: 5 eq. K2CO3. See below for atropisomer separation conditions Step 1: 2,4-dichloro-7-fluoro-3-methylq uinoline (see J. Med. Chem. 2012, 55, 17,7667-7685) and tert-butyl 5-methyl-2,6-diazaspiro[3.4]oc tane-2-carboxylate (Enamine) 2-61 N-, *^N^ mn f^^ Ci n-nh (P)-l-((5S)-6-(7-fluoro-3-methyl-4-(5-methyl- 1H-indazol-4-yl)~2-quinolinyl)-5-methyl-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting isomer) Step 1: 3 eq. DIPEA. Isomer separation after Step 1 see below for conditions. Peak 1 used Step 2: PdCl2(dppf) used. Step 4: 5 eq. K2CO3. See below for Step 1: 2,4-dichloro-7-fluoro-3-methylquinoline (see J. Med. Chem. 2012, 55, 17,7667-7685) and tert-butyl 5-methyl-2,6-diazaspiro[3.4]oc tane-2-carboxylate (Enamine) Ex.# Chemical Structure Name Method changes Reagent atropisomer separation conditions 2-62 [ / 1 —\ / ° / T"-7    z—X   ) \ / O                    ' 1-(6-(4-(5-hydroxy-2-methylphenyl)-3,7,7-trimethyl- 5,6,7,8- tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Alternative Step 1 performed in analogous manner to Example 2-11. Step 2: SPhos Pd G3 and K3PO4 used. Step 1: Intermediate 36. Step 2:5-hydroxy-2-methylph enylbor onic acid (Combi-Blocks) 2-63 7\       r-z^° -   r=\ \=< o / \ z (lR,9R)-6-(2-chlorophenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,7]undeca-2,4,6-triene-5-carbonitrile See below for Alternative Step 1. Step 2: SPhos Pd G3 and K3PO4. Step 1: Intermediate §2, XPhos Pd G2, CS2CO3, toluene. Step 2: 2-chlorophenylbor onic acid (Matrix Scientific) 2-64 0 / 7 N~y N lil -W'O OH (lR,9R)-6-(2-chloro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,7]undeca-2,4,6-triene-5-carbonitrile Alternative Step 1 performed in analogous manner to Example 2-52. Step 2: SPhos Pd G3 and K3PO4. Step 1: Intermediate 82, XPhos Pd G2, CS2CO3, toluene. Step 2: boronic acid, (2-chloro-5-hydroxyphenyl)-(Synnovator) Ex.# Chemical Structure Name Method changes Reagent 2-65 / r--7   z—( <—7 (lR,9R)-6-(2-chloro-5-(hydroxymethyl) phenylj-10,10-dimethyl-4-(2-(2-propenoyl)- 2,6- ’ diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,7]undeca-2,4,6-triene-5-carbonitrile Alternative Step 1 performed in analogous manner to Example 2-52. Step 2: SPhos Pd G3 and K3PO4. Step 1: Intermediate 82, XPhos Pd G2, CS2CO3, toluene. Step 2: (2-chloro-5-(hydroxymethyl) phenyl)boronic acid (Combi- Blocks) 2-66 z □.- / ’A-O 1 'i7   z—\ (lR,9R)-6-(2-fluoro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2- ’ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02l']undeca-2,4,6-triene-5-carbonitrile Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. Step 1: Intermediate 21. Step 2: 2-fluoro-5-hydroxyphenylbo ronic acid (Combi-Blocks) 2-67 0 OH (lR,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,']undeca-2,4,6-triene-5-carbonitrile Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. Step 1: Intermediate 21. Step 2: 5-hydroxy-2-methylphenylbor onic acid (Combi-Blocks) Ex.# Chemical Structure Name Method changes Reagent 2-68 z \_ o )—' (M)-(lR,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02-7]undeca- 2,4,6-triene-5-carbonitrile (1st eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 21. Step 2: 5-hydroxy-2-methylphenylbor onic acid (Combi-Blocks) 2-69 o z \_ / o  )—' \ _ / CL (P)-(lR,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl- 4-(2-(2- ’ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,7]undeca- 2,4,6-triene-5-carbonitrile (2nd eluting isomer) Step 1: DIPEA and DMF replaced DM A. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 21. Step 2: 5-hydroxy-2-methylphenylbor onic acid (Combi-Blocks) 2-70 0 % ,CN j>YjQ F (1R OR)-6-(3-fluoro-2-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3- azatricyclo[7.1.1 .02,7]undeca- 2,4,6-triene-5-carbonitrile Step 1: DIPEA and DM 1 replaced DMA. Step 2: SPhos Pd G3 and Kdhb Step 1: Intermediate 21. Step 2: 3-fluoro-' 2-hydroxybenzene boronic acid (Combi-Blocks) Ex.# Chemical Structure Name Method changes Reagent 2-71 z \_ / o )\ \o r-^\   /  \ x / f-- /    z—( (P)-(lR,9R)-6- (3-fluoro-2-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02-7]undeca- 2,4,6-triene-5-carbonitrile (1st eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 21. Step 2: 3-fluoro-2-hy droxybenzen e boronic acid (Combi-Blocks) 2-72 S— z \_ / 0 )—\ (M)-(lR,9R)-6- (3-fluoro-2-hydroxyphenyl)-10,10-dimethyl- 4-(2-(2- ’ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,']undeca-2,4,6-triene-5-carbonitrile (2nd eluting isomer) Step 1: DIPEA and DMF replaced DM A. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 21. Step 2: 3-fluoro hydroxybenzene boronic acid (Combi-Blocks) 2-73 0 N-j X.CN r-n ii r _mQ0 OH (lR,9R)-6-(2-fluoro-6-(hydroxymethyl) phenylj-10,10-dimethyl-4-(2-(2-propenoyl)-2,6- ’ diazaspiro[3.4]o c tan- 6 -y 1) - 3 -azatricyclo[7.1.1 .(E’^undeca-2,4,6-triene-5-carbonitrile Step 1: DIPEA and DMF replaced DMA. Step 2: RuPhos, RuPhosPd G2 and K3PO4. Step 1: Intermediate 21. Step 2: (2-fluoro-6-(hydroxymethyl) phenyl)boronic acid (A OB Chem) Ex.# Chemical Structure Name Method changes Reagent 2-74 z__ \ — / □_ r-p-O^ °^~J (P)-(lR,9R)-6-(2-chloro-5-hydroxyphenyl)-10,10-dimethyl- 4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02-7]undeca- 2,4,6-triene-5-carbonitrile (1st eluting isomer) Alternative Step 1 performed in analogous manner to Example 2-52. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 82, XPhos Pd G2, CS2CO3, toluene. Step 2: boronic acid, (2-chloro-5-hydroxyphenyl)-(Synnovator) 2-75 0 / 7 y N ifl if j OH (M)-(lR,9R)-6-(2-chloro-5-hydroxyphenyl)-10,10-dimethyl- 4-(2-(2- ’ propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3-azatricyclo[7.1.1 .02,']undeca- 2,4,6-triene-5-carbonitrile (2nd eluting isomer) Alternative Step 1 performed in analogous manner to Example 2-52. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 82, XPhos PdG2, CS2CO3, toluene. Step 2: boronic acid, (2-chloro-5-hydroxyphenyl)-(Synnovator) 2-76 X O o \=^ 1        z-\ o a V 1-(6-(3-chi oro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimefnyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-I-one Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and Kdhb Step 1: Intermediate 24. Step 2: 3-hydroxynaphthal ene-1-boronic acid (eNovation Chemicals LLC) Ex.# Chemical Structure Name Method changes Reagent 2-77 X o J o (M)-l-(6-(3-chloro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2:3-hydroxynaphthal ene-l-boronic acid (eNovation Chemicals LLC) T M Tl T 2-78 / \          z V_# Vz / =\ "□ >=< vkQ o X (P)~l-(6-(3-chloro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)- ’ 2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2:3-hydr oxynaphtha 1 ene-1 -boronic acid (eNovation Chemicals LLC) 2-79 J / \         r~z q Vz ^Jj MM - o X l-(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos PdG3 and K3PO4 Step 1: Intermediate 24. Step 2: 5-hydroxy-2-methylphenylbor onic acid (Combi-Blocks) Ex.# Chemical Structure Name Method changes Reagent 2-80 I o d o (M)-l-(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2:5-hydroxy-2-methylphenylbor onic acid (Combi-Blocks) T M T| T 2-81 / \             r~-z. °\        zsL / v_# / =\ Q O t (P)-l -(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-’ 2,6- diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2:5-hydroxy-2-methylph enylbor onic acid (Combi-Blocks) 2-82 0: £^ / ° / dd / z^O“^ / p-7   Z-\ O 1-(6-(4-(5- hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)- ' " 2,6- diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4 Step 1: Intermediate 22. Step 2: Intermediate 83 Ex.# Chemical Structure Name Method changes Reagent 2-83 J / \          / —z O Vz        / 2 Z.-J \__ 1 V V l-(6-(3-chloro-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. Step 1: Intermediate 24 2-84 J / / V 1 \ 4 / =^2 rX / Z"\\ / / ^7   z-\ o ,2- /         \ / (P)-1-(6-(3-chloro-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. See below for atropisomer separation conditions Step 1: Intermediate 24 2-85 J jmA "° CT n-nh (M)-1-(6-(3-chloro-7,7-dimethyl-4-(5-methyl-lH-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (lsl eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4, See below for atropisomer separation conditions Step 1: Intermediate 24 Ex.# Chemical Structure Name Method changes Reagent 2-86 XjTi JU —N N=^ l-(6-(3-chloro-4-(l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-" 2,6- ' diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and KEPO. Additional N-methylation performed using procedure from Example 2-19 after step 2 Step 1: Intermediate 24. Step 2: 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-87 - |mY] —N (M)-l-(6-(3-chloro-4-(l ,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridm-2-yl)-2,6- diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (l5t eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and KPCX: Additional N-methylation performed using procedure from Example 2-19 after step 2. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2: 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-88 <2 J 7 ~(\ / r\ 1                   o \ / (P)-l-(6-(3-ch!oro-4-(l,6-dimetbyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4. Additional N-m ethylation performed using procedure from Example 2-19 after step 2. See below for Step 1: Intermediate 24. Step 2: 6-methyl-7-(4,43,5-tetramethyl-1,3,2-" dioxaborolan-2-yl)-lH-indazole (PharmaBlock) Ex.# Chemical Structure Name Method changes Reagent atropisomer separation conditions 2-89 — o l-(6-(3-chloro-4-(1,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and K3PO4 Additional N-m ethylation performed using procedure from Example 2-19 after step 2 Step 1: Intermediate 24. Step 2: Intermediate 37 — N jr 2-90 X. / rcl । T M || —N jr (M)-l-(6-(3-chloro-4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)- . 2’6" diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (1st eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3 and k3po4. Additional N-methylation performed using procedure from Example 2-19 after step 2. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2: Intermediate 37 2-91 o / / ^7   z-\ o \ / (P)-1 -(6-(3-chloro-4-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)- 2,6-diazaspiro[3.4]o Step 1: DIPEA and DMF replaced DM A. Step 2: SPhos Pd G3 and K3PO4. Additional N-methylation performed using procedure from Step 1: Intermediate 24. Step 2: Intermediate 37 Ex.# Chemical Structure Name Method changes Reagent ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Example 2-19 after step 2. See below for atropisomer separation conditions 2-92 J <T n-nh l-(6-(3-chloro-4-(6-chloro-5-methyl-lH-indazol-4-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3. Step 1: Intermediate 24. Step 2: 6-chloro-5-methyl-l-(tetrahydro-2H-pyran-2-vl)-4-(4,4,5,5-tetramethyl-1,3,2-“ dioxaborolan-2-yl)-lH-indazole (PharmaBlock)) 2-93 N—, A n-nh 1-(5-methyl- 1H-indazol-4-yl)-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-5,6,7,8- tetrahydro-2-naphthalenecarb onitrile Alternative Step 1 see below. Step 2: SPhos Pd G3. Step 1: Intermediate 81. Ex.# Chemical Structure Name Method changes Reagent 2-94 / —N J N-^ J\.CN CjYj 0 Ct n-nh 6-(2-((2E)-4-(dimethylam ino) -2-butenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-8-(5-methyl-lH-indazol-4-yl)- 3,4-dihydro-lH-2-benzopyran-7-carbonitrile Step 1 performed using procedure from Example 2-93. Step 4: Replace with Step 5 from Method 4 Step 1: Intermediate 78. Step 4: (E)-4-(dimethylamino) but-2-enoic acid hydrochloride (Oakwood Chemical) 2-95 o / \ o           / ">■— / '—\ / -z ] C*=O i V V 8-(5-methyl- 1H-indazol-4-yl)~6-(2-(2- ' propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-lH-2-benzopyran-7- carbonitrile Step 1 performed using procedure from Example 2-93. Step 1: Intermediate 78. 2-96 cR1 z—Z S— / "T"7        o Z—J         \__ / o 8-(l,6-dimethyl-lH-indazol-7-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-lH-2-benzopyran-7-carbonitrile Step 1 performed using procedure from Example 2-93. Step 2: bistdi-tert-butyl(4-dimethylamino phenyl)phosphi ne)dichloropall adium(II) (0.2 equiv), K3PO4 (4.0 equiv) replaced Pd(PPh3)4 and K2CO3. Step 1: Intermediate 78. Step 2: 1,6-dimethyl-7-(4,4,5^,5-tetramethyl-1,3,2-“ dioxaborolan-2-yl)-lH-indazole (PharmaBlock) Ex.# Chemical Structure Name Method changes Reagent 2-97 N—, £11 jOxj N=^ l-(l,6-dimethyl-lH-indazol-7-yl)-6,6-dimethyl-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-5,6,7,8-tetrahydro-2-naphthalenecarb onitrile Step 1 performed using procedure from Example 2-93. Step 2: bis(di-tert-butyl(4-dimethylamino phenyl)phosphi ne)dichloropall adium(II) (0.2 equiv), K3PO4 (4.0 equiv) replaced Pd(PPhs)4 and K2CO3. Step 1: Intermediate 77. Step 2: 1,6-dimethyl-7-(4,4,5,5-tetramethvl-1,3,2-" dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-98 .2 rj tot 3'-hydroxy-6,6-dimethyl-3-(2-(2-propenoyl)-'     2,6- diazaspiro[3.4]o ctan-6-yl)-5,6,7,8-tetrahydro[l,l'-binaphthalene]-2-carbonitrile Step 1 performed using procedure from Example 2-93. Step 2: bis(di-tert-butyl(4-dimethylamino phenyl)phosphi ne)dichloropall adium(II) (0.2 equiv), K3PO4 (4.0 equiv) replaced Pd(PPh3)4 and K2CO3. Step 1: Intermediate 77. Step 2: 3-hydroxynaphthal ene-l-boronic acid (eNovation Chemicals) Ex.# Chemical Structure Name Method changes Reagent 2-99 __r       —\ o Z—J         \__ / o (M)-8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-lH-2-benzopyran-7-carbonitrile (1st eluting isomer) Step 1 performed using procedure from Example 2-93. Step 1: Intermediate 78. 2-100 o / \ o / -\ / "4-J '—\ / -z ] "0 )==( 0=0 i V V (P)-8-(5-methyl-lH-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-lH-2-benzopyran-7-carbonitrile (2nd eluting isomer) Step 1 performed using procedure from Example 2-93. Step 1: Intermediate 78. 2-101 4 J\ / CN "~N J 8-(1,6-dimethyl-lH-indazol-7-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile Step 1 performed using procedure from Example 2-93. Step 2: bis(di-tert-butyl(4-dimethylamino phenyl)phosphi ne)dichloropall adium(II) (0.2 equiv), K3PO4 (4.0 equiv) replaced Pd(PPh3)4 and K CO;. Step 1: Intermediate 79. Step 2: 1,6-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (PliarmaBlock) Ex.# Chemical Structure Name Method changes Reagent 2-102 III eno "N T N=^ l-(6-(7-chloro-8-(l,6-dimethyL lH-indazol-7-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6- diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1 performed using procedure from Example 2-93. Step 2: SPhos Pd G3, K3PO4. Additional N-methylation performed using procedure from Example 2-19 after step 2. Step 1: Intermediate 80. Step 2: 6-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (Synnovator) 2-103 4 N—J a n-nh l-(6-(7-chloro-8-(5-(trifluoromethyl) -lH-indazol-4-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1 performed using procedure from Example 2-93. Step 2: SPhos Pd G3, K3PO4. Step 1: Intermediate 80. Step 2: 1-(tetrahydro-2H-pyran-2-yl)-5-(tri fluorom ethyl-lh-indazol-4-ylboronic acid (Apollo Scientific Ltd.) 2-104 4 jCX^xL / CI ~~N J 8-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile Step 1 performed using procedure from Example 2-94. Step 2: SPhos Pd G3, K3PO4. Additional N-methylation performed using procedure from Example 2-19 after step 2. Step 1: Intermediate 79. Step 2: Intermediate 37. Ex.# Chemical Structure Name Method changes Reagent 2-105 J ) N-j F JuOk 000 / n-nh 2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-7,7-dimethyl-4-(5- methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarboni trile Alternative Step 1 performed in analogous manner to Example 2-93. Step 1: Intermediate 6 and tert-butyl 8,8-difluoro-2,6-diazaspiro[3.4]oc tane-2-carboxylate (PharmaBlock). 2-106 m<^CN oti so2nh2 3-(3-cyano-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-5,6,7,8- tetrahydro-4-quinolinyl)-4-methylbenzenes ulfonamide Step 1 performed using procedure from Example 2-93, with XPhos Pd G4 and CS2CO3 in place of XantPhos Pd G3 and K-CO3 Step 2: SPhos Pd G3, K3PO4. Step 1: Intermediate 6. Step 2: 2m ethyl-5-sulfamoylphenyl boronic acid pinacol ester (Combi-Blocks) 2-107 02 sl JX_.CN jCX "N 7 N=^ 8-(5-chloro-l,6-dimethyl-lH-indazol-7-yl)-6-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]o ctan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile Step 1 performed using procedure from Example 2-93. Step 2: SPhos Pd G3, K3PO4. Additional N-methylation performed using procedure from Example 2-19 after step 2. Step 1: Intermediate 78 and Amine 3. Step 2: Intermediate 37. Ex.# Chemical Structure Name Method changes Reagent 2-108 ACI । TM T T x° <r n-nh (M)-1-(6-(3-chloro-4-(6-chloro-5-methyl-lH-indazol-4-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (lsl eluting isomer) Step 1: DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2: 6-chloro-5-methyl-l-(tetrahydro-2H-pyran-2-vl)-4-(4,4,5^5-tetramethyl-1,3,2-" dioxaborolan-2-yl)-lH-indazole (PharmaBlock) 2-109 x ]fCI 1 AA\Ax / C TPY J r° Cr n-nh (P). 1-(6-(3-chloro-4-(6-chloro - 5 -methy 1-lH-indazol-4-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) Step k DIPEA and DMF replaced DMA. Step 2: SPhos Pd G3. See below for atropisomer separation conditions Step 1: Intermediate 24. Step 2: 6-chloro-5-methyl-1-(tetrahydro-2H-pvran-2-yl)-4-' (4,4,5,5-teframethyl-1,3,2-dioxaborolan-2-yl)-lH-indazole (Phann aBlock)) 2-110 C / O jO^ " N J l-(6-(7-chloro-8-(5-chloro-1,6-dimethyl-lH-indazol-7-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6-diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one Step 1 performed using procedure from Example 2-94. Additional N-methylation performed using procedure from Example 2-19 after step 2. Step 1: Intermediate 8(1 Step 2: Intermediate 37 Ex.# Chemical Structure Name Method changes Reagent 2-111 mT J (M)-l-(6-((lS,8R)-5-methyl-6-(l,5,6-trimethyl-lH-indazol-7-yl)-3-azatricyclo[6.2.1 .02,7]undeca-2,4,6-trien-4-yl)-2,6- diazaspiro[3.4]o ctan-2-yl)-2-propen-l-one (2nd eluting isomer) See alternate Step 1 from Example 2-11. Enantiomer separation after Step 1. Additional N-methylation performed using procedure from Example 2-19 after step 2. atropisomer separation conditions describe below. Step 1: Intermediate 117. Step 2: Intermediate 38. Synthesis of boronic ester for Example 2-6 Br THP B2(pin)2 Pd(dppf)CI2, KOAc dioxane A mixture of 4-bromo-5,6-dimethyl-l-(tetrahydro-2H-pyran-2-yl)-lH-indazole (2.3 g, 7.44 mmol), 4,4,4',4',5,5,5',5,-octamethyl-2,2,-bi(l,3,2-dioxaborolane) (2.27 g, 8.93 mmol), 5   potassium acetate (1.46 g, 14.9 mmol), PdChidppf) (1.09 g, 1.49 mmol) and 1,4-dioxane (40 mL) under N2 was stirred at 100 °C for 12 h. Upon completion, the reaction was quenched with water (50 mL) and the mixture was extracted with DCM (50 mL x 3). The combined organic extracts were washed with brine, dried over NaaSO^ and concentrated. The residue was purified by chromatography (PE: EtOAc = 20:1) to afford 5,6-dimethyl-l-(tetrahydro- 10 2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazole (1.9 g, 72% yield) as a colorless oil. m / z (ESI): 357.1 (M+H)+. Alternative Step 1 for Example 2-11 To a 250-mL RBF with a stirring bar was added K3PO4 (13.04 g, 61.4 mmol, Sigma-Aldrich), Cui, (0.585 g, 3.07 mmol, Sigma-Aldrich), [(2,6-difluorophenyl)carbamoyl]formic acid (2.471 g, 12.29 mmol, Enamine), 2-(tert-butoxycarbonyl)-2,6-diazaspiro[3.4]octane (6.52 g, 30.7 mmol, PharmaBlock) and 2,4-dichloro-3,7,7-trimethyl-5,6,7,8-tetrahydroquinoline (5 g, 20.48 mmol, Intermediate 36). The reaction flask was evacuated and backfilled with nitrogen (3X) before addition of DMSO (102 mL). The reaction mixture was heated to 95 °C. Upon completion, the reaction was diluted with aqueous saturated NH4CI (100 mL) and EtOAc (200 mL). After extraction, the organic phase was washed with water (2 x 100 mL), and the combined aqueous phases were extracted with EtOAc (100 mL). The organic phases were washed with brine (100 mL), dried over Na?SO4, and concentrated in vacuo. The crude material was purified using Biotage Sfar HCD 100 g column with acetone in DCM (0-8%) to provide tert-butyl 6-(4-chloro-3,7,7-trimethyl-5,6,7,8-tetrahydroquinolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (6.3 g, 73.2 %), was obtained as a light yellow solid, m / z (ESI): (M+H)+ - 420.2. H NMR (400 MHz, CDCL) 5 ppm 3.91 - 3.98 (m, 2 H), 3.82 - 3.91 (m, 2 H), 3.59 (s, 2 H), 3.47 (t, 7=6.9 Hz, 2 H), 2.71 (t, 7=6.7 Hz, 2 H), 2.54 (s, 2 H), 2.30 (s, 3 H), 2.11 (t, 7=7.0 Hz, 2 H), 1.53 - 1.61 (m, 2 H), 1.47 (s, 9 H), 1.01 (s, 6 H). Atropisomer separation for Examples 2-11 and 2-12. The racemic mixture was separated by preparative SFC using a AZ column (250 x 21 mm, 5mm) with a mobile phase of 60% liquid CO2 and 40% MeOH using a flowrate of 70 mL / min to provide the respective P and M isomers of 1-(6-(3,7,7-trimethyl-4-(5-methyl-lH-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the M isomer and 2nd eluting atropisomer assigned as the P isomer. Atropisomer separation for Examples 2-14 and 2-15, The racemic mixture was separated by preparative SFC using a Chiralcel OJ column, (250 x 21 mm), mobile phase of 75% liquid CO2 and 25% MeOH w / 0.2% TEA using a flow rate of 80 mL / min to provide the respective P and M isomers of l-(6-(4-(6-hydroxy-l-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2- quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the M isomer and 2lld eluting atropisomer assigned as the P isomer. 5 Atropisomer separation for Examples 2-17 and 2-18. The racemic mixture was separated by preparative SFC using a Chiralpak IC column (250 x 21, 5 pm), with a mobile phase of 85% CO2 and 15% MeOH with 0.2% TEA using a flowrate of 120 mL / min to provide the respective P and M isomers of 4-(2-amino-7-fluoro-l,3-benzothiazol-4-yl)~7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3- 10 carbonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. 13‘ eluting atropisomer assigned as the P isomer and 2n<1 eluting atropisomer assigned as the M isomer. N-methylation for Example 2-19 To a 0 °C solution of tert-butyl 6-(3,7,7-trimethyl-4-(6-methyl-lH-indazol-7-yl)-5,6,7,8-tetrahydroquinolin-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (270 mg, 0.524 mmol) in THE (10.471 mL) was added LiHMDS, IM in THE (0.524 mL, 0.524 mmol, Sigma-Aldrich) dropwise. After stirring at 0 °C for 30 min, iodomethane (0.098 mL, 1.571 mmol, Sigma- 20 Aldrich) was added at 0 °C. The reaction mixture was stirred at 0 °C for 1.5 h. The reaction ■was quenched by 6 mL of aqueous samrated NH4CI. The crude material was extracted with EtOAc (3x5 mL), washed writh brine, dried over NazSO^ and concentrated in vacuo. The crude material was purified using Biotage Sfar HCD 5 g column with acetone in DCM (05%) to provide tert-butyl 6-(4-(1,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyi-5,6,7,8- tetrahydroquinolm-2-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (250 mg, 90% yield). m / z (ESI): (M+H)+ = 530.4. Atropisomer separation for Examples 2-20 and 2-21. The racemic mixture was separated by preparative SFC using a (S,S) Whelk-01 column (250 x 21 mm, 5 pm) with a mobile phase of 75% liquid CO2 and 25% MeOH with 0.2% TEA using a flowrate of 80 mL / min to provide the respective P and M isomers of 1-(6-(4-(1,6-dimethyl-lH-indazol-7-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan~2-yl)-2-propen-l-one. The stereochemistry of structures was arbitrarily assigned and is not established. lsl eluting atropisomer assigned as the M isomer and 2n<1 eliding atropisomer assigned as the P isomer. Atropisomer separation for Examples 2-24 and 2-2S. The racemic mixture wras separated by preparative SFC using an ID column (250 x 21 mm, 5 pm) with a mobile phase of 55% liquid CO2 and 45% MeOH with 0.2% TEA using a flowrate of 70 mL / min to provide the respective P and M isomers of 1-(6-(3,7,7-trimethyl-4-(6-methyl-lH-indazol~7-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the M isomer and 2nd eluting atropisomer assigned as the P isomer. Atropisomer separation for Examples 2-33 and 2-34. The racemic mixture was separated by preparative SFC using a Chiralpak IG column (250x21 mm, 5 pm) with a mobile phase of 50% liquid CO2 and 50% MeOH using a flowrate of 80 mL / min to provide the respective P and M isomers of l-(6-(4-(5-chloro-l-methyl-lH-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry’ of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the P isomer and 2”° eluting atropisomer assigned as the M isomer. Isomer separation for Examples 2-39 and 2-40. The racemic mixture was separated by preparative SFC using a Chiralpak AS (21x 250 mm, 5 pm) column with a mobile phase of 75% liquid CO2 and 25% MeOH with 0.2% TEA using a flowrate of 80 mL / min to provide the respective P and M isomers of (lR,8S)-6-(3-hydroxy-l-naphthalenyr)-4-(2-(2-propenoyl)- 2,6-diazaspiro[3.4]octan-6-yl)-3-azatncyclo[6.2.1.02,7]undeca-2,4,6-tnene-5-carbonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. The 1st and 2nd eluting peaks were not resolved completely. The 3rd eluting isomer was assigned as the P,1S,8R isomer and 4th eluting isomer assigned as the M,1S,8R isomer. Atropisomer separation for Examples 2-44 and 2-45. The racemic mixture was separated by preparative SFC using a Chiralpak IC (21 x 150 mm, 5 pm) with a mobile phase of 55% liquid CO2 and 45% MeOH using a flowrate of 80 mL / min to provide the respective P and M isomers of (lR,9R)-6-(6-hydroxy-8-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02 ?]undeca-2,4,6-triene-5-carbonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. lsl eluting atropisomer assigned as the M isomer and 2“ eluting atropisomer assigned as the P isomer. Atropisomer separation for Examples 2-46 and 2-47. The racemic mixture was separated by preparative SFC using a Chiralcel OX (21 x 250 mm, 5 pm) with a mobile phase of 55% liquid CO2 and 45% MeOH using a flowrate of 60 mL / min to provide the respective P and M isomers of (lR,9R)-6-(7-hydroxy-5-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’7]undeca-2,4,6-triene-5-carbonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the P isomer and 2nd eluting atropisomer assigned as the M isomer. Alternative Step 1 for Example 2-52. XantPhos Pd G3 K2CO3, dioxane Boc N A mixture of 6,8-dibromochromane-7-carbonitrile (306 mg, 0.965 mmol, Intermediate 79), K2CO3 (267 mg, 1.931 mmol, Sigma-Aldrich), 2-(tert-butoxycarbonyl)-2,6- diazaspiro[3.4]octane (184 mg, 0.869 mmol, PharmaBlock), and Xantphos Pd G3 (92 mg, 0.097 mmol, Sigma-Aldrich) in 1,4-dioxane (6 mL) was stirred at 100 °C overnight. The mixture was concentrated in vacuo and chromatographic purification of the residue (silica gel, 0-100% EtOAc / heptanes) provided tert-butyl 6-(8-bromo-7-cyanochroman-6-yl)-2,6-diazaspiro[3.4]octane-2-carboxylate (110 mg, 25.4% yield) as a yellow solid, m / z (ESI): 448.1 (M H i . lH NMR (400 MHz, DMSO-7,) 8 ppm 6.63 (s, 1 H), 4.14 - 4.21 (m, 2 H), 3.74 - 3.87 (m, 4 H), 3.57 (s, 2 H), 3.45 (t, 7=6.8 Hz, 2 H), 2.79 (t, >6.4 Hz, 2 H), 2.13 (t, >6.8 Hz, 2 H), 1.85 - 1.94 (m, 2 H), 1.39 (s, 9 H). Atropisomer separation for Examples 2-5 and 2-54. The racemic mixture was separated by preparative SFC using a Chiralpak AS (21 x 250, 5 pm) column "with a mobile phase of 60% liquid CO2 and 40% MeOH using a flowrate of 80 mL / min to provide the respective P and M isomers of 8-(3-hydroxy-l-naphthalenyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the P isomer and 2na eliding atropisomer assigned as the M isomer. Atropisomer separation for Examples 2-55 and 2-56. The racemic mixture was separated by preparative SFC using a Chiralpak ID (21x150 mm, 5 pm) column with a mobile phase of 55% liquid CO2 and 45% MeOH with 0.2% TEA using a flowrate of 80 mL / min to provide the respective P and M isomers of l-(6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the P isomer and 2nd eluting atropisomer assigned as the M isomer. Isomer separation for Examples 2-57. The racemic mixture was separated by preparative SFC suing a Chiral Technologies IG column (250 x 21 mm, 5 pm) with a mobile phase of 80% liquid CO2 and 20% MeOH with 0.2% TEA using a flowrate of 60 mL / min to provide the respective R and S isomers of l-((5S)-5-methyl-6-(3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1 -one. The 1st eluting isomer assigned as the S isomer and 2nd eluting isomer assigned as the R isomer. Isomer separation for Examples 2-58 and 2-59. Trie racemic mixture was separated by preparative SFC using a Chiral Technologies IG column (250 x 21 mm, 5 pm) with a mobile phase of 90% liquid CO2 and 10% MeOH with 0.2% TEA using a flowrate of 65 mL / min to provide the respective R and S isomers of l-(6-(7-fluoro-3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-5-methyl-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry of structures was arbitrarily assigned and is not established. The Ist eluting isomer assigned as the S isomer and 2nd eluting isomer assigned as the R isomer. Atropisomer separation for Examples 2-60 and 2-61. The racemic mixture was separated by preparative SFC using a column 2x Chiralcel OD (250 x 21 mm, 5 pm) with a mobile phase of mobile phase of 80% liquid CO2 and 20% MeOH with 0.2% TEA using a flowrate of 65 mL / min to provide the respective P and M isomers of l-((5S)-6-(7-fluoro-3-methyl-4-(5-methyl-lH-indazol-4-yl)-2-quinolinyl)-5-methyl-2.,6-diazaspiro[3.4]octan-2-yr)-2-propen-1-one. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the M isomer and 2nd eluting atropisomer assigned as the P isomer. Atropisomer separation for Examples 2-68 and 2-69. The racemic mixture was separated by preparative SFC using a Chiralpak AS column (21 x 250 mm) "with a mobile phase of 75% liquid CO2 and 25% MeOH with 0.2% TEA using a flowrate of 80 mL / min to provide the respective P and M isomers of (lR,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricycTo[7.1.1.02’ / ]undeca-2,4,6-triene-5-carbonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. 13! eluting atropisomer assigned as the M isomer and 2lld eluting atropisomer assigned as the P isomer. Atropisomer separation for Examples 2-71 and 2-72. The racemic mixture was separated by preparative SFC using a (S,S) Whelk O-l column (21 x250 mm) with a mobile phase of 60% liquid CO2 and 40% MeOH using a flowrate of 80 mL / min to provide the respective P and M isomers of (lR,9R)-6-(3-fluoro-2-hydroxyphenyl)-l0,10-dimethyl-4-(2-(2-propen oyl)- 2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.(^^1004603-2,4,6-triene-5-carbonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the P isomer and 2Iia eluting atropisomer assigned as the M isomer. Atropisomer separation for Examples 2-74 and 2-75. The racemic mixture was separated by preparative SFC using a Chiralpak IE column (21 x 250 mm) with a mobile phase of 65% liquid CO2 and 35% MeOH using a flowrate of 80 mL / min to provide the respective P and M isomers of ((lR,9R)-6-(2-chloro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02’7]undeca-2,4,6-triene-5-caibonitrile. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the P isomer and 2”° eluting atropisomer assigned as the M isomer. Atropisomer separation for Examples 2-77 and 2-78. The racemic mixture was separated by preparative SFC using a Sepax OD (21 x 250, 5 pm) column with a mobile phase of 60% liquid CO2 and 40% MeOH with 0.2% TEA using a flowrate of 80 mL / min to provide the respective P and M isomers of l-(6-(3-chloro-4-(3-hydroxy-l-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[43-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the M isomer and 2“* eluting atropisomer assigned as the P isomer. Atropisomer separation for Examples 2-80 and 2-81.. The racemic mixture was separated by preparative SFC using a Chiralpak AS (21 x 250, 5 pm) with a mobile phase of 80% liquid CO2 and 20% MeOH with 0.2% TEA using a flowrate of 80 mL / min to provide the respective P and M isomers of l-(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-l-one. The stereochemistry’ of structures was arbitrarily assigned and is not established. 1st eluting atropisomer assigned as the M isomer and 2nd eluting atropisomer assigned as the P isomer. Atropisomer sepa...

Claims

1. A compound of Formula Ior a pharmaceutically acceptable salt thereof, whereinR1 at each occurrence independently is H, 2H, C1-4haloalkyl, C1-4alkoxy, -CH2OH, -(CH2)O(C1-4alkyl), -(CH2)O(C1-4haloalkyl), -(CH2)-C1-4dialkylamino, aziridin-1-yl-methyl, azetidin-1-yl-methyl, pyrrolidine-1-yl-methyl, piperidin-1-yl-methyl, or morpholin-1-yl-methyl;R2 is H, 2H, halogen, -CN, C1-4alkyl, C1-4haloalkyl, -CH2CN, -CH2OH, C1-4alkoxy, or C1-4haloalkoxy;wherein, optionally, one R1 and R2 together with the carbon atoms to which they, i = r1are attached form a <         group;R3 at each occurrence independently is H, halogen, CN, OH, C1-4alkyl, C1-4haloalkyl, -CH2CN, -CH2OH, C1-4alkoxy, or C1-4haloalkoxy, wherein two substituents R3 attached to the same carbon atom optionally form together with said carbon atom a C3-6cycloalkyl or a carbonyl group;A at each occurrence independently is CR3R3 or absent;R4 is 1,2,3,4-tetrahydro-8-quinolinyl, 6 or 10 membered aryl, or 5 to 10 membered heteroaryl,wherein the aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected from OH, halogen, -CN, NH2, C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, C1-4alkoxy, C1-4haloalkoxy, -SO2NH2, -NHSO2CH3,wherein the C1-4alkyl is optionally substituted with OH;X1 is CR5 or N;X2 is CH, CF, or N;2021363262   14 Oct 2026X3 is C or N;X4 is C or N;R5 is H, halogen, CN, -COO(C1-4alkyl), C1-4alkyl, C2-4alkenyl, C1-4haloalkyl, -(CH2)m(C1-4alkoxy), -(CH2)m(C1-4haloalkoxy), C3-5cycloalkyl, C3-5cyclohaloalkyl, or C3-5heterocycloalkyl;B together with the atoms to which it is attached forms a 4 to 7 membered fully saturated, fully unsaturated, or partially unsaturated carbocyclic or heterocyclic ring system,wherein the heterocyclic ring system comprises 1 to 5 heteroatoms independently selected from N, O, and S,wherein the ring system is optionally substituted with 1 to 5 substituentsR6;R6 at each occurrence independently is halogen, OH, -CN, -NH2, C1-6alkyl, C1-6haloalkyl, Ci-4alkoxy, Ci-4haloalkoxy, -C(=O)Ci-6alkyl, -R7-(C3—5cycloalkyl), -R7-(C3. 5cyclohaloalkyl), -R7-(C3-6heterocycloalkyl), -R7-(phenyl), or - R7-(5 to 6 membered heteroaryl),wherein the C1-6alkyl is optionally substituted with C1-4alkoxy, C1-4alkylamino, C1-4dialkylamino, -CO(C1-4alkylamino) or -CO(C1-4dialkylamino), wherein the C1-6haloalkyl is optionally substituted with a OH,wherein the C3-6heterocycloalkyl is optionally substituted with 1 to 3 substituents independently selected from (=O) and C1-6alkyl,wherein the phenyl is optionally substituted with 1 to 3 substituents independently selected from halogen and C1-4alkoxy,wherein the heteroaryl is optionally substituted with 1 to 3 substituents independently selected from halogen, -(CH2)1-3OH, (CH2)1-3O(C1-4alkyl), -(CH2)1-3O(C1-4haloalkyl), C1-4alkyl, and C1-4haloalkyl,wherein two substituents R6 together optionally form a -(CH2)n- group creating a ring together with the ring atom or ring atoms to which the two substituents R6 are attached,wherein the -(CH2)n- group optionally has one -CH2- group substituted with one heteroatom selected from N, O, and S, andwherein the -(CH2)n- group is optionally substituted with 1 to 3 substituents independently selected from halogen and C1-6alkyl;R7 is (CH2)m or CO;2021363262   14 Oct 2026n is 1, 2, 3, 4, 5 or 6; andm is 0 or 1.

2. The compound according to Claim 1 or a pharmaceutically acceptable saltthereof, wherein the compound has an IC50 of less than 10 uM in the 2h coupled exchange assay or the 20h coupled exchange assay.

3. The compound according to any one of Claims 1-2 or a pharmaceuticallyacceptable salt thereof, wherein:(a) R1 at each occurrence independently is H, 2H, C1-4haloalkyl, -CH2OH, -(CH2)O(C1-4alkyl), -(CH2)O(C1-4haloalkyl), or -(CH2)-C1-4dialkylamino; or(b) R1 at each occurrence independently is H, 2H, C1-4haloalkyl, or -(CH2)-C1-4dialkylamino; orR1 is H; or(c) one R1 and R2 together with the carbon atoms to which they are attached formi ~ r1a e          group; or.(d) one R1 and R2 together with the carbon atoms to which they are attached form -^=-H .

4. The compound according to any one of Claims 1-3 or a pharmaceuticallyacceptable salt thereof, wherein:(a) R2 is H or halogen; or(b)R2 is H.

5. The compound according to any one of Claims 1-4 or a pharmaceuticallyacceptable salt thereof, wherein:(a) R3 at each occurrence independently is H, halogen, C1-4alkyl, C1-4haloalkyl, or -CH2OH; or(b) R3 at each occurrence independently is H, halogen, or C1-4alkyl; or(c) R3 is H.2021363262   14 Oct 20266.     The compound according to any one of Claims 1-5 or a pharmaceuticallyacceptable salt thereof, wherein:(a) one A is absent and the other A is CR3R3; or(b) both A are absent.

7. The compound according to any one of Claims 1-6 or a pharmaceuticallyacceptable salt thereof, wherein:(a)(b)is8.     The compound according to any one of Claims 1-7 or a pharmaceuticallyacceptable salt thereof, wherein:(a) R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl,wherein the aryl or heteroaryl is optionally substituted with 1 to 5 substituents independently selected from OH, halogen, -CN, NH2, C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, C1-4alkoxy, -SO2NH2, -NHSO2CH3, wherein the C1-4alkyl is optionally substituted with OH; or(b) R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl,wherein the aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from OH, halogen, -CN, NH2, C1-4alkyl, or C1-4haloalkyl; or2021363262   14 Oct 2026(c) R4 is 6 or 10 membered aryl or 5 to 10 membered heteroaryl,wherein the aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from OH, F, Cl, or methyl.

9. The compound according to Claim 8 or a pharmaceuticallyacceptable salt thereof, wherein:(a) the 6 or 10 membered aryl is phenyl; or(b) the 6 or 10 membered aryl is naphthalenyl; or(c) the 5 to 10 membered heteroaryl is 1,3-thiazolyl, pyrazolyl, pyridyl, benzothiophenyl, indolyl, indazolyl, 1,3-benzothiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-benzoxadiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, imidazo[1,5-a]pyridinyl, or pyrazolo[3,4-b]pyridinyl; or (d) the 5 to 10 membered heteroaryl is indazolyl.

10. The compound according to any one of Claims 1-9 or apharmaceutically acceptable salt thereof, wherein(a) R4 is2021363262   14 Oct 2026; or(b) R4 is11.    The compound according to any one of Claims 1-10 or apharmaceutically acceptable salt thereof, whereinX1 is N, X2 is N, X3 is C, and X4 is C; orX1 is CR5, X2 is N, X3 is C, and X4 is C; orX1 is CR5, X2 is CH, X3 is C, and X4 is C; orX1 is CR5, X2 is CH, X3 is N, and X4 is C; orX1 is CR5, X2 is CH, X3 is C, and X4 is N.

12. The compound according to any one of Claims 1-11 or apharmaceutically acceptable salt thereof, wherein:(a) R5 is H, halogen, CN, -COO(C1-4alkyl), C1-4alkyl, C2-4alkenyl, C1-4haloalkyl, -(CH2)m(C1-4alkoxy), or, C3-5cycloalkyl; or(b) R5 is halogen, CN, or C1-4alkyl; or(c) R5 is F, Cl, or methyl.2021363262   14 Oct 202613.    The compound according to any one of Claims 1-12 or apharmaceutically acceptable salt thereof, wherein:(a) B together with the atoms to which it is attached forms a ring system selected from, andwherein the ring system is optionally substituted with 1 to 5 substituents R6; or(b) B together with the atoms to which it is attached forms a ring system selected from;wherein the ring system is optionally substituted with 1 to 5 substituents R6; or(c) B together with the atoms to which it is attached forms a ring system selected fromand2021363262   14 Oct 202614.    The compound according to any one of Claims 1-12 or apharmaceutically acceptable salt thereof, wherein:(a) the compound is a compound of Formula II(II), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 5; or(b) the compound is a compound of Formula III(III), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4,R5, and R6 at each occurrence independently are defined as in the preceding claims; and2021363262   14 Oct 2026(c) the compound is a compound of Formula IV(IV), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 5; or(d) the compound is a compound of Formula V(V), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 4; or(e) the compound is a compound of Formula VI(VI), wherein2021363262   14 Oct 2026R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; and p is 0 to 5; or(f) the compound is a compound of Formula VII(VII), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 5; or(g) the compound is a compound of Formula VIII(VIII), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; and2021363262   14 Oct 2026(h) the compound is a compound of Formula IX(IX), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 5; or(i) the compound is a compound of Formula X(X), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; and2021363262   14 Oct 2026(j) the compound is a compound of Formula XIR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 2; or(k) the compound is a compound of Formula XII(XII), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; and2021363262   14 Oct 2026(l) the compound is a compound of Formula XIII(XIII), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 5; or(m) the compound is a compound of Formula XIV(XIV), whereinR1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; andp is 0 to 5; or(n) the compound is a compound of Formula XV(XV), wherein2021363262   14 Oct 2026R1 at each occurrence independently, R2, R3 at each occurrence independently, R4, R5, and R6 at each occurrence independently are defined as in the preceding claims; and p is 0 to 3.

15. The compound according to any one of Claims 1-14 or apharmaceutically acceptable salt thereof, wherein:(a) R6 at each occurrence independently is Ci-6alkyl, Ci-6haloalkyl, Ci-4alkoxy, -R7-(C3-5cycloalkyl),-R7-(C3-6heterocycloalkyl), -R7-(phenyl), or - R7-(5 to 6 membered heteroaryl),wherein the C1-6alkyl is optionally substituted with C1-4alkoxy,wherein the C3-6heterocycloalkyl is optionally substituted with C1-6alkyl,wherein the phenyl is optionally substituted with C1-4alkoxy,wherein the heteroaryl is optionally substituted with 1 to 3 substituents independently selected from halogen, -(CH2)1-3OH and C1-4alkyl, andwherein two substituents R6 together optionally form a -(CH2)n- group creating a ring together with the ring atom or ring atoms to which the two substituents R6 are attached,wherein the -(CH2)n- group optionally has one -CH2- group substituted with an -O- atom; or(b) R6 at each occurrence independently is methyl, oxetan-3-yl, or 1,4-dimethyl-1H-pyrazol-5-yl,wherein two substituents R6 together optionally form a -(CH2)n- group creating a ring together with the ring atom or ring atoms to which the two substituents R6 are attached.

16. The compound according to any one of Claims 1-15 or apharmaceutically acceptable salt thereof, whereinR7 is (CH2)m.

17. The compound according to any one of Claims 1-16 or apharmaceutically acceptable salt thereof, whereinn is 1.2021363262   14 Oct 202618.    The compound according to any one of Claims 1-17 or apharmaceutically acceptable salt thereof, whereinm is 0.

19. The compound according to Claim 1 or a pharmaceuticallyacceptable salt thereof, (a) wherein the compound is8-fluoro-2-(5-(fluoromethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(5-methyl-1H-indazol-4-yl)-3-quinolinecarbonitrile;8-(5-methyl-1H-indazol-4-yl)-3-(4-methyl-1-piperazinyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)imidazo[1,2-a]pyridine-7-carbonitrile;8-(5-methyl-1H-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-2-(1,3-thiazol-2-yl)imidazo[1,2-a]pyridine-7-carbonitrile;4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carbonitrile;(P)-1-(6-(3,7,7-trimethyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(1,6-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(3,7,7-trimethyl-4-(6-methyl-1H-indazol-7-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(3-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3,7,7-trimethyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 2026(1R,9R)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6-(5-(trifluoromethyl)-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;1-(6-(4-(6-chloro-5-methyl-1H-indazol-4-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-(1R,8S)-6-(3-hydroxy-1-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,8S)-6-(3-hydroxy-1-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile or (1S,8R)-6-(3-hydroxy-1-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(M)-(1R,8S)-6-(3-hydroxy-1-naphthalenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,9R)-6-(6-hydroxy-8-isoquinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,9R)-6-(7-hydroxy-5-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1R,9R)-6-(6-hydroxy-8-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1R,9R)-6-(7-hydroxy-5-quinolinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;1-(6-(7-methoxy-3-methyl-4-(5-methyl-1H-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;8-(3-hydroxy-1-naphthalenyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile;(M)-8-(3-hydroxy-1-naphthalenyl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile;1-((5S)-5-methyl-6-(3-methyl-4-(5-methyl-1H-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-((5S)-6-(7-fluoro-3-methyl-4-(5-methyl-1H-indazol-4-yl)-2-quinolinyl)-5-methyl-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(1R,9R)-6-(2-chloro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;2021363262   14 Oct 2026(1R,9R)-6-(2-fluoro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1R,9R)-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1R,9R)-6-(2-chloro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;1-(6-(3-chloro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(3-chloro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(3-chloro-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-chloro-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(3-chloro-4-(1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-chloro-4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(3-chloro-4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-chloro-4-(6-chloro-5-methyl-1H-indazol-4-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(5-methyl-1H-indazol-4-yl)-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-2-naphthalenecarbonitrile;8-(5-methyl-1H-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-1H-2-benzopyran-7-carbonitrile;1-(1,6-dimethyl-1H-indazol-7-yl)-6,6-dimethyl-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-2-naphthalenecarbonitrile;3'-hydroxy-6,6-dimethyl-3-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro[1,1'-binaphthalene]-2-carbonitrile;2021363262   14 Oct 2026(P)-8-(5-methyl-1H-indazol-4-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-1H-2-benzopyran-7-carbonitrile;8-(1,6-dimethyl-1H-indazol-7-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile;1-(6-(7-chloro-8-(1,6-dimethyl-1H-indazol-7-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;8-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile;2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;8-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-6-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3,4-dihydro-2H-chromene-7-carbonitrile;(P)-1-(6-(3-chloro-4-(6-chloro-5-methyl-1H-indazol-4-yl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(7-chloro-8-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1S,8R)-5-methyl-6-(1,5,6-trimethyl-1H-indazol-7-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(1R,9R)-6-(7-fluoro-5-methyl-1H-indazol-4-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;4-(5-chloro-1H-indol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(1R,9R)-6-(5-chloro-6-methyl-1H-indazol-4-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,9R)-10,10-dimethyl-6-(7-methylimidazo[1,5-a]pyridin-8-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;4-(3-chloro-6-methyl-1H-indol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;2021363262   14 Oct 20261-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3-methyl-7-(2-propanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3-methyl-7-(2-propanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-methyl-7-(2-propanyl)-4-(1,5,6-trimethyl-1H-indazol-7-yl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(1R,9R)-6-(2-chloro-3-fluoro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,9R)-6-(2-chloro-5-hydroxy-3-pyridinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1R,9R)-6-(7-hydroxy-5-quinoxalinyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;4-(6-hydroxy-1-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(M)-1-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(2-chloro-5-hydroxy-3-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-((2H3)-2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;2-(2-((2E)-4-(dimethylamino)-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;2-(2-((2E)-4,4-difluoro-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(7R)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(trifluoromethyl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile or (7S)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(trifluoromethyl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4'-(5-methyl-1H-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7',8'-dihydro-5'H-spiro[cyclopropane-1,6'-quinoline]-3'-carbonitrile;6,6-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;2021363262   14 Oct 2026(5R,7S)-5,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile or (5S,7R)-5,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,1'-cyclopropane]-3-carbonitrile;4-(1,6-dimethyl-1H-indazol-7-yl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;(P)-4-(1,6-dimethyl-1H-indazol-7-yl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;(7R)-4-(2-chlorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile or (7S)-4-(2-chlorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(7R)-4-(2-chlorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(7S)-4-(2-chlorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(7R)-4-(2-fluorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile or (7S)-4-(2-fluorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(P)-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;1-(6-(3-(difluoromethyl)-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;4'-(5-methyl-1H-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-2,3,5,5',6,8'-hexahydrospiro[pyran-4,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile;(3R)-4'-(5-methyl-1H-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4,5,5',8'-tetrahydrospiro[furan-3,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile or (3S)-4'-2021363262   14 Oct 2026(5-methyl-1H-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4,5,5',8'-tetrahydrospiro[furan-3,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile;6,6-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile or 6,6-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;(P)-6,6-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;(P)-4-(1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(6aR,7aR)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5R)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aR,7aR)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aR,7aS)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5R)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aR,7aS)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aR)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5R)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aR)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aS)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5R)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aS)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-((5S)-5-(hydroxymethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile;4-(3-hydroxy-1-naphthalenyl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;(P)-4-(3-hydroxy-1-naphthalenyl)-6,6-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;2021363262   14 Oct 2026(P)-(6aR,7aS)-4-(4-fluoro-3-hydroxy-1-naphthalenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile;(M)-(6aR,7aS)-4-(4-fluoro-3-hydroxy-1-naphthalenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile;(P)-4-(4-fluoro-3-hydroxy-1-naphthalenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(M)-2-((5S)-5-(fluoromethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile and (P)-2-((5R)-5-(fluoromethyl)-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(5aR,6aR)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-b]pyridine-3-carbonitrile or (5aR,6aS)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-b]pyridine-3-carbonitrile or (5aS,6aR)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-b]pyridine-3-carbonitrile or (5aS,6aS)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-b]pyridine-3-carbonitrile;(4bR,5aR)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile or (4bR,5aS)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile or (4bS,5aR)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile or (4bS,5aS)-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile;(6R)-6-cyclopropyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile or (6S)-6-cyclopropyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;2021363262   14 Oct 2026(4bR,5aR)-5,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile or (4bR,5aS)-5,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile or (4bS,5aR)-5,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile or (4bS,5aS)-5,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4b,5,5a,6-tetrahydrocyclopropa[3,4]cyclopenta[1,2-b]pyridine-3-carbonitrile;(P)-(6aR,7aS)-2-(2-((2E)-4-(dimethylamino)-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(3-hydroxy-1-naphthalenyl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile (3rd eluting isomer);(P)-(6aS,7aR)-2-(2-((2E)-4-(dimethylamino)-2-butenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(3-hydroxy-1-naphthalenyl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile;7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(1,5,6-trimethyl-1H-indazol-7-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(1,5,6-trimethyl-1H-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(P)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-4-(1,5,6-trimethyl-1H-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(1R,9R)-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,9R)-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-4-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile or (1R,9R)-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-4-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;2021363262   14 Oct 20264'-(5-methyl-1H-indazol-4-yl)-2'-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5',8'-dihydrospiro[cyclobutane-1,7'-pyrano[4,3-b]pyridine]-3'-carbonitrile;7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,7-dihydrofuro[3,4-b]pyridine-3-carbonitrile;4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydrospiro[cyclopenta[b]pyridine-7,1'-cyclopropane]-3-carbonitrile;(1R,9R)-6-(1,6-dimethyl-1H-indazol-7-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(M)-(1R,9R)-6-(1,6-dimethyl-1H-indazol-7-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,9R)-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1s,9s)-6-(1,6-dimethyl-1H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(1s,9s)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(M)-(1R,9R)-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(6aR,7aS)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile or (6aS,7aR)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile;(M)-(1s,9s)-6-(1,6-dimethyl-1H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1s,9s)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-4-(5-hydroxy-2-methylphenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(P)-(1R,9R)-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;2021363262   14 Oct 2026(1s,9s)-3-(1,6-dimethyl-1H-indazol-7-yl)-5-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-4-carbonitrile;(M)-(1s,9s)-3-(1,6-dimethyl-1H-indazol-7-yl)-5-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-4-carbonitrile;(M)-(6aR,7aS)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile;(M)-(6aS,7aR)-4-(1,6-dimethyl-1H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,6a,7,7a-tetrahydro-5H-cyclopropa[h]quinoline-3-carbonitrile;4-(1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(5-chloro-1H-indazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(P)-4-(1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(7-fluoro-5-methyl-1H-indazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(7-fluoro-5-methyl-1H-indazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;4-(5-chloro-1H-indazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;7,7-dimethyl-4-(5-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(2-chloro-5-hydroxy-3-methylphenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;4-(2-amino-3,5-dichloro-6-fluorophenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(P)-4-(2-amino-3,5-dichloro-6-fluorophenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;1-(6-((1R,9R)-5-fluoro-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 20264-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;(1S,8R)-6-(5-methyl-1H-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,8S)-6-(5-methyl-1H-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1S,8R)-6-(5-methyl-1H-indazol-4-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1R,8S)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1S,8R)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1R,8S)-6-(5-hydroxy-2-methylphenyl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(1S,8R)-6-(1,6-dimethyl-1H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(P)-(1S,8R)-6-(1,6-dimethyl-1H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene-5-carbonitrile;4-(6-chloro-5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;7-cyclopropyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-methoxy-4-(5-methyl-1H-indazol-4-yl)-3-quinolinecarbonitrile;7-methoxy-4-(5-methyl-1H-indazol-4-yl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile or 7-methoxy-4-(5-methyl-1H-indazol-4-yl)-2-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;1-(6-(3,7,7-trimethyl-4-(5-methyl-1H-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(1R,9R)-6-(1H-indazol-7-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;1-(6-(4-(3-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 2026(P)-(1R,9R)-6-(1H-indazol-7-yl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;(M)-1-(6-(4-(5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(3,7,7-trimethyl-4-(5-methyl-1H-indazol-4-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3,7,7-trimethyl-4-(1,5,6-trimethyl-1H-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(3,7,7-trimethyl-4-(1,5,6-trimethyl-1H-indazol-7-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(2-chlorophenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-3-quinolinecarbonitrile;(1R,9R)-10,10-dimethyl-6-(6-methyl-1H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;1-(6-((1R,9R)-5-fluoro-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-(1R,9R)-10,10-dimethyl-6-(6-methyl-1H-indazol-7-yl)-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;4-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(P)-4-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(P)-1-(6-((1R,9R)-5-fluoro-6-(5-hydroxy-2-methylphenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-fluoro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 2026(P)-1-(6-(3-fluoro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-((1R,9R)-5-fluoro-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1R,9R)-5-fluoro-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-((1R,9R)-5-fluoro-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3-fluoro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;7,7-dimethyl-4-(6-methyl-1H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(P)-7,7-dimethyl-4-(6-methyl-1H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;(1R,9R)-6-(2-chloro-4-fluoro-5-hydroxyphenyl)-10,10-dimethyl-4-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-triene-5-carbonitrile;1-(6-(4-(5-chloro-6-methyl-1H-indazol-7-yl)-3-fluoro-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(5-hydroxy-2-(trifluoromethyl)phenyl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(5-chloro-6-methyl-1H-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-7,7-dimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;2021363262   14 Oct 20261-(6-((7R)-4-(2,4-difluorophenyl)-7-(1,4-dimethyl-1H-pyrazol-5-yl)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-((7R)-4-(1,6-dimethyl-1H-indazol-7-yl)-7-(1,4-dimethyl-1H-pyrazol-5-yl)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(4-(3-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(6-chloro-1,5-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2-amino-7-fluoro-4-(3,7,7-trimethyl-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridin-4-yl)-1-benzothiophene-3-carbonitrile;(M)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3-fluoro-7-(3-oxetanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; (P)-1-(6-(4-(1,6-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(5-methyl-1H-indazol-4-yl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;1-(6-(3-methyl-4-(5-methyl-1H-indazol-4-yl)-7-(4-methyl-1,3-thiazol-5-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(2-chlorophenyl)-7-(1-methyl-1H-imidazol-2-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;1-(6-(4-(2-chloro-5-hydroxyphenyl)-3-methyl-7-(1-methyl-1H-pyrazol-5-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(2-chlorophenyl)-2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(1-methyl-1H-pyrazol-5-yl)-3-quinolinecarbonitrile;4-(2-chlorophenyl)-7-(2-methyl-1H-imidazol-1-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(2-methyl-1H-imidazol-1-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(5-methyl-1H-imidazol-1-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-chlorophenyl)-7-(5-methyl-1H-imidazol-1-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;2021363262   14 Oct 20261-(6-(4-(6-hydroxy-1-naphthalenyl)-3-methyl-7-(2-propanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(6-hydroxy-1-naphthalenyl)-3-methyl-7-(2-propanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(6-hydroxy-1-naphthalenyl)-3,7-dimethyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(6-hydroxy-1-naphthalenyl)-3-methyl-7-(3-oxetanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(6-hydroxy-1-naphthalenyl)-7-((2R)-1-methoxy-2-propanyl)-3-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one or 1-(6-(4-(6-hydroxy-1-naphthalenyl)-7-((2S)-1-methoxy-2-propanyl)-3-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(2-fluoro-5-hydroxyphenyl)-3-methyl-7-(4-methyl-1,3-thiazol-5-yl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(7-cyclopropyl-4-(6-hydroxy-1-naphthalenyl)-3-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(6-hydroxy-1-naphthalenyl)-3-methyl-7-((2R)-3,3,3-trifluoro-2-hydroxypropyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one or 1-(6-(4-(6-hydroxy-1-naphthalenyl)-3-methyl-7-((2S)-3,3,3-trifluoro-2-hydroxypropyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-methyl-4-(5-methyl-1H-indazol-4-yl)-7-(2-propanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(2,3-dimethylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;(P)-4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2,4-difluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;2021363262   14 Oct 20264-(2-chlorophenyl)-7-(2-(hydroxymethyl)-4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;4-(2-fluorophenyl)-7-(4-(hydroxymethyl)-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;(P)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;(M)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;(M)-4-(2,3-dimethylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;(P)-4-(2,3-dimethylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;(P)-4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2,3-dimethylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;(M)-4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;(P)-4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;4-(2,4-difluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-1,5-naphthyridine-3-carbonitrile;4-(2-fluorophenyl)-7-(4-(methoxymethyl)-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(4-(hydroxymethyl)-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;2021363262   14 Oct 20264-(2-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(2,4-difluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;(8R)-4-(2-fluorophenyl)-8-methyl-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile or (8S)-4-(2-fluorophenyl)-8-methyl-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;(8R)-4-(2-fluorophenyl)-8-methyl-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(2,4-difluorophenyl)-7-(4-methoxyphenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(2-chloro-5-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(3-fluoro-2-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(2,4-difluorophenyl)-2-((5S)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(4-methyl-1,3-thiazol-5-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(2,4-difluorophenyl)-2-((5R)-5-methyl-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-(4-methyl-1,3-thiazol-5-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(2-fluoro-5-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;(P)-4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;(M)-4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;2021363262   14 Oct 2026(P)-4-(2-chloro-5-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;4-(3-fluoro-2-pyridinyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-((2H3)-2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;7-cyclopropyl-4-(2-fluorophenyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;1-(6-((7R)-4-(2,3-dimethylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(7R)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile or (7S)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(M)-(7R)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(P)-(7S)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(P)-(7R)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(M)-(7S)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(7S)-4-(2-fluorophenyl)-7-methyl-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(7R)-4-(2-fluorophenyl)-7-methyl-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(2-chlorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;(7R)-4-(2,4-difluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile or (7S)-2021363262   14 Oct 20264-(2,4-difluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;4-(2-chloro-4-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2,4-difluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(M)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(P)-4-(2-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(7R)-4-(2-chloro-4-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7,8-dihydro-5H-pyrano[4,3-b]pyridine-3-carbonitrile;4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(4-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(P)-4-(2-chloro-4-fluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-chloro-6-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-fluoro-5-methoxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(P)-4-(2-chlorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-chloro-5-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2,3-difluorophenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;2021363262   14 Oct 20264-(2-fluoro-5-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-fluoro-6-methylphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(P)-4-(2-fluoro-6-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(4-(methoxymethyl)-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(3-fluoro-2-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(3-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;4-(2-fluorophenyl)-7-(4-(hydroxymethyl)-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6-dihydro-3-quinolinecarbonitrile;(7R)-4-(3-fluoro-2-pyridinyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile or (7S)-4-(3-fluoro-2-pyridinyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;(7S)-4-(3-fluoro-2-pyridinyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(2-chloro-5-(difluoromethyl)phenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;(6R)-4-(5-methyl-1H-indazol-4-yl)-6-(2-propanyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile or (6S)-4-(5-methyl-1H-indazol-4-yl)-6-(2-propanyl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile;(P)-1-(6-(3-ethenyl-4-(5-methyl-1H-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-fluoro-7-methoxy-4-(5-methyl-1H-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-chloro-4-(5-methyl-1H-indazol-4-yl)-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 20261-(6-(7-chloro-8-(5-methyl-1H-indazol-4-yl)-3,4-dihydro-2H-chromen-6-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;4-(2-fluoro-3-hydroxyphenyl)-7-(4-methyl-1,3-thiazol-5-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carbonitrile;(P)-1-(6-(4-(1,6-dimethyl-1H-indazol-7-yl)-3-methyl-7-(3-methyl-3-oxetanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; (P)-7,7-dimethyl-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;1-(6-(4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-5,6,7,8-tetrahydro-2-quinazolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;8-(5-methyl-1H-indazol-4-yl)-2-phenyl-6-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)imidazo[1,2-a]pyridine-7-carbonitrile;7-methoxy-4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile;2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitrile;(7)-2-(8,8-difluoro-2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-7-methyl-4-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile;4-(5,6-dimethyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-3-quinolinecarbonitrile; or4-(5-methyl-1H-indazol-4-yl)-2-(2-(2-propenoyl)-2,6-diazaspiro[3.4]octan-6-yl)-5,6,7,8-tetrahydro-3-quinolinecarbonitrile; or(b) wherein the compound is1-(6-(4-(3-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(5-fluoro-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-chloro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 20261-(6-(5-methyl-6-(1,5,6-trimethyl-1H-indazol-7-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(5-fluoro-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(3-fluoro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3-fluoro-7-(3-oxetanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; or1-(6-(4-(2,4-difluorophenyl)-7-(1,4-dimethyl-1H-pyrazol-5-yl)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; or(c) wherein the compound is(M)-1-(6-(4-(3-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-((1R,9R)-5-fluoro-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(3-chloro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1S,8R)-5-methyl-6-(1,5,6-trimethyl-1H-indazol-7-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1R,9R)-5-fluoro-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 2026(P)-1-(6-(3-fluoro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3-fluoro-7-(3-oxetanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; or1-(6-((7R)-4-(2,4-difluorophenyl)-7-(1,4-dimethyl-1H-pyrazol-5-yl)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; or(d) wherein the compound is(P)-1-(6-(4-(3-hydroxy-1-naphthalenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1R,9R)-5-fluoro-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-((1S,9S)-5-fluoro-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1S,9S)-5-fluoro-6-(3-hydroxy-1-naphthalenyl)-10,10-dimethyl-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(3-chloro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(3-chloro-5-hydroxy-2-methylphenyl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-((1S,8R)-5-methyl-6-(1,5,6-trimethyl-1H-indazol-7-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1R,8S)-5-methyl-6-(1,5,6-trimethyl-1H-indazol-7-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;2021363262   14 Oct 2026(P)-1-(6-((1R,8S)-5-methyl-6-(1,5,6-trimethyl-1H-indazol-7-yl)-3-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3,7,7-trimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-((1R,9R)-5-fluoro-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-((1S,9S)-5-fluoro-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-((1S,9S)-5-fluoro-10,10-dimethyl-6-(5-methyl-1H-indazol-4-yl)-3-azatricyclo[7.1.1.02,7]undeca-2,4,6-trien-4-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(M)-1-(6-(3-fluoro-4-(3-hydroxy-1-naphthalenyl)-7,7-dimethyl-7,8-dihydro-5H-pyrano[4,3-b]pyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one;(P)-1-(6-(4-(5-chloro-1,6-dimethyl-1H-indazol-7-yl)-3-fluoro-7-(3-oxetanyl)-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one; or1-(6-((7S)-4-(2,4-difluorophenyl)-7-(1,4-dimethyl-1H-pyrazol-5-yl)-3-methyl-5,6,7,8-tetrahydro-2-quinolinyl)-2,6-diazaspiro[3.4]octan-2-yl)-2-propen-1-one.

20. A pharmaceutical composition comprising the compoundaccording to any one of Claims 1-19 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

21. A method of treating cancer, said method comprising administeringa therapeutically effective amount of the compound according to any one of Claims 1-19 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Claim 20, to a subject in need thereof, wherein one or more cells express KRAS G12C mutant protein.2021363262   14 Oct 202622.    Use of the compound according to any one of Claims 1-19 or apharmaceutically acceptable salt thereof, or the pharmaceutical composition according to Claim 20, in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein one or more cells express KRAS G12C mutant protein.

23. The method of Claim 21, or use of Claim 22, wherein the cancer isnon-small cell lung cancer, small bowel cancer, appendiceal cancer, colorectal cancer, cancer of unknown primary, endometrial cancer, mixed cancer types, pancreatic cancer, hepatobiliary cancer, small cell lung cancer, cervical cancer, germ cell cancer, ovarian cancer, gastrointestinal neuroendocrine cancer, bladder cancer, myelodysplastic / myeloproliferative neoplasms, head and neck cancer, esophagogastric cancer, soft tissue sarcoma, mesothelioma, thyroid cancer, leukemia, or melanoma.

24. The method or use of Claim 23, wherein the cancer is: (a) nonsmall cell lung cancer; or(b) colorectal cancer; or(c) pancreatic cancer.

25. The method of any one of Claims 21, and 23 to 24, or useaccording to any one of Claims 22 to 24, wherein the subject has a cancer that was determined to have one or more cells expressing the KRAS G12C mutant protein prior to administration of the compound or a pharmaceutically acceptable salt thereof.

26. The method of any one of Claims 21, and 23 to 25, or useaccording to any one of Claims 22 to 25, wherein the method further comprises simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor, AKT inhibitor, arginase inhibitor, CDK4 / 6 inhibitor, ErbB family inhibitor, ERK inhibitor, FAK inhibitor, FGFR inhibitor, glutaminase inhibitor, IGF-1R inhibitor, KIF18A inhibitor, MCL-1 inhibitor, MEK inhibitor, mTOR inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PI3K inhibitor, Raf kinase inhibitor, SHP2 inhibitor, SOS1 inhibitor, Src kinase inhibitor, or one or more chemotherapeutic agent; or wherein the medicament is administered or is to be administered in combination with simultaneous, separate, or sequential administration of an effective amount of a second compound, wherein the second compound is an Aurora kinase A inhibitor, AKT inhibitor, arginase inhibitor,2021363262   14 Oct 2026CDK4 / 6 inhibitor, ErbB family inhibitor, ERK inhibitor, FAK inhibitor, FGFR inhibitor, glutaminase inhibitor, IGF-1R inhibitor, KIF18A inhibitor, MCL-1 inhibitor, MEK inhibitor, mTOR inhibitor, PD-1 inhibitor, PD-L1 inhibitor, PI3K inhibitor, Raf kinase inhibitor, SHP2 inhibitor, SOS1 inhibitor, Src kinase inhibitor, or one or more chemotherapeutic agent.Amgen Inc.Patent Attorneys for the Applicant / Nominated Person SPRUSON & FERGUSON